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 Along with the venerable Wacker oxidation reaction
1
 thought to proceed 
historically via anti-oxypalladtion of alkenes,
2
 anti-aminopalladation reactions have 
similarly become highly developed over the past 35 years.
3,4,5
 In contrast, Pd-mediated 
syn-aminopalladations of alkenes have been discovered only in relatively recent times. In 
1992, Boncella and co-workers provided direct evidence for intramolecular syn-insertion 
of DMAD (I-2) into Pd-amido complex I-1 to form vinyl Pd-complex I-3 (Scheme I.1),
6
 
but the analogous alkene insertion had not been demonstrated with a Pd-catalyst. Syn-
aminopalladation was a topic of research in the late 1980s to the mid-1990s mainly using 
transition metals other than Pd. Casalnuovo and co-workers reported Ir(I)-catalyzed 
addition of aniline to norbornylene in 1988.
7
 Around the same time, Trogler and Cowan 
reported insertion of acrylonitrile into a Pt-amido complex, which was conceptually 










Despite being a more recent phenomenon, mechanistic and synthetic work has 
begun to reveal intermolecular syn-aminopalladation of alkenes as an expedient method 
for the preparation of linear, functionalized amines such as I-5 (Scheme I.2).
11
 Recent 
direct evidence for intermolecular Pd-mediated syn-aminopalladations of ethylene and 1-
octene has been put forth by Hartwig and co-workers.
12
 Stahl and Liu have also shown 
that oxidative, intramolecular anti- or syn-aminopalladations are both possible depending 
on the nature of the catalyst employed.
13
 For example, a catalyst composed of 
Pd(OAc)2/DMSO/O2 yields only anti-aminopalladation product I-7 whereas a 
Pd(OAc)2/pyridine/O2 catalyst system affords syn-aminopalladation products I-8 and I-9 
(Scheme I.3). 
Scheme I.2 Aminoacetoxylation of Terminal Alkenes with Phthalimide and Acetate 
 
Scheme I.3 Syn- and Anti-Aminopalladation Dependent on Reaction Conditions 
 
In addition, intramolecular aminopalladation processes have been demonstrated as 
a preferred route for the synthesis of valuable nitrogen heterocycles. For example, 










 have appeared in the literature for the synthesis of a 
plethora of valuable nitrogen-containing structures. 
Scheme I.4 Alkene Diamination with a Urea Substrate  
 
Pd-catalyzed carboamination of alkenes has also become a useful method for the 
synthesis of a broad array of nitrogen-containing heterocycles.
17,18
 In 2004, Wolfe and 
Ney reported the Pd-catalyzed coupling of γ-aminoalkenes such as I-12 with aryl 
bromides to yield 2-benzylpyrrolidines such as I-14 (Scheme I.5).
19
 In addition to 
pyrrolidines being an interesting class of medicinally-relevant compounds,
20
 this 
carboamination method was demonstrated to involve a novel, intramolecular syn-
aminopalladation step. In 2005, Wolfe and Ney illustrated that carboamination of γ-N-
arylaminoalkene substrate I-15 gave products I-17 and I-19 derived from syn-addition of 
the nitrogen and aryl group across the pendant alkene (Scheme I.6).
21
  
Scheme I.5 Pd-Catalyzed Carboamination Reactions to Afford 2-Benzylpyrrolidines 
 





From this initial work, a catalytic cycle was postulated involving: (1) oxidative 
addition of the ArBr to a Pd(0) complex to afford I-20; (2) transmetalation of the 
deprotonated amine substrate I-21 with complex I-20 to give a Pd-amido complex; (3) 
syn-aminopalladation from the Pd-amido complex through transition state I-22 to give 
Pd-complex I-23; and (4) reductive elimination to liberate pyrrolidine I-24 and 
regenerate the Pd(0) species (Scheme I.7).  
Scheme I.7 Generic Catalytic Cycle for Wolfe Group Carboamination Reactions 
 
Since this seminal work, several syntheses of other important nitrogen-containing 














 as well as polycyclic nitrogen-containing 
heterocycles.
30,31
 In another recent development, an enantioselective synthesis of N-Boc 
pyrrolidines has been communicated.
32
 Moreover, advances such as the general use of 
aryl chlorides as coupling partners
33
 and a synthetic route to trans-2,5-disubstituted 
pyrrolidines
34




In addition to Wolfe Group syn-aminopalladation reactions, other researchers 
have been active in this field. Earlier this year, Yang and Yip demonstrated a tandem syn-
amidopalladation sequence using a Pd(OAc)2 pre-catalyst with an ethyl nicotinate ligand 
for the synthesis of polycyclic nitrogen-containing heterocycle I-26 from I-25 (Scheme 
I.8).
35
 In 2009 Michael and co-workers demonstrated the synthesis of 2-
benzylpyrrolidines via a Pd(II)/Pd(IV) sequence involving tandem intramolecular alkene 
aminopalladation and C–H activation of solvent arene molecules.
36
 Additionally, in 2009 
Oshima demonstrated Pd-catalyzed carboamination to be a convenient method for 
accessing aziridine products.
37
 Metal-catalyzed carboamination reactions for the 
synthesis of nitrogen-containing heterocycles employing other metals such as Cu and Au 





Scheme I.8 Intramolecular Syn-Amidopalladation and C–H Activation Sequence 
 
A large body of literature has been amassed since 2004 by the Wolfe Group for 
the Pd-catalyzed synthesis of nitrogen-containing heterocycles. However, little was 
known about the key intramolecular syn-aminopalladation step in the catalytic cycle until 
work described in Chapters III and IV of this dissertation. In addition, Wolfe Group 
methodology had not yet been expanded to the synthesis of 7-membered ring 
heterocycles until the studies described in Chapter II of this dissertation. 
Specifically, 7-membered ring benzodiazepine heterocycles have captured the 




important benzodiazepines have been in the treatment of anxiety etc. in humans, the 
common benzodiazepine drug diazepam (I-27) has been cited in > 30,000 journal articles 
according to SciFinder Scholar as of 04/26/2011. Related benzodiazepine alprazolam (I-
28) had been cited 2,831 times whereas clonazepam (I-29) had been cited 4,999 times in 
journal articles according to SciFinder Scholar as of 04/26/2011 (Figure I.1). 
Figure I.1 Structures of Commonly Prescribed Anti-Anxiety Benzodiazepines 
 
A key feature of most biologically active benzodiazepines to date is various 
degrees of unsaturation such as a double bond in the 7-membered ring or a carbonyl 
moiety. Despite intense interest in and many methods for convenient syntheses of new 
and potentially therapeutic benzodiazepines, most recent methods are not suited for 
expeditious synthesis of fully saturated benzodiazepine variants. Literature methods for 












 electrophilic aromatic 
substitution,
45
 and multicomponent reactions
46
 especially those using amino acids.
47,48,49  
In Chapter II, we illustrate a new method utilizing syn-aminopalladation of alkenes to 
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Synthesis of Saturated 1,4-Benzodiazepines via Pd-Catalyzed Carboamination 
Reactions 
 
The benzodiazepine moiety is considered a privileged scaffold in medicinal 
chemistry, and many biologically active compounds bear this core.
50
 Although much 
effort has been directed towards the construction of unsaturated 1,4-benzodiazepines,
51 
fewer methods for the synthesis of saturated derivatives have been developed.
52
 This 
remains an important goal, as saturated 1,4-benzodiazepines are displayed in both natural 
products and pharmaceutical leads (Figure II.1). For example, anthramycin (II-1) is a 
naturally occurring antitumor antibiotic,
53
 and analogs such as II-2 display 
antileishmanial activity.
54
 Benzodiazepine II-3 is an inhibitor of mitochondrial F1F0 ATP 
hydrolase, and has been examined as a potential candidate for treatment of cardiac 
ischemic conditions.
55









Our group has demonstrated that Pd-catalyzed carboamination reactions between 
aryl or alkenyl halides and amines bearing pendant alkenes are effective for the synthesis 






 However, our 
prior studies suggested that generation of seven-membered heterocycles via this strategy 
would be quite challenging, as both yields and reaction rates diminish with increasing 
ring size. This appears to be due to two main problems related to the mechanism of these 
transformations: as ring size increases, (a) Syn-aminopalladation of the alkene (Scheme 
II.1), II-6II-7, becomes more difficult due to entropic and stereoelectronic effects; and 
(b) competing formation of enamine side products II-9 or II-10, via -hydride 
elimination from intermediate II-7, becomes more problematic.
29
 The application of this 
methodology to the construction of seven-membered rings has not previously been 
demonstrated, and the formation of seven-membered nitrogen heterocycles via other 
metal-catalyzed alkene difunctionalization reactions is very rare.
61
 For example, Michael 
has described a conceptually related Pd(II)-catalyzed C–H activation/carboamination of a 
N-allyl-2-(aminomethyl)aniline derivative that afforded a 3-substituted 1,4-
benzodiazepine. However, only a single example was reported, and the yield was modest 
(53%).
36 





To determine the feasibility of forming seven-membered nitrogen heterocycles 
via Pd-catalyzed carboamination reactions, we elected to examine the synthesis of 
saturated 1,4-benzodiazepines. The substrates II-14 for these studies were prepared in 
three steps from readily available diarylamines II-11 (Scheme II.2), which can be 
generated via Pd-catalyzed N-arylation of methyl-2-aminobenzoate.
62
 Saponification of 
the ester followed by coupling of the resulting acid II-12 with an allylic amine provided 
amides II-13. Reduction of the amides with LiAlH4 then afforded II-14 in moderate to 
good yield. 
Scheme II.2 Synthesis of Substrates 
 
In our preliminary experiments we examined the Pd-catalyzed coupling of II-14a 
with 4-bromobiphenyl (Table II.1). Our previous studies indicated that use of P(2-fur)3 as 
a ligand gave satisfactory results in six-membered ring forming reactions.
27
 However, use 
of this ligand in a reaction of II-14a provided desired product II-15 in a modest 58% 
NMR yield, along with 13% of ketone II-16. This side product presumably results from 
hydrolysis of an enamine (II-9, n = 3), which is generated via a competing -hydride 
elimination pathway (Scheme II.1). In order to minimize this side reaction, several other 
monodentate ligands were examined. Use of S-Phos failed to afford the desired product. 




additional experimentation we discovered that a catalyst composed of PdCl2(MeCN)2 and 
PPh2Cy provided acceptable results (79% NMR yield), and upon isolation the desired 
product II-15 was obtained in 65% yield. 
Table II.1 Optimization of Reaction Conditions 
 
Conditions: 1.0 equiv II-14a, 2.0 equiv 4-bromobiphenyl, 2.0 equiv NaOt-Bu, 2 mol % [Pd], 4 mol % 
ligand. Product II-15 was formed with >20:1 dr. a Yields were determined by 1H NMR analysis of crude 
reaction mixtures using phenanthrene as an internal standard. b The major product resulted from N-arylation 

















Table II.2 Synthesis of Saturated 1,4-Benzodiazepines 
 
 
Conditions: Reactions were conducted on a 0.15 mmol scale using 1.0 equiv substrate, 2.0 equiv ArBr, 2.0 
equiv NaOt-Bu, 2 mol % PdCl2(MeCN)2, 4 mol % PPh2Cy, xylenes (0.2 M), 135 °C, 18–24 h reaction 
time. a Isolated yield (average of two experiments). In all cases, 2,3-disubstituted products were obtained 




As shown in Table II.2, the transformations were effective for a number of 
different substrate combinations. Aryl bromides bearing electron-donating or electron-
withdrawing groups were coupled in good yields. However, N-arylation of the substrate 
was observed with highly electron-poor aryl bromides such as 4-bromo-2-
fluorobenzonitrile. In most cases reactions were also effective for aryl bromides bearing 
o-alkyl substituents (Table II.2, entries 3, 10–11) including the very hindered 2,4,6-
triisopropylbromobenzene (Table II.2, entry 11). However, no reaction was observed in 
the attempted coupling of 1-bromo-2-chlorobenzene with II-14a, and no desired product 
was obtained in a reaction between 1-bromopentamethylbenzene and II-14d; competing 
Heck arylation of the starting material was observed. Efforts to employ alkenyl bromides 
have thus far been unsuccessful. 
Although sterically bulky aryl bromides were reasonably well-tolerated, 
transformations of hindered diamine substrates proved to be more challenging. For 
example, substrates that contained an allylic-methyl group were stereoselectively 
transformed to cis-2,3-disubstituted products with >20:1 dr (Table II.2, entries 6–11). 
However, substrates bearing either larger substituents at the allylic position, or 1,1-
disubstituted alkenes, failed to react. The electronic properties of the N-aryl group on the 
cyclizing nitrogen atom did not have a large influence on chemical yield, as substrates 
bearing N-phenyl-, N-PMP-, and N-(3,5-dichlorophenyl)-groups were all effectively 
converted to products in moderate to good yield. However, attempts to employ substrates 
with a benzyl group on the cyclizing nitrogen atom were unsuccessful. 
The stereochemical outcome of transformations involving substrates II-14a and 






 Our prior studies have indicated that 
alkene aminopalladations proceed via organized transition states in which the alkene is 
eclipsed with the Pd–N bond. This suggests reactions of substrates II-14a and II-14e, 
which afford cis-2,3-disubstituted products, most likely occur via boat-like transition 
state II-27 (Scheme II.3).
64
 Pathways leading to the trans-disubstituted products appear 
to be high in energy. Chair-like transition state II-28 suffers from unfavorable steric 
interactions between the N-aryl group and the C5 methylene unit, and boat-like transition 
state II-29 is presumably disfavored due to the axial orientation of the C3 methyl group. 
Scheme II.3 Origin of Observed Diastereoselectivity
 
 
In order to further explore the scope of benzodiazepine-forming reactions, we 
examined the use of amides II-13 as substrates for the carboamination reactions. As 
shown in Scheme II.4, the conditions that were optimized for transformations of diamine 
substrates provided good yields of II-30 in the coupling of II-13b with 4-bromobiphenyl, 
although small amounts of regioisomer II-31 were also obtained.
65
 After some additional 
optimization we found that use of P(4-F-C6H4)3 as ligand provided slightly improved 
selectivities. The regioisomer was separable by chromatography, and II-30 was obtained 




amides II-13b, II-13d, and II-13f with a number of different aryl bromides (Table II.3). 
However, efforts to employ an amide substrate bearing an allylic methyl group were 
unsuccessful; complex mixtures of regioisomers were obtained.  
Scheme II.4 Subtle Differences in Regioselectivity
 
 
In conclusion we have developed an efficient entry into saturated 1,4-
benzodiazepines and 1,4-benzodiazepin-5-ones via Pd-catalyzed alkene carboamination 
reactions. The method is effective for a variety of different aryl bromide coupling 
partners, and cis-2,3-disubstituted 1,4-benzodiazepines are formed with >20:1 dr. These 
transformations are rare examples of 7-membered ring-forming alkene 
difunctionalization reactions. Further studies toward enantioselective synthesis of 1,4-
benzodiazepines and application of this strategy to biologically active targets are 











Table II.3 Synthesis of 1,4-Benzodiazepin-5-one Products 
 
 
Conditions: Reactions were conducted on a 0.15 mmol scale using 1.0 equiv substrate, 2.0 equiv ArBr, 2.0 
equiv NaOt-Bu, 1 mol % Pd2(dba)3, 4 mol % P(4-F-C6H4)3, xylenes (0.2 M), 135 °C, 18–24 h reaction 
time. a Isolated yield (average of two experiments). 
 
Experimental 
All reactions were carried out under a dry nitrogen atmosphere in flame-dried 
glassware using standard Schlenk techniques. All reagents were obtained from 
commercial sources and used without further purification. Toluene, THF, diethyl ether, 



















 and tert-butyl 4-bromobenzoate
70
 were prepared according 
to literature procedures. (E)-but-2-enyl acetate was prepared by treatment of crotyl 
alcohol with acetic anhydride, triethylamine and DMAP at rt in dichloromethane. Yields 
refer to isolated yields of compounds estimated to be ≥95% pure as determined by 
1
H 
NMR analysis unless otherwise noted. The product yields reported in the experimental 
section are the result of a single experiment whereas the yields in Chapter II are an 
average of two experiments.  
 
General Procedure 1: Saponifcation of Benzoate Substrates. A flask equipped with a 
magnetic stirbar was charged with the benzoate substrate (1.0 equiv) and a 1:1 mixture of 
water:EtOH (7.5 mL/mmol substrate). Finely ground KOH (2.5 equiv) was added, and 
the resulting mixture was heated to reflux for 3 h. The mixture was then cooled to rt and 
concentrated to remove all of the EtOH. Additional water (15 mL) was added, the 
mixture was acidified to pH ~ 2 with HCl (1 M), and a precipitate formed. The precipitate 
was collected by filtration and the crude product was purified by flash column 
chromatography on silica gel to furnish the pure carboxylic acid product.  
 
General Procedure 2: Peptide Coupling of Acid Substrates with Allylic Amines. A 
flame-dried flask equipped with a magnetic stirbar was charged with the appropriate 




was purged with nitrogen for 5 min, then the appropriate allylic amine substrate (1.0 
equiv), diisopropylethylamine (3.0 equiv), and dichloromethane (3 mL/mmol substrate) 
were added. The resulting clear solution was stirred for ca. 2 min, then 
diisopropylcarbodiimide (1.05 equiv) was added. The reaction mixture was stirred for 
12–24 h and then concentrated in vacuo. The crude material was purified by flash column 
chromatography on silica gel to afford the pure benzamide product. 
 
General Procedure 3: Reduction of Amides to Amine Substrates. A flame-dried flask 
equipped with a magnetic stirbar was charged with the appropriate benzamide substrate 
(1.0 equiv) and purged with nitrogen for 5 min. THF (1 mL/mmol substrate) was added, 
the resulting solution was cooled to 0 °C, and a 1 M solution of LiAlH4 in diethyl ether 
(1.0 equiv) was added slowly over 5 min. The reaction mixture was stirred at 0 °C for 15 
min then warmed to rt and stirred until TLC analysis indicated complete consumption of 
starting material. The reaction mixture was cooled to 0 °C, then water (0.05 mL/mmol 
substrate), 6 M NaOH (0.05 mL/mmol substrate) and additional water (0.15 mL/mmol 
substrate) were sequentially added. The resulting white suspension was stirred vigorously 
for 30 min, then filtered and the white precipitate was washed with diethyl ether (3 × 30 
mL). The organic solution was dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The resulting product was purified by flash column 
chromatography on silica gel.  
 
N-Allyl-N-benzyl-2-(phenylamino)benzamide (II-13b). 2-(Phenylamino)benzoic acid 




24 h using General Procedure 2. Flash chromatography on silica gel (90:10 hexanes:ethyl 
acetate) afforded 1.40 g (89%) of the title compound as a white solid, m.p. 73–75 °C. 
1
H 
NMR (500 MHz, CDCl3, 60 °C) δ 7.33 (d, J = 8.0 Hz, 1 H), 7.29–7.18 (m, 8 H), 7.04 (d, 
J = 8.0 Hz, 2 H), 6.97–6.89 (m, 2 H), 6.83 (t, J = 8.0 Hz, 1 H), 5.81–5.69 (m, 1 H), 5.20–
5.08 (m, 2 H), 4.67 (s, 2 H), 4.04–3.90 (m, 2 H); 
13
C NMR (100 MHz, CDCl3, 60°C) δ 
171.4, 142.6, 142.2, 136.9, 133.0, 130.2, 129.3, 128.7, 127.7, 127.49, 127.47, 124.7, 
121.5, 119.8, 118.9, 117.9, 117.7, 49.4, one aliphatic carbon signal is incidentally 
equivalent; IR (film) 3332, 1627 cm
–1
. MS (ESI) 343.1801 (343.1805 calcd for 




N-Allyl-N-benzyl-2-(3,5-dichlorophenylamino)benzamide (II-13d). Methyl 2-(3,5-
dichlorophenylamino)benzoate (2.50 g, 8.4 mmol) was saponified according to General 
Procedure 1. Purification via flash chromatography on silica gel using 50:50 
hexanes:ethyl acetate → 100% ethyl acetate as the eluent to afforded 1.81 g (76%) of 2-
(3,5-dichlorophenylamino)benzoic acid as a fluffy white solid, m.p. 245–246 °C. 
1
H 
NMR (400 MHz, DMSO-d6) δ 13.1 (s, br, 1 H), 9.54 (s, br, 1 H), 7.91 (d, J = 8.0 Hz, 1 
H), 7.52–7.44 (m, 1 H), 7.35 (d, J = 8.4 Hz, 1 H), 7.22 (d, J = 2.0 Hz, 2 H), 7.11 (s, 1 H), 
6.95 (t, J = 7.2 Hz, 1 H); 
13
C NMR (125 MHz, DMSO-d6) δ 169.3, 144.3, 144.2, 134.7, 
134.1, 131.9, 120.7, 120.0, 117.3, 116.6, 115.9. 
The above 2-(3,5-dichlorophenylamino)benzoic acid (998 mg, 3.5 mmol) was 
coupled with N-benzylprop-2-en-1-amine (556 mg, 3.8 mmol) for 15 h using General 
Procedure 2. Flash chromatography on silica gel (85:15 hexanes:ethyl acetate) afforded 
1.24 g (85%) of the title compound as a white solid, m.p. 131–132 °C. 
1




MHz, CDCl3, 62 °C) δ 7.38–7.21 (m, 7 H), 7.17 (s, br, 1 H), 7.07–7.00 (m, 1 H), 6.97 (dt, 
J = 0.8, 7.6 Hz, 1 H), 6.88–6.83 (m, 3 H), 5.81–5.66 (m, 1 H), 5.22–5.07 (m, 2 H), 4.65 
(s, 2 H), 4.04–3.83 (m, 2 H); 
13
C NMR (100 MHz, CDCl3, 62 °C) δ 170.8, 145.2, 139.9, 
136.7, 135.7, 130.6, 128.9, 128.6, 127.7, 127.5, 121.9, 121.8, 120.5, 120.4, 118.1, 115.3, 
115.2, 49.1, two aliphatic carbon signals are incidentally equivalent; IR (film) 3298, 1621 
cm
–1




N-Allyl-N-octyl-2-(phenylamino)benzamide (II-13f). Methyl 2-(phenylamino)benzoate 
(2.76 g, 12.1 mmol) was saponified according to General Procedure 1. Purification via 
flash chromatography on silica gel using 70:30 hexanes:ethyl acetate as the eluent to 
afforded 1.96 g (76%) of 2-(phenylamino)benzoic acid as a white solid, m.p. 185–187 
°C. 
1
H NMR (400 MHz, CDCl3, 60 °C) δ 10.8 (s, br, 1 H), 9.32 (s, br, 1 H), 8.04 (dd, J = 
0.8, 6.4 Hz, 1 H), 7.40–7.32 (m, 3 H), 7.30–7.20 (m, 3 H), 7.13 (t, J = 5.6 Hz, 1 H), 6.76 
(t, J = 6.0 Hz, 1 H); 
13
C NMR (100 MHz, CDCl3, 60 °C) δ 173.7, 148.9, 140.3, 135.2, 
132.6, 129.4, 124.1, 123.2, 117.2, 114.0, 110.4; IR (film) 3339, 1658 cm
–1
. 
The above 2-(phenylamino)benzoic acid (1.0 g, 4.7 mmol) was coupled with N-
allyloctan-1-amine (790 mg, 4.7 mmol) for 24 h using General Procedure 2. Flash 
chromatography on silica gel (90:10 hexanes:ethyl acetate) afforded 1.55 g (91%) of the 
title compound as a viscous, colorless oil. 
1
H NMR (400 MHz, CDCl3, 60°C) δ 7.33 (d, J 
= 8 Hz, 1 H), 7.29–7.15 (m, 4 H), 7.05 (d, J = 7.6 Hz, 2 H), 6.92 (t, J = 7.2 Hz, 1 H), 
6.88–6.81 (m, 2 H), 5.87–5.71 (m, 1 H), 5.23–5.12 (m, 2 H), 4.10–3.96 (m, 2 H), 3.46–
3.31 (m, 2 H), 1.61–1.48 (m, 2 H), 1.31–1.15 (m, 10 H), 0.86 (t, J = 6.4 Hz, 3 H); 
13
C 




121.4, 119.6, 119.0, 118.8, 117.4, 46.8, 31.8, 29.2, 29.1, 27.9, 26.9, 22.6, 13.9, one 
aliphatic carbon signal is incidentally equivalent; IR (film) 3311, 1622 cm
–1
. MS (ESI) 





(phenylamino)benzamide (4.95 g, 14.5 mmol) was reduced according General Procedure 
3. Flash chromatography on silica gel (98:2 hexanes:ethyl acetate) afforded 3.19 g (67%) 
of the title compound as a white solid, m.p. 70–71 °C . 
1
H NMR (400 MHz, CDCl3) δ 
8.47 (s, br, 1 H), 7.38 (d, J = 8.0 Hz, 1 H), 7.32–7.15 (m, 11 H), 6.89 (t, J = 7.2 Hz, 1 H), 
6.78 (t, J = 7.2 Hz, 1 H), 5.96–5.84 (m, 1 H), 5.18 (dd, J = 2.4, 14.4 Hz, 2 H), 3.66 (s, 2 
H), 3.54 (s, 2 H), 3.06 (d, J = 6.4 Hz, 2 H); 
13
C NMR (100 MHz, CDCl3) δ 143.5, 143.0, 
138.6, 134.4, 131.1, 129.3, 129.2, 128.4, 128.1, 127.1, 125.2, 120.2, 119.2, 118.8, 117.7, 
114.9, 57.9, 57.7, 55.8;  IR (film) 3255, 1593 cm
–1
. MS (ESI) 329.2017 (329.2018 calcd 




2-{[Allyl(benzyl)amino]methyl}-N-(4-methoxyphenyl)aniline (II-14c). Methyl 2-(4-
methoxyphenylamino)benzoate (6.12 g, 23.8 mmol) was saponified according to General 
Procedure 1. Purification via flash chromatography on silica gel using 50:50 
hexanes:ethyl acetate → 100% ethyl acetate as the eluent to afforded 5.20 g (89%) of 2-
(4-methoxyphenylamino)benzoic acid as a light yellow solid, m.p. 185–186 °C. 
1
H NMR 
(500 MHz, CDCl3) δ 11.7 (s, br, 1 H), 9.14 (s, br, 1 H), 8.02 (dd, J = 1.5, 8.0 Hz, 1 H), 




3.83 (s, 3 H); 
13
C NMR (100 MHz, CDCl3) δ 173.5, 157.0, 150.5, 135.2, 132.9, 132.5, 
126.4, 116.3, 114.7, 113.4, 109.4, 55.5; IR (film) 3323, 1664 cm
–1
. 
The above 2-(4-methoxyphenylamino)benzoic acid (2.0 g, 8.2 mmol) was coupled 
with N-benzylprop-2-en-1-amine (1.2 g, 8.2 mmol) for 18 h using General Procedure 2. 
Flash chromatography on silica gel (80:20 hexanes:ethyl acetate) afforded 2.96 g (97%) 
of N-allyl-N-benzyl-2-(4-methoxyphenylamino)benzamide as a viscous, yellow oil. 
1
H 
NMR (400 MHz, CDCl3, 60 °C) δ 7.40–7.02 (m, 10 H), 6.89–6.83 (m, 2 H), 6.79–6.71 
(m, 1 H), 5.84–5.75 (m, 1 H), 5.22–5.11 (m, 2 H), 4.69 (s, 2 H), 3.98 (d, J = 4.4 Hz, 2 H), 
3.79 (s, 3 H); 
13
C NMR (125 MHz, CDCl3, 60 °C) δ 171.7, 155.8, 144.2, 137.1, 135.4, 
133.1, 130.4, 128.8, 127.8, 127.52, 127.51, 123.0, 122.6, 118.4, 117.9, 115.6, 115.0, 55.7, 
49.6, 2 aliphatic carbon signals are incidentally equivalent; IR (film) 3351, 1626 cm
–1
. 
MS (ESI) 373.1911 (373.1911 calcd for C24H24N2O2, [M + H]
+
). 
N-Allyl-N-benzyl-2-(4-methoxyphenylamino)benzamide (2.96 g, 8.0 mmol) was 
reduced according General Procedure 3. Flash chromatography on silica gel (95:5 
hexanes:ethyl acetate) afforded 1.68 g (59%) of the title compound as an off-white, solid, 
m.p. 59–60 °C. 
1
H NMR (400 MHz, CDCl3) δ 8.19 (s, br, 1 H), 7.29 (d, J = 4.4 Hz, 4 H), 
7.26–7.19 (m, 1 H), 7.16–7.02 (m, 5 H), 6.89–6.83 (m, 2 H), 6.72 (dt, J = 1.6, 6.8 Hz, 1 
H), 5.97–5.85 (m, 1 H), 5.22–5.15 (m, 2 H), 3.80 (s, 3 H), 3.66 (s, 2 H), 3.55 (s, 2 H), 
3.06 (d, J = 6.8 Hz, 2 H); 
13
C NMR (100 MHz, CDCl3) δ 154.5, 145.1, 138.7, 136.1, 
134.5, 131.0, 129.2, 128.3, 128.2, 127.1, 123.8, 121.3, 118.7, 118.1, 114.6, 113.0, 58.0, 
57.6, 55.8, 55.6; IR (film) 3240, 1599 cm
–1
. MS (ESI) 359.2120 (359.2133 calcd for 







benzyl-2-(3,5-dichlorophenylamino)benzamide (950 mg, 2.3 mmol) was reduced 
according General Procedure 3. Flash chromatography on silica gel (98:2 hexanes:ethyl 
acetate) afforded 712 mg (78%) of the title compound as a viscous, colorless oil. 
1
H 
NMR (500 MHz, CDCl3) δ 8.56 (s, br, 1 H), 7.35–7.17 (m, 7 H), 7.15 (dd, J = 1.0, 7.5 
Hz, 1 H), 6.89 (dt, J = 1.0, 7.5 Hz, 1 H), 6.86–6.76 (m, 3 H), 5.93–5.82 (m, 1 H), 5.24–
5.15 (m, 2 H), 3.61 (s, 2 H), 3.52 (s, 2 H), 3.04 (d, J = 7.0 Hz, 2 H); 
13
C NMR (100 MHz, 
CDCl3) δ 145.3, 141.6, 138.3, 135.3, 134.2, 131.3, 129.3, 128.5, 128.3, 127.4, 126.7, 
121.2, 119.23, 119.17, 117.1, 114.4, 57.9, 57.5, 56.0; IR (film) 3238, 1594 cm
–1
. MS 





Methoxyphenylamino)benzoic acid (494 mg, 1.8 mmol) was coupled with N-benzylbut-
3-enyl-2-amine (314 mg, 1.9 mmol) for 22 h using General Procedure 2. Flash 
chromatography on silica gel (80:20 hexanes:ethyl acetate) afforded 499 mg (66%) of N-
benzyl-N-(but-3-en-2-yl)-2-(4-methoxyphenylamino)benzamide as a viscous, yellow oil. 
1
H NMR (500 MHz, CDCl3, 60 °C) δ 7.37–7.10 (m, 6 H), 7.07–6.97 (m, 3 H), 6.88–6.83 
(m, 2 H), 6.76 (dt, J = 1.0, 7.5 Hz, 1 H), 6.69–6.63 (m, 1 H), 5.95–5.84 (m, 1 H), 5.19–
5.08 (m, 2 H), 4.88–4.80 (m, 1 H), 4.77 (d, J = 15.5 Hz, 1 H), 4.44 (d, J = 16.0 Hz, 1 H), 
3.79 (s, 3 H), 1.24 (d, J = 7.0 Hz, 3 H); 
13
C NMR (125 MHz, CDCl3, 60 °C) δ 172.1, 
155.8, 144.0, 138.6, 135.4, 130.2, 128.4, 127.30, 127.26, 126.9, 123.6, 122.4, 118.6, 




equivalent; IR (film) 3354, 1626 cm
–1
. MS (ESI) 387.2067 (387.2067 calcd for 
C25H26N2O2, [M + H]
+
). 
The above N-benzyl-N-(but-3-en-2-yl)-2-(4-methoxyphenylamino)benzamide 
(1.49 g, 2.0 mmol) was reduced according General Procedure 3. Flash chromatography 
on silica gel (95:5 hexanes:ethyl acetate) afforded 701 mg (49%) of the title compound as 
a viscous, colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 8.10 (s, br, 1 H), 7.35–7.05 (m, 8 
H), 7.01 (d, J = 8.8 Hz, 2 H), 6.85 (d, J = 8.8 Hz, 2 H), 6.69 (dt, J = 2.0, 7.2 Hz, 1 H), 
6.03–5.91 (m, 1 H), 5.23 (d, J = 10.4 Hz, 1 H), 5.11 (d, J = 17.2 Hz, 1 H), 3.80 (s, 3 H), 
3.74 (d, J = 12.8 Hz, 1 H), 3.65–3.55 (m, 2 H), 3.53–3.46 (m, 1 H), 3.38 (quint, J = 6.4 
Hz, 1 H), 1.22 (d, J = 6.8 Hz, 3 H); 
13
C NMR (100 MHz, CDCl3) δ 154.4, 145.2, 139.6, 
138.4, 136.0, 131.1, 129.1, 128.3, 128.1, 127.0, 123.7, 121.3, 118.0, 116.9, 114.5, 112.9, 
55.6, 55.1, 53.61, 53.57, 14.5; IR (film) 3240, 1599 cm
–1
. MS (ESI) 373.2276 (373.2274 




2-{[Benzyl(but-3-en-2-yl)amino]methyl}-N-phenylaniline (II-14e).  
2-(Phenylamino)benzoic acid (995 mg, 4.7 mmol) was coupled with N-benzylbut-3-enyl-
2-amine (748 mg, 4.6 mmol) for 22 h using General Procedure 2. Flash chromatography 
on silica gel (80:20 hexanes:ethyl acetate) afforded 1.52 g (92%) of N-benzyl-N-(but-3-
en-2-yl)-2-(phenylamino)benzamide as a viscous, yellow oil. 
1
H NMR (400 MHz, 
CDCl3, 60 °C) δ 7.31 (d, J = 8.0 Hz, 1 H), 7.28–7.13 (m, 8 H), 7.02 (d, J = 8.4 Hz, 2 H), 
6.93 (t, J = 7.6 Hz, 1 H), 6.88–6.79 (m, 2 H), 5.91–5.78 (m, 1 H), 5.15–5.04 (m, 2 H), 
4.85–4.72 (m, 2 H), 4.41 (d, J = 15.6 Hz, 1 H), 1.20 (d, J = 6.8 Hz, 3 H); 
13
C NMR (100 




126.9, 126.6, 125.6, 121.4, 120.0, 118.8, 117.8, 116.3, 55.6, 46.7, 17.9; IR (film) 3377, 
1624 cm
–1
. MS (ESI) 357.1962 (357.1961 calcd for C24H24N2O, [M + H]
+
). 
The above N-benzyl-N-(but-3-en-2-yl)-2-(phenylamino)benzamide (5.34 g, 15 
mmol) was reduced according General Procedure 3. Flash chromatography on silica gel 
(98:2 hexanes:ethyl acetate) afforded 3.17 g (62%) of the title compound as a viscous, 
light yellow oil. 
1
H NMR (400 MHz, CDCl3) δ 8.42 (s, br, 1 H), 7.35 (d, J = 8.0 Hz, 1 H), 
7.33–7.01 (m, 9 H), 7.05 (d, J = 8.4 Hz, 2 H), 6.88 (dt, J = 0.8, 7.6 Hz, 1 H), 6.77 (t, J = 
7.2 Hz, 1 H), 6.03–5.91 (m, 1 H), 5.22 (d, J = 10.4 Hz, 1 H), 5.11 (d, J = 17.2 Hz, 1 H), 
3.76 (d, J = 13.2 Hz, 1 H), 3.65–3.54 (m, 2 H), 3.49 (d, J = 13.2 Hz, 1 H), 3.37 (quint, J = 
6.8 Hz, 1 H), 1.22 (d, J = 6.4 Hz, 3 H); 
13
C NMR (100 MHz, CDCl3) δ 143.5, 142.9, 
139.5, 138.3, 131.2, 129.2, 129.1, 128.4, 128.0, 127.0, 125.0, 120.2, 119.2, 117.8, 117.0, 
114.6, 55.2, 53.7, 53.5, 14.5; IR (film) 3253, 1593 cm
–1
. MS (ESI) 343.2171 (343.2169 




General Procedure 4: Pd-Catalyzed Synthesis of 1,4-Benzodiazepines. A flame-dried 
Schlenk tube was cooled under a stream of nitrogen and charged with PdCl2(MeCN)2 (2 
mol %), PPh2Cy (4 mol %), NaOt-Bu (2.0 equiv), and ArBr (2.0 equiv). The tube was 
purged with nitrogen and a solution of the amine substrate (1.0 equiv) in xylenes (5 
mL/mmol amine) was added. The mixture was heated to 135 °C with stirring until the 
starting material had been consumed as judged by TLC analysis (18–24 h; the reaction 
times were not minimized). The reaction mixture was cooled to room temperature, 
quenched with saturated aqueous NH4Cl (2 mL) and diluted with ethyl acetate (10 mL). 




mL). The combined organic extracts were dried over anhydrous sodium sulfate, filtered, 
and concentrated in vacuo. The crude product was then purified by flash chromatography 
on silica gel. 
 
4-Benzyl-1-phenyl-2-(3,4,5-trimethoxybenzyl)methyl]-2,3,4,5-tetrahydro-1H-
benzo[e][1,4]diazepine (II-17). General Procedure 4 was used for the coupling of 2-
{[allyl(benzyl)amino]methyl}-N-phenylaniline (50 mg, 0.15 mmol) with 5-bromo-1,2,3-
trimethoxybenzene (75 mg, 0.30 mmol) to afford 60 mg (79%) of the title compound as a 
foamy, white solid with a wide m.p. range 51–64 °C. 
1
H NMR (500 MHz, CDCl3) δ 
7.41–7.36 (m, 2 H), 7.33 (t, J = 8.0 Hz, 2 H), 7.29–7.21 (m, 2 H), 7.18–7.12 (m, 4 H), 
7.05 (d, J = 8.0 Hz, 1 H), 6.77–6.71 (m, 3 H), 6.40 (s, 2 H), 4.49 (m, 1 H), 3.81 (s, 3 H), 
3.73 (s, 6 H), 3.72–3.63 (m, 2 H), 3.60 (d, J = 14.0 Hz, 1 H), 3.41 (d, J = 13.0 Hz, 1 H), 
2.81–2.67 (m, 4 H); 
13
C NMR (100 MHz, CDCl3) δ 153.0, 148.5, 143.7, 139.3, 137.1, 
136.3, 135.5, 130.4, 129.7, 129.1, 128.4, 128.3, 127.8, 127.0, 125.6, 118.2, 115.4, 106.1, 
62.6, 60.8, 58.9, 57.9, 57.7, 56.0, 39.0; IR (film) 1591 cm
–1
. MS (ESI) 495.2637 





benzo[e][1,4]diazepine (II-18). General Procedure 4 was used for the coupling of 2-
{[allyl(benzyl)amino]methyl}-N-phenylaniline (51 mg, 0.15 mmol) with 4-
bromobiphenyl (71 mg, 0.30 mmol) to afford 65 mg (88%) of the title compound as a 
foamy, white solid with a wide m.p. range 50–66 °C. 
1
H NMR (400 MHz, CDCl3) δ 




4.55–4.47 (m, 1 H), 3.67–3.59 (m, 3 H), 3.44 (d, J = 12.8 Hz, 1 H), 2.90–2.71 (m, 4 H); 
13
C NMR (100 MHz, CDCl3) δ 148.6, 143.8, 141.0, 139.3, 139.0, 138.9, 137.0, 130.4, 
129.6, 129.5, 129.2, 128.9, 128.7, 128.3, 128.0, 127.04, 127.03, 126.9, 125.6, 118.2, 
115.5, 62.7, 59.0, 58.0, 56.8, 37.3, one aromatic carbon signal is incidentally equivalent; 
IR (film) 1593 cm
–1





benzo[e][1,4]diazepine (II-19). General Procedure 4 was used for the coupling of 2-
{[allyl(benzyl)amino]methyl}-N-(4-methoxyphenyl)aniline (49 mg, 0.14 mmol) with 1-
bromo-2-ethylbenzene (39 μL, 0.28 mmol) to afford 60 mg (94%) of the title compound 
as a viscous, colorless oil. 
1
H NMR (500 MHz, CDCl3) δ 7.42–7.38 (m, 2 H), 7.34 (t, J = 
7.5 Hz, 2 H), 7.31–7.26 (m, 1 H), 7.20–7.01 (m, 7 H), 6.94 (d, J = 8.0 Hz, 1 H), 6.77–
6.73 (m, 2 H), 6.72–6.67 (m, 2 H), 4.36–4.30 (m, 1 H), 3.75 (s, 3 H), 3.68 (d, J = 14.0 
Hz, 2 H), 3.59 (d, J = 13.5 Hz, 1 H), 3.40 (d, J = 13.0 Hz, 1 H), 2.83 (d, J = 7.0 H, 2 H), 
2.77–2.55 (m, 4 H), 1.15 (t, J = 7.5 Hz, 3 H); 
13
C NMR (100 MHz, CDCl3) δ 152.9, 
145.4, 143.0, 142.3, 139.3, 137.6, 136.0, 130.2, 130.1, 128.8, 128.30, 128.27, 127.8, 
127.0, 126.3, 125.7, 124.3, 118.8, 114.6, 62.7, 59.2, 59.1, 57.6, 55.6, 34.5, 25.4, 15.3, one 
aromatic carbon signal is incidentally equivalent; IR (film) 1507 cm
–1
. MS (ESI) 





1H-benzo[e][1,4]diazepine (II-20). General Procedure 4 was used for the coupling of N-




1-bromo-4-(trifluoromethyl)benzene (38 μL, 0.27 mmol) to afford 53 mg (74%) of the 
title compound as a viscous, colorless oil. 
1
H NMR (500 MHz, CDCl3) δ 7.46 (d, J = 8.0 
Hz, 2 H), 7.38–7.24 (m, 7 H), 7.21 (d, J = 6.5 Hz, 1 H), 7.16 (d, J = 8.0 Hz, 2 H), 6.97 (d, 
J = 7.0 Hz, 1 H), 6.69 (t, J = 2.0 Hz, 1 H), 6.48 (d, J = 1.0 Hz, 2 H), 4.45–4.35 (m, 1 H), 
3.67 (d, J = 13.0 Hz, 1 H), 3.60 (d, J = 13.0 Hz, 2 H), 3.38 (d, J = 13 Hz, 1 H), 2.85–2.65 
(m, 4 H); 
13
C NMR (100 MHz, CDCl3) δ 149.7, 143.1, 141.2, 138.8, 135.6, 130.8, 130.0, 
129.4, 128.9, 128.5, 128.43, 128.40, 127.4, 127.3, 125.33, 125.29, 124.2 (q, J = 272 Hz), 
117.5, 112.2, 62.9, 59.2, 57.2, 37.6, 29.7; 
19
F NMR (376 MHz, CDCl3) δ –62.4 (m); IR 
(film) 1580 cm
–1





1H-benzo[e][1,4]diazepine (II-21). General Procedure 4 was used for the coupling of N-
{2-[(allyl<benzyl>amino)methyl]phenyl}-3,5-dichloroaniline (53 mg, 0.13 mmol) with 
1-bromo-3-(trifluoromethyl)benzene (38 μL, 0.27 mmol) to afford 56 mg (78%) of the 
title compound as a viscous, colorless film. 
1
H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 
7.2 Hz, 1 H), 7.38–7.22 (m, 10 H), 7.19 (d, J = 6.8 Hz, 1 H), 6.92 (d, J = 6.8 Hz, 1 H), 
6.63 (t, J = 1.6 Hz, 1 H), 6.47 (d, J = 1.2 Hz, 2 H), 4.41 (m, 1 H), 3.64 (s, 2 H), 3.60 (d, J 
= 13.2 Hz, 1 H), 3.36 (d, J = 13.2 Hz, 1 H), 2.85–2.67 (m, 4 H); 
13
C NMR (100 MHz, 
CDCl3) δ 149.8, 141.2, 139.8, 138.7, 137.5, 135.6, 132.3, 130.8, 130.5, 130.1, 128.8, 
128.4, 127.33, 127.26, 126.20, 126.16, 124.1 (q, J = 272 Hz), 123.3, 123.2, 117.5, 112.3, 
62.9, 58.9, 57.4, 37.5, 29.7; 
19
F NMR (376 MHz, CDCl3) δ –62.6 (m); IR (film) 1580 cm
–
1








tetrahydro-1H-benzo[e][1,4]diazepine (II-15). General Procedure 4 was used for the 
coupling of 2-{[benzyl(but-3-en-2-yl)amino]methyl}-N-(4-methoxyphenyl)aniline (52 
mg, 0.14 mmol) with 4-bromobiphenyl (64 mg, 0.28 mmol) to afford 48 mg (65%) of the 
title compound as a viscous, colorless oil. 
1
H NMR (500 MHz, CDCl3) δ 7.60 (d, J = 7.5 
Hz, 2 H), 7.52 (d, J = 7.5 Hz, 2 H), 7.48–7.18 (m, 11 H), 7.12–7.04 (m, 2 H), 6.89 (d, J = 
8.0 Hz, 1 H), 6.63 (d, J = 9.0 Hz, 2 H), 6.47 (d, J = 9.0 Hz, 2 H), 4.41 (td, J = 2.3, 11.0 
Hz, 1 H), 3.85–3.65 (m, 7 H), 3.48 (dq, J = 2.0, 6.8 Hz, 1 H), 2.97 (d, J = 13.5 Hz, 1 H), 
2.50 (dd, J = 10.5, 14.0 Hz, 1 H), 1.42 (d, J = 7.0 Hz, 3 H); 
13
C NMR (100 MHz, CDCl3) 
δ 152.8, 145.0, 143.4, 141.0, 140.8, 140.0, 138.8, 137.0, 130.8, 129.7, 129.5, 128.7, 
128.5, 128.3, 127.9, 127.0, 126.98, 126.95, 126.8, 124.3, 119.0, 114.4, 67.5, 61.2, 57.1, 
55.6, 52.4, 33.8, 19.2; IR (film) 1504 cm
–1
. MS (ESI) 525.2909 (525.2900 calcd for 




(±)-3-{benzyl[2-(phenylamino)benzyl]amino}butan-2-one (II-16). General Procedure 
4 was used for the coupling of 2-{[benzyl(but-3-en-2-yl)amino]methyl}-N-phenylaniline 
(49 mg, 0.14 mmol) with 1-bromo-3,5-dichlorobenzene (66 mg, 0.29 mmol) to afford 8.7 
mg (12%) of the title compound as a viscous, colorless film. 
1
H NMR (500 MHz, CDCl3) 
δ 7.82 (s, br, 1 H), 7.37–7.31 (m, 3 H), 7.30–7.11 (m, 7 H), 7.09–7.04 (m, 2 H), 6.90 (tt, J 
= 1.0, 7.5 Hz, 1 H), 6.77 (td, J = 7.5, 1.5 Hz, 1 H), 3.89 (d, J = 13.0 Hz, 1 H), 3.72 (d, J = 
13.0 Hz, 1 H), 3.53 (d, J = 13.0 Hz, 1 H), 3.44 (q, J = 7.0 Hz, 1 H), 3.42 (d, J = 13.5 Hz, 
1 H), 2.15 (s, 3 H), 1.28 (d, J = 7 Hz, 3 H); 
13
C NMR (100 MHz, CDCl3) δ 209.6, 143.3, 




115.0, 62.8, 54.6, 53.9, 27.9, 8.1; IR (film) 1714, 1593 cm
–1
. MS (ESI) 359.2117 





2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine (II-22). General Procedure 4 was used 
for the coupling of 2-{[benzyl(but-3-en-2-yl)amino]methyl}-N-phenylaniline (50 mg, 
0.15 mmol) with 2-bromo-6-methoxynaphthalene (70 mg, 0.28 mmol) to afford 59 mg 
(81%) of the title compound as a foamy, light yellow solid with a wide m.p. range 51–69 
°C. This material contained ca. 8% of ketone II-16, which could not be separated by 
chromatography. 
1
H NMR (400 MHz, CDCl3) δ 7.66 (d, J = 8.4 Hz, 1 H), 7.61 (d, J = 9.6 
Hz, 1 H), 7.43–7.15 (m, 9 H), 7.12–7.07 (m, 3 H), 7.06–7.00 (m, 2 H), 6.86 (dd, J = 2.0, 
7.2 Hz, 1 H), 6.63 (t, J = 7.2 Hz, 1 H), 6.54 (d, J = 8.0 Hz, 2 H), 4.68 (dt, J = 2.0, 10.8 
Hz, 1 H), 3.90 (s, 3 H), 3.80 (d, J = 14.0 Hz, 1 H), 3.73–3.63 (m, 3 H), 3.58 (dd, J = 2.4, 
6.8 Hz, 1 H), 3.07 (dd, J = 2.0, 15.2 Hz, 1 H), 2.54 (dd, J = 10.8, 15.2 Hz, 1 H), 1.46 (d, J 
= 7.2 Hz, 3 H); 
13
C NMR (100 MHz, CDCl3) δ 157.2, 148.8, 143.4, 140.8, 138.4, 135.2, 
133.1, 131.1, 130.9, 129.0, 128.9, 128.4, 128.3, 127.8, 127.7, 127.3, 126.8, 126.7, 125.6, 
118.6, 117.7, 115.3, 110.0, 105.6, 64.6, 60.8, 56.8, 55.3, 52.1, 33.6, 19.1; IR (film) 1605, 
1592 cm
–1





benzo[e][1,4]diazepin-2-yl)methyl]-N,N-dimethylaniline (II-23). General Procedure 4 
was used for the coupling of 2-{[benzyl(but-3-en-2-yl)amino]methyl}-N-(4-




0.28 mmol) to afford 55 mg (81%) of the title compound as a viscous, colorless film. 
This material contained ca. 8% of ketone II-16, which could not be separated by 
chromatography. 
1
H NMR (400 MHz, CDCl3) δ 7.42–7.16 (m, 6 H), 7.11–6.99 (m, 4 H), 
6.90 (d, J = 7.6 Hz, 1 H), 6.69 (d, J = 8.4 Hz, 2 H), 6.63 (d, J = 9.2 Hz, 2 H), 6.47 (d, J = 
9.2 Hz, 2 H), 4.32 (td, J = 2.0, 10.4 Hz, 1 H), 3.81–3.67 (m, 6 H), 3.64 (d, J = 14.0 Hz, 1 
H), 3.51–3.41 (m, 1 H), 2.91 (s, 6 H), 2.83 (dd, J = 2.0, 14.8 Hz, 1 H), 2.33 (dd, J = 10.8, 
14.8 Hz, 1 H), 1.38 (d, J = 6.8 Hz, 3 H); 
13
C NMR (100 MHz, CDCl3) δ 152.6, 149.1, 
145.3, 143.6, 140.9, 136.9, 130.8, 129.7, 129.6, 128.8, 128.5, 128.2, 127.8, 126.7, 124.0, 
119.1, 114.4, 113.0, 67.7, 61.2, 57.0, 55.6, 52.1, 40.9, 33.1, 19.1; IR (film) 1506 cm
–1
. 





1H-benzo[e][1,4]diazepine (II-24). General Procedure 4 was used for the coupling of 2-
{[benzyl(but-3-en-2-yl)amino]methyl}-N-phenylaniline (49 mg, 0.14 mmol) with 1-
bromo-3,5-dichlorobenzene (66 mg, 0.29 mmol) to afford 44 mg (63%) of the title 
compound as a viscous, colorless film. 
1
H NMR (400 MHz, CDCl3) δ 7.41–7.33 (m, 4 
H), 7.32–7.22 (m, 2 H), 7.21–7.03 (m, 5 H), 7.01–6.97 (m, 2 H), 6.85 (dd, J = 1.2, 7.6 
Hz, 1 H), 6.70 (t, J = 7.2 Hz, 1 H), 6.55 (d, J = 8.0 Hz, 2 H), 4.52 (td, J = 2.4, 11.6 Hz, 1 
H), 3.69 (s, 2 H), 3.63–3.57 (m, 2 H), 3.50 (dq, J = 2.4, 6.8 Hz, 1 H), 2.90 (dd, J = 2.4, 
15.2 Hz, 1 H), 2.41 (dd, J = 11.2, 15.2 Hz, 1 H), 1.41 (d, J = 7.2 Hz, 3 H); 
13
C NMR (100 
MHz, CDCl3) δ 148.5, 143.7, 142.9, 140.5, 138.3, 134.5, 131.0, 130.8, 129.2, 128.33, 
128.30, 127.5, 126.9, 126.3, 125.9, 118.2, 115.4, 64.5, 60.6, 57.0, 52.7, 33.2, 19.1; IR 
(film) 1592 cm
–1








tetrahydro-1H-benzo[e][1,4]diazepine (II-25). General Procedure 4 was used for the 
coupling of 2-{[benzyl(but-3-en-2-yl)amino]methyl}-N-(4-methoxyphenyl)aniline (52 
mg, 0.14 mmol) with 2-bromo-meta-xylene (37 μL, 0.28 mmol) to afford 58 mg (87%) of 
the title compound as a viscous, colorless film. 
1
H NMR (500 MHz, CDCl3) δ 7.40–7.32 
(m, 4 H), 7.29–7.25 (m, 1 H), 7.08–7.03 (m, 1 H), 7.02–6.89 (m, 5 H), 6.69–6.65 (m, 2 
H), 6.63–6.56 (m, 3 H), 4.48–4.42 (m, 1 H), 3.99 (d, J = 14.5 Hz, 1 H), 3.88 (d, J = 14.0 
Hz, 1 H), 3.72 (s, 3 H), 3.57 (d, J = 14.0 Hz, 1 H), 3.53 (d, J = 14.5 Hz, 1 H), 3.24 (dq, J 
= 2.5, 7.0 Hz, 1 H), 3.02 (dq, J = 8.0, 14.5 Hz, 2 H), 2.16 (s, 6 H), 1.23 (d, J = 7.5 Hz, 3 
H); 
13
C NMR (100 MHz, CDCl3) δ 153.9, 146.7, 146.0, 142.9, 140.7, 137.2, 137.1, 
132.8, 130.6, 128.6, 128.3, 127.8, 126.7, 126.5, 125.8, 122.5, 122.0, 114.4, 65.3, 60.9, 
56.1, 55.5, 55.3, 29.9, 20.7, 19.2; IR (film) 1506 cm
–1
. MS (ESI) 477.2905 (477.2900 





2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine (II-26). General Procedure 4 was used 
for the coupling of 2-{[benzyl(but-3-en-2-yl)amino]methyl}-N-(4-methoxyphenyl)aniline 
(52 mg, 0.14 mmol) with 2-bromo-1,3,5-triisopropylbenzene (71 μL, 0.28 mmol) to 
afford 51 mg (64%) of the title compound as a viscous, colorless oil. 
1
H NMR (500 MHz, 
CDCl3) δ 7.34–7.22 (m, 5 H), 7.12 (td, J = 1.5, 8.0 Hz, 1 H), 7.05–7.01 (dd, J = 1.5, 7.5 
Hz, 1 H), 6.95 (td, J = 1.0, 7.0 Hz, 1 H), 6.90 (s, 2 H), 6.78 (d, J = 7.5 Hz, 1 H), 6.73–




3.78–3.70 (m, 4 H), 3.54 (dd, J = 10.5, 14.0 Hz, 2 H), 3.22–3.10 (m, 4 H), 2.90 (dd, J = 
5.5, 15.0 Hz, 1 H), 2.89–2.81 (m, 1 H), 1.24 (d, J = 7.0 Hz, 6 H), 1.13 (d, J = 7.0 Hz, 3 
H), 1.11 (d, J = 6.5 Hz, 6 H), 1.03 (d, J = 7.0 Hz, 6 H); 
13
C NMR (100 MHz, CDCl3) δ 
154.0, 147.4, 147.2, 146.5, 142.9, 140.5, 132.7, 132.2, 130.6, 128.6, 128.2, 127.8, 126.7, 
126.1, 122.6, 122.4, 120.8, 114.4, 67.5, 60.1, 56.0, 55.9, 55.5, 34.1, 29.2, 29.0, 24.6, 24.1, 
23.8, 18.8; IR (film) 1507 cm
–1





General Procedure 5: Pd-Catalyzed Synthesis of 1,4-Benzodiazepin-5-ones. A flame-
dried Schlenk tube was cooled under a stream of nitrogen and charged with Pd2(dba)3 (1 
mol % complex, 2 mol % Pd) or Pd(dba)2 (2 mol %), P(4-F-C6H4)3 (4 mol %), NaOt-Bu 
(2.0 equiv), and ArBr (2.0 equiv). The tube was purged with nitrogen and a solution of 
the amine substrate (1.0 equiv) in xylenes (5 mL/mmol amine) was added. The mixture 
was heated to 135 °C with stirring until the starting material had been consumed as 
judged by TLC analysis (18–24 h; the reaction times were not minimized). The reaction 
mixture was cooled to room temperature, quenched with saturated aqueous NH4Cl (2 
mL) and diluted with ethyl acetate (10 mL). The layers were separated and the aqueous 
layer was extracted with ethyl acetate (2 × 5 mL). The combined organic extracts were 
dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude 
product was then purified by flash chromatography on silica gel. 
 
2-([1,1'-Biphenyl]-4-ylmethyl)-4-benzyl-1-phenyl-3,4-dihydro-1H-




coupling of N-allyl-N-benzyl-2-(phenylamino)benzamide (40 mg, 0.12 mmol) with 4-
bromobiphenyl (52 mg, 0.22 mmol) to afford 44 mg (76%) of the title compound as a 
white solid with a wide m.p. range 67–85 °C. 
1
H NMR (500 MHz, CDCl3) δ 7.88 (dd, J = 
1.5, 7.5 Hz, 1 H), 7.62–7.58 (m, 2 H), 7.55–7.40 (m, 6 H), 7.39–7.34 (m, 1 H), 7.32–7.20 
(m, 3 H), 7.19–7.01 (m, 7 H), 6.77 (t, J = 7.5 Hz, 1 H), 6.52 (d, J = 8 Hz, 2 H), 5.10 (d, J 
= 14.5 Hz, 1 H), 4.15 (d, J = 14.5 Hz, 1 H), 3.99–3.89 (m, 1 H), 3.27 (dd, J = 11.5, 15.5 
Hz, 1 H), 3.22–3.09 (m, 2 H), 2.44 (dd, J = 10.0, 14.0 Hz, 1 H); 
13
C NMR (125 MHz, 
CDCl3) δ 169.5, 148.3, 140.6, 139.8, 139.6, 137.0, 136.4, 136.2, 132.3, 130.4, 130.3, 
129.03, 129.02, 128.8, 128.6, 128.4, 127.5, 127.4, 127.3, 127.1, 127.0, 118.3, 113.7, 62.9, 
51.3, 50.1, 36.4; IR (film) 1648 cm
–1
. MS (ESI) 495.2423 (495.2431 calcd for 





2-yl)methyl]benzoate (II-32). General Procedure 5 was used for the coupling of N-allyl-
N-benzyl-2-(phenylamino)benzamide (36 mg, 0.10 mmol) with tert-butyl 4-
bromobenzoate (40 μL, 0.20 mmol) to afford 39 mg (72%) of the title compound as a 
foamy white solid with a wide m.p. range 68–85 °C. 
1
H NMR (400 MHz, CDCl3) δ 7.93–
7.86 (m, 3 H), 7.52 (dt, J = 2.0, 7.6 Hz, 1 H), 7.42 (dt, J = 1.2, 7.6 Hz, 1 H), 7.29–7.20 
(m, 2 H), 7.17–7.08 (m, 4 H), 7.07–6.98 (m, 4 H), 6.77 (t, J = 7.2 Hz, 1 H), 6.47 (d, J = 
8.0 Hz, 2 H), 5.14 (d, J = 14.4 Hz, 1 H), 4.06 (d, J = 14.4 Hz, 1 H), 3.94–3.82 (m, 1 H), 
3.30–3.10 (m, 2 H), 3.04 (dd, J = 5.2, 15.2 Hz, 1 H), 2.44 (dd, J = 6.0, 14.0 Hz, 1 H), 
1.61 (s, 9 H); 
13
C NMR (100 MHz, CDCl3) δ 169.4, 165.5, 148.2, 142.1, 139.6, 136.9, 




113.6, 81.1, 62.7, 51.3, 50.2, 36.8, 28.2; IR (film) 1711, 1649 cm
–1
. MS (ESI) 541.2465 





one (II-33). General Procedure 5 was used for the coupling of N-allyl-N-benzyl-2-
(phenylamino)benzamide (34 mg, 0.10 mmol) with 4-bromobenzophenone (52 mg, 0.20 
mmol) to afford 33 mg (64%) of the title compound as a viscous, colorless oil. 
1
H NMR 
(500 MHz, CDCl3) δ 7.89 (dd, J = 1.5, 7.5 Hz, 1 H), 7.81–7.76 (m, 2 H), 7.72 (d, J = 8 
Hz, 2 H), 7.64–7.59 (m, 1 H), 7.56–7.48 (m, 3 H), 7.47–7.41 (m, 2 H), 7.28–7.21 (m, 1 
H), 7.16–7.10 (m, 6 H), 7.04 (d, J = 7.5 Hz, 2 H), 6.78 (t, J = 7.5 Hz, 1 H), 6.48 (d, J = 
7.5 Hz, 2 H), 5.15 (d, J = 14.5 Hz, 1 H), 4.13 (d, J = 14.5 Hz, 1 H), 3.98–3.90 (m, 1 H), 
3.27 (dd, J = 11.5, 15.5 Hz, 1 H), 3.19 (dd, J = 4.5, 14.0 Hz, 1 H), 3.09 (dd, J = 5.0, 15.0 
Hz, 1 H), 2.50 (dd, J = 9.5, 14.0 Hz, 1 H); 
13
C NMR (100 MHz, CDCl3) δ 196.2, 169.5, 
148.2, 142.3, 139.5, 137.5, 136.8, 136.2, 136.1, 132.5, 132.4, 130.6, 130.4, 130.3, 130.0, 
129.1, 128.7, 128.6, 128.4, 128.3, 127.6, 127.2, 118.4, 113.6, 62.7, 51.3, 50.2, 36.9; IR 
(film) 1649, 1603 cm
–1





benzo[e][1,4]diazepin-5(2H)-one (II-S1). General Procedure 5 was used for the 
coupling of N-allyl-N-benzyl-2-(phenylamino)benzamide (34 mg, 0.10 mmol) with 4-
bromobenzophenone (52 mg, 0.20 mmol) to afford 5 mg (9%) of the title compound as 
an off-white film in ca. 80% purity. The structure and relative stereochemistry of II-31 
was assigned based on analogy to II-S1. 
1




8.0 Hz, 1 H), 7.86 (d, J = 8.4 Hz, 2 H), 7.84–7.79 (m, 2 H), 7.64–7.58 (m, 1 H), 7.54–
7.43 (m, 3 H), 7.39 (d, J = 8.4 Hz, 2 H), 7.29–7.21 (m, 1 H), 7.16–7.09 (m, 3 H), 7.00–
6.94 (m, 2 H), 6.85 (t, J = 7.6 Hz, 2 H), 6.79 (d, J = 7.6 Hz, 2 H), 6.63 (d, J = 7.2 Hz, 2 
H), 5.21 (d, J = 15.2 Hz, 1 H), 4.79 (d, J = 10.4 Hz, 1 H), 3.40–3.31 (m, 1 H), 2.45 (d, J = 
14.8 Hz, 1 H), 1.46 (d, J = 6.8 Hz, 3 H); 
13
C NMR (100 MHz, CDCl3) δ 196.2, 161.7, 
147.8, 146.7, 142.4, 137.5, 136.6, 135.6, 132.9, 132.5, 130.7, 130.0, 129.2, 128.7, 128.4, 
128.3, 128.1, 127.8, 127.1, 124.1, 123.4, 123.3, 122.9, 121.3, 79.8, 48.9, 43.8, 18.2; IR 
(film) 1653, 1603 cm
–1





benzo[e][1,4]diazepin-5(2H)-one (II-34). General Procedure 5 was used for the 
coupling of N-allyl-N-benzyl-2-(3,5-dichlorophenylamino)benzamide (35 mg, 0.09 
mmol) with 3-bromopyridine (17 μL, 0.17 mmol) to afford 32 mg (78%) of the title 
compound as a white solid, m.p. 153–155 °C. 
1
H NMR (500 MHz, CDCl3) δ 8.52 (dd, J 
= 1.5, 4.5 Hz, 1 H), 8.30 (d, J = 2.0 Hz, 1 H), 7.90 (dd, J = 2.0, 8.0 Hz, 1 H), 7.58 (dt, J = 
1.5, 7.5 Hz, 1 H), 7.51 (dt, J = 1.5, 7.5 Hz, 1 H), 7.34–7.27 (m, 2 H), 7.26–7.21 (m, 1 H), 
7.20–7.15 (m, 3 H), 7.05–7.01 (m, 2 H), 6.72 (t, J = 1.5 Hz, 1 H), 6.10 (s, 2 H), 5.33 (d, J 
= 14.5 Hz, 1 H), 3.93 (d, J = 14.5 Hz, 1 H), 3.62–3.54 (m, 1 H), 3.25 (dd, J = 11.5, 15.0 
Hz, 1 H), 3.09 (dd, J = 5.5, 15.5 Hz, 1 H), 2.89 (dd, J = 5.0, 14.0 Hz, 1 H), 2.42 (dd, J = 
9.0, 14.0 Hz, 1 H); 
13
C NMR (100 MHz, CDCl3) δ 168.6, 150.0, 149.8, 148.6, 137.4, 
136.9, 136.0, 135.4, 132.8, 132.2, 130.8, 130.1, 128.9, 128.5, 128.4, 128.0, 123.6, 118.1, 
111.4, 62.9, 51.0, 50.1, 34.1; IR (film) 1643 cm
–1
. MS (ESI) 488.1292 (488.1291 calcd 







benzo[e][1,4]diazepin-5(2H)-one (II-35). General Procedure 5 was used for the 
coupling of N-allyl-N-benzyl-2-(3,5-dichlorophenylamino)benzamide (36 mg, 0.09 
mmol) with 1-bromo-2-(trifluoromethyl)benzene (23 μL, 0.17 mmol) to afford 25 mg 
(50%) of the title compound as a white solid, m.p. 235–237 °C. 
1
H NMR (400 MHz, 
CDCl3) δ 7.92 (dd, J = 1.6, 7.6 Hz, 1 H), 7.69–7.60 (m, 2 H), 7.54 (t, J = 7.6 Hz, 1 H), 
7.38 (quint, J = 7.6 Hz, 2 H), 7.32–7.23 (m, 2 H), 7.19–7.09 (m, 3 H), 7.08–7.02 (m, 2 
H), 6.62 (t, J = 1.6 Hz, 1 H), 5.81 (d, J = 2.0 Hz, 2 H), 5.39 (d, J = 14.4 Hz, 1 H), 3.90 (d, 
J = 14.0 Hz, 1 H), 3.83–3.73 (m, 1 H), 3.28 (dd, J = 11.6, 15.2 Hz, 1 H), 3.09 (dd, J = 
4.8, 14.8 Hz, 1 H), 2.85 (dd, J = 7.2, 14.4 Hz, 1 H), 2.75–2.64 (m, 1 H);
 19
F NMR (376 
MHz, CDCl3) δ –59.0 (m); 
13
C NMR (100 MHz, CDCl3) δ 168.6, 150.5, 137.3, 136.9, 
136.5, 135.6, 135.1, 132.9, 132.1, 131.6, 130.9, 130.5, 128.8, 128.6, 128.5, 127.9, 127.2, 
126.6, 126.5, 124.3 (q, J = 275 Hz), 117.8, 111.4, 63.4, 51.5, 50.3, 33.6; IR (film) 1646 
cm
–1





one (II-36). General Procedure 5 was used for the coupling of N-allyl-N-octyl-2-
(phenylamino)benzamide (35 mg, 0.10 mmol) with 4-bromobenzophenone (52 mg, 0.20 
mmol) to afford 36 mg (69%) of the title compound as a viscous, colorless oil. 
1
H NMR 
(500 MHz, CDCl3) δ 7.86–7.78 (m, 4 H), 7.61 (dt, J = 1.5, 7 Hz, 1 H), 7.55–7.47 (m, 3 
H), 7.44–7.38 (m, 3 H), 7.28–7.24 (m, 2 H), 7.19–7.12 (m, 2 H), 6.77 (t, J = 7.0 Hz, 1 H), 
6.65 (d, J = 8.0 Hz, 2 H), 4.54–4.40 (m, 1 H), 3.62–3.53 (m, 1 H), 3.43–3.20 (m, 3 H), 




0.83 (t, J = 7.5 Hz, 3 H); 
13
C NMR (100 MHz, CDCl3) δ 196.2, 169.3, 148.3, 142.5, 
139.5, 137.5, 136.6, 136.3, 132.5, 132.1, 130.8, 130.4, 130.01, 129.98, 129.1, 128.9, 
128.3, 127.1, 118.6, 113.7, 63.5, 52.1, 47.1, 37.2, 31.7, 29.4, 29.1, 28.7, 26.6, 22.6, 14.1; 
IR (film) 1649, 1602 cm
–1






benzo[e][1,4]diazepin-5(2H)-one (II-37). General Procedure 5 was used for the 
coupling of N-allyl-N-octyl-2-(phenylamino)benzamide (38 mg, 0.10 mmol) with 9-
bromophenanthrene (50 mg, 0.19 mmol) to afford 41 mg (74%) of the title compound as 
a viscous, colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 8.85–8.76 (m, 1 H), 8.69 (d, J = 
8.4 Hz, 1 H), 8.22–8.16 (m, 1 H), 7.87–7.80 (m, 3 H), 7.77–7.79 (m, 2 H), 7.69–7.55 (m, 
4 H), 7.46 (dt, J = 1.2, 7.6 Hz, 1 H), 7.37 (dd, J = 0.8, 8 Hz, 1 H), 7.15–7.07 (m, 2 H), 
6.73 (t, J = 7.6 Hz, 1 H), 6.66 (d, J = 8.4 Hz, 1 H), 4.87–4.77 (m, 1 H), 3.72 (dd, J = 5.2, 
14.8 Hz, 1 H), 3.58–3.46 (m, 1 H), 3.40 (dd, J = 11.6, 14.8 Hz, 1 H), 3.20–2.97 (m, 3 H), 
1.42–0.95 (m, 12 H), 0.82 (t, J = 6.8 Hz, 3 H); 
13
C NMR (100 MHz, CDCl3) δ 169.3, 
148.8, 139.6, 137.1, 132.2, 131.8, 131.5, 131.1, 130.9, 130.6, 130.4, 129.9, 129.2, 128.2, 
127.8, 127.3, 127.0, 126.9, 126.7, 126.6, 123.9, 123.6, 122.5, 118.3, 113.6, 62.4, 52.6, 
47.0, 34.5, 31.7, 29.3, 29.0, 28.6, 26.5, 22.6, 14.1; IR (film) 1646 cm
–1
. MS (ESI) 









Assignment of Stereochemistry 
The stereochemistry of II-15 was assigned on the basis of nOe correlations as 
shown below. In addition, the measured value of Jab = 2.0 Hz correlates well with the 
calculated value of 1.5 Hz for a cis-arrangement of these protons. The stereochemistry of 
other disubstituted products was assigned based on analogy to II-15. 
Figure II.2 Assignment of Stereochemistry 
 
The trans-stereochemistry of II-S1 was assigned on the basis of the measured value of Jab 
= 10.4 Hz. The stereochemistry of II-31 was assigned based on analogy to II-S1. 
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Intramolecular Alkene Aminopalladation Reactions of 
(dppf)Pd(Ar)[N(Ar
1
)(CH2)3CH=CH2] Complexes. Insertion of Unactivated Alkenes 
into Pd–N Bonds 
 
The prospect of effecting syn-migratory insertion of alkenes into palladium-
nitrogen bonds has been of longstanding interest in organometallic chemistry. Studies on 
the viability of this transformation were a focal point of early work towards the 
development of late-metal catalyzed hydroamination reactions.
71,72
 However, a number of 
experiments suggested that aminopalladation reactions of alkenes generally proceed 
through outer-sphere anti-addition pathways.
73
 More recently, the syn-insertion of 
alkenes into Pd–N bonds has been implicated as a key step in many useful Pd-catalyzed 











 and hetero-Heck transformations.
79,80 
However, despite the considerable interest in these processes, the syn-migratory insertion 
of an alkene into the Pd–N bond of a well-characterized palladium amido complex has 
yet to be observed.
81,82 
In this Chapter we describe the synthesis of (dppf)Pd(C6H4-p-
F)[N(Ar
1
)(CH2)3CH=CH2] complexes III-3, which are thought to be intermediates in Pd-
catalyzed alkene carboamination reactions. We illustrate that these complexes are 
transformed to 2-benzylpyrrolidines via migratory insertion of the alkene into the Pd–N 




(dppf)palladium(aryl)(pyrrolidin-2-ylmethyl) complexes. These are the first examples of 
insertions of alkenes into Pd–N bonds of well-defined complexes. 
Scheme III.1 Overall Reaction Sequence 
 
Prior studies on the synthesis of LnPd(Ar)(NRR’) complexes suggested that the 
high reactivity of these species would preclude their isolation in most cases.
83
 As such, 
the isolable (dppf)Pd(C6H4-p-F)(Br) complex III-1 was prepared using previously 
described routes
83,84
 and the potassium anilide salt of N-(C6H4-p-F)-pent-4-enylamine 
(III-2a) was synthesized via deprotonation of the corresponding amine with KHMDS.
83
 
As shown in Scheme III.1, a solution of III-1 in THF or THF-d8 was treated with III-2a 
(1.05 equiv) in the presence of 2-fluorotoluene as internal standard and dppf (2 equiv) as 
a trap for Pd(0). The conversion of III-1 to III-3a was complete upon mixing, and the 
formation of amido complex III-3a was evident by the presence of a pair of doublets at 
24.9 ppm (JPP = 38.1 Hz) and 9.0 ppm (JPP = 35.5 Hz) in the 
31
P NMR spectrum, which 





New signals at –123.7 and –137.3 ppm were also observed in the 
19




 amido complex III-3a underwent reaction to generate a 
new intermediate complex (III-A), which exhibited 
19




133.3 ppm, and 
31
P NMR signals at 21.3 ppm (JPP = 24.1 Hz) and 16.6 ppm (JPP = 21.7 
Hz). This intermediate was transformed to pyrrolidine III-4a and (dppf)2Pd at a rate that 
appeared to be roughly comparable to that of its formation from III-3a. Overall, the 
conversion of III-3a to III-4a proceeded in 86% NMR yield in 45 min at 24 °C. No 
additional intermediates on the pathway from III-3a to III-4a were detected, and no side 
products resulting from -hydride elimination were observed.  
Figure III.1 Possible Structures of Intermediate III-A 
 
As shown in Figure III.1, it seemed most likely that intermediate III-A was either 
a 5-coordinate alkene complex (III-5a), or an aryl(alkyl) palladium complex (III-6a). In 
addition, although Pd-catalyzed carboamination reactions have been shown to proceed 
through aminopalladation rather than carbopalladation pathways, we sought to exclude 
the possible intermediacy of III-7a in the stoichiometric transformation. However, the 
data obtained in our initial experiments could not be used to assign the structure of III-A. 
For example, the 
1
H NMR alkene signals of III-3a decreased as the reaction proceeded, 
but this region of the spectrum was sufficiently complicated that the presence of a new 
alkene containing intermediate (III-5a) could not be definitively confirmed or refuted. 
Similarly, the complicated 
1
H NMR data also did not allow for differentiation of III-6a 
vs. III-7a. We observed that (dppf)Pd(C6H4-p-F)[CH2(cyclopentyl)] (III-8) generated in 
situ from III-1 and (cyclopentyl)CH2MgBr underwent C–C bond-forming reductive 
elimination in < 5 min at rt,
87




However, the reductive elimination of III-6a could be significantly slowed relative to 
III-8 due to the inductive electron-withdrawing effect of the nitrogen atom in III-6a.
88
 





C–Labeling Experiment to Ascertain the Structure of Intermediate III-A  
 
In order to elucidate the structure of III-A we prepared and examined the 
reactivity of 
13
C labeled amido complex III-3a-
13





P NMR indicated that intermediate III-A is the aryl(alkyl)palladium 
complex III-6a. The chemical shifts of the labeled carbon atoms in III-A were not 
consistent with an alkene, and the chemical shift of Cb indicated it was located adjacent to 
a heteroatom. Thus, this data ruled out the possible intermediacy of III-5a and III-7a. 
Moreover, the 
31
P chemical shifts, coupling constants, and JCP correlate well with data 
reported by Brown for (dppf)Pd(Ph)(Me).
89

Having ascertained the structure of intermediate III-A, kinetic data were 
measured at 24 °C for the transformation of amido complex III-3a to pyrrolidine III-4a 
by way of intermediate III-6a (Scheme III.3 and Figure III.2). Rate constants were 













magnitude from each other.
90
 The activation parameters for the conversion of related 
amido complex III-3b to III-4b were determined by Eyring plot analysis (25–60 °C),
91
 
and are similar for both steps of the transformation. For the conversion of III-3b to III-
6b H
‡
 = 24.8 ± 0.6 kcal/mol, S
‡
 = 4.6  ± 1.8 eu. For the reductive elimination of III-4b 
from III-6b H
‡
 = 23.3 ± 0.8 kcal/mol, S
‡
 = 4.6 ± 2.5 eu. The reaction enthalpies are 
comparable to those observed for insertion of alkenes into late-metal–carbon bonds,
92a–c
 
and for C–C bond-forming reductive elimination processes.
92d
 The small entropy values 
are consistent with unimolecular transformations.
92 
Scheme III.3 Reaction Scheme with Different N-Aryl Groups  
 
 































The stereochemistry of the aminopalladation reaction was determined through 
reaction of deuterated amido complex III-3c. As shown in Scheme III.4, this complex 
was cleanly transformed to pyrrolidine III-4c with net syn-addition of the aryl group and 
the N-atom across the C–C double bond. This supports a mechanism involving syn-
migratory insertion of the alkene into the Pd–N bond, rather than amide dissociation, 
alkene coordination, and outer-sphere attack of the pendant nucleophile. This result is 
also consistent with the stereochemical outcome of Pd-catalyzed carboamination 
reactions between aminoalkene derivatives and aryl bromides.
24
  
Scheme III.4 Deuterium Labeling Study to Establish Syn-Insertion 
 
In conclusion, we have described the first examples of intramolecular syn-
migratory insertion reactions of alkenes into well-defined palladium(aryl)(amido) 
complexes. These reactions proceed with complete chemoselectivity for insertion into the 
Pd–N bond vs. the Pd–C bond, and provide observable (dppf)palladium(aryl)(pyrroldin-
2-ylmethyl) complexes. These results provide further support for postulated syn-










All reactions were carried out under a dry nitrogen atmosphere in flame-dried 
glassware using standard Schlenk techniques or in a nitrogen-filled glovebox. All 











were prepared using methods analogous to those previously described by Buchwald.
95
 
Pent-4-ynyl-4-methylbenzenesulfonate was prepared by treatment of 4-pentyn-1-ol with 
1.2 equiv TsCl, 2 equiv Et3N, and 0.1 equiv DMAP at 0 °C in dichloromethane. Toluene, 
THF, diethyl ether, and dichloromethane solvents used in the synthesis of organic 
substrates or air-stable Pd-complexes were purified using a GlassContour solvent 
purification system. THF and THF-d8 solvents used for preparation of Pd-amido 
complexes and kinetics experiments were dried over sodium/benzophenone overnight 
under vacuum and then vacuum transferred before use. 2-Fluorotoluene and 4-
fluorotoluene were purified by distillation from CaH2 under nitrogen. Benzaldehyde was 
purified by distillation from CaSO4 under nitrogen. CD2Cl2, acetic acid-d4, and propargyl 
alcohol-
13
C3 were obtained anhydrous from Cambridge Isotope Laboratories and used as 
received. Yields refer to isolated yields of compounds estimated to be ≥95% pure as 
determined by 
1
H NMR analysis unless otherwise noted. The yields reported in the 
experimental section describe the result of a single experiment, whereas all kinetic data 
have been averaged over duplicate experiments. All kinetic experiments were set up in a 
glovebox under nitrogen atmosphere. All glassware and microsyringes associated with 
kinetic experiments were oven dried at 120 °C overnight before use. 
31




given relative to an 85% H3PO4 external standard. 
1
H NMR shifts for the experimental 
section are reported downfield of TMS in CDCl3 or referenced to residual protia in THF-
d8. 
19
F NMR shifts are referenced to 2-fluorotoluene (–117.2 ppm) or 4-fluorotoluene (–
117.9 ppm) in THF-d8. 
 
Preparation and Characterization of Potassium Amide Substrates 
General Procedure 6: Conversion of N-aryl-pent-4-enamides to N-aryl-pent-4-
enylamines. A flame-dried flask equipped with a magnetic stirbar was charged with the 
appropriate N-aryl-pent-4-enamide (1.0 equiv) and purged with nitrogen for 5 min. THF 
(4 mL/mmol substrate) was added and the resulting solution was cooled to 0 °C. To this 
solution, a 1 M solution of LiAlH4 in diethyl ether (1.2 equiv) was added slowly over 10 
min. The reaction mixture was stirred at 0 °C for 15 min then warmed to rt and stirred 
overnight (ca. 16 h). The reaction mixture was cooled to 0 °C, then water (0.05 mL/mmol 
substrate), 6 M NaOH (0.05 mL/mmol substrate) and additional water (0.15 mL/mmol 
substrate) were sequentially added. The resulting white suspension was stirred vigorously 
for 30 min, then filtered through glass wool and the white precipitate was washed with 
diethyl ether (3 × 30 mL). The filtrate was dried over anhydrous sodium sulfate, filtered, 
and concentrated in vacuo. The resulting product was purified by flash chromatography 
on silica gel.  
 
General Procedure 7: Conversion of N-aryl-pent-4-enylamines to Potassium N-aryl-
pent-4-enyl Amides. A flame-dried flask equipped with a magnetic stirbar was charged 




min. In the glovebox, a separate flame-dried Schlenk flask equipped with a magnetic 
stirbar was charged with solid KHMDS (1.0 equiv), capped with a septum, removed from 
the glovebox, and connected to a vacuum/nitrogen manifold. Toluene (5 mL/mmol 
KHMDS) was added to each flask to afford clear solutions. Subsequently the amine 
solution was added dropwise to the KHMDS solution at rt to afford a bright yellow 
solution. The solution was stirred for 1.5 h at rt, over which time the solution became 
progressively more cloudy. The solvent was removed under high vacuum to afford a 
crude solid, which was taken into the glovebox under vacuum. The crude solid was 
purified on a medium glass frit via rinsing/trituration with pentane (4  10 mL) The 
resulting potassium N-aryl-pent-4-enyl amides were determined to contain ca. 1.6–1.8% 
KHMDS as judged by 
1
H NMR analysis. This material was used without further 
purification. 
 
Potassium (4-fluorophenyl)(pent-4-enyl)amide (III-2a). A flame-dried flask equipped 
with a magnetic stirbar was charged with 4-pentenoic acid (2.0 mL, 19.6 mmol) and 
purged with nitrogen for 5 min. Dichloromethane (35 mL) and DMF (50 μL) were 
subsequently added and the resulting solution was cooled to 0 °C. To this solution oxalyl 
chloride (19.8 mmol) was added dropwise over 5 min. The resulting solution was stirred 
for 15 min at 0 °C and then allowed to warm to rt over 3 h. The solution was then cooled 
to 0 °C and added dropwise to a solution of 4-fluoroaniline (3.8 mL, 40 mmol) in 
dichloromethane (20 mL). The reaction mixture was warmed to rt and stirred overnight 
(ca. 16 h). Water (50 mL) was added and the resulting biphasic mixture was transferred 




with diethyl ether (3 × 40 mL). The combined organic layers were washed with water (30 
mL) and brine (30 mL) then were dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The resulting product was purified by flash chromatography on 
silica gel. This procedure afforded 3.28 g (81%) of N-(4-fluorophenyl)pent-4-enamide as 
a white solid, m.p. 75–78.5 °C.
 1
H NMR (400 MHz, CDCl3) δ 7.51 (s, br, 1 H), 7.49–7.41 
(m, 2 H), 7.02–6.93 (m, 2 H), 5.93–5.80 (m, 1 H), 5.11 (dd, J = 1.6, 17.2 Hz, 1 H), 5.05 
(d, J = 10.8 Hz, 1 H), 2.51–2.40 (m, 4 H); 
13
C NMR (100 MHz, CDCl3) δ 170.9, 159.5 
(d, J = 244 Hz), 137.0, 134.0, 122.0 (d, J = 7.6 Hz), 116.2, 115.8 (d, J = 23.0 Hz), 36.8, 
29.6; 
19
F NMR (376 MHz, CDCl3) δ –118.0 (m). 
N-(4-Fluorophenyl)pent-4-enamide (1.50 g, 7.8 mmol) was reduced using a 
solution LiAlH4 in diethyl ether (9.36 mL, 9.36 mmol) according to General Procedure 6. 
This procedure afforded 1.20 g (86%) of 4-fluoro-N-(pent-4-enyl)aniline as a pale yellow 
oil.
 1
H NMR (400 MHz, CDCl3) δ 6.94–6.84 (m, 2 H), 6.58–6.49 (m, 2 H), 5.90–5.77 (m, 
1 H), 5.10–4.97 (m, 2 H), 3.49 (s, br, 1 H), 3.08 (t, J = 7.2 Hz, 2 H), 2.22–2.13 (m, 2 H), 
1.70 (quint, J = 7.2 Hz, 2 H); 
13
C NMR (100 MHz, CDCl3) δ 155.9 (d, J = 235 Hz), 145.0 
(d, J = 2.3 Hz), 138.2, 115.8 (d, J = 22.2 Hz), 115.4, 113.7 (d, J = 7.6 Hz), 44.3, 31.5, 
28.8; 
19
F NMR (376 MHz, CDCl3) δ –128.5 (m); IR (film) 3414, 1221 cm
–1
. MS (EI) 
179.1109 (179.1110 calcd for C11H14FN).  
General Procedure 7 was used for the conversion of 4-fluoro-N-(pent-4-
enyl)aniline (266 mg, 1.5 mmol) to the title compound. This procedure afforded 189 mg 
(69%) of the title compound as a tan powder that contained ca. 1.8% KHMDS as judged 
by 
1
H NMR analysis. This material was used without further purification. 
1
H NMR (400 




4.91 (d, J = 10.0 Hz, 1 H), 2.87–2.78 (m, 2 H), 2.24–2.15 (m, 2 H), 1.80–1.68 (m, 2 H, 
partially obscured by THF signal); 
13
C NMR (100 MHz, THF-d8) δ 159.0, 150.4 (d, J = 
219 Hz), 141.0, 116.2 (d, J = 20.0 Hz), 114.0, 109.5 (br), 52.7, 34.1, 33.9; 
19
F NMR (376 
MHz, THF-d8) δ –143.9 (s, br). 
 
Potassium (4-cyanophenyl)(pent-4-enyl)amide (III-2b). General Procedure 7 was used 
for the conversion of 4-(pent-4-enylamino)benzonitrile
19
 (400 mg, 2.1 mmol) to the title 
compound. This procedure afforded 309 mg (80%) of the title compound as a peach-
colored powder that contained ca. 1.8% KHMDS as judged by 
1
H NMR analysis. This 
material was used without further purification.  
1
H NMR (400 MHz, THF-d8) δ 6.77 (d, J 
= 8.4 Hz, 2 H), 6.05–5.80 (m, 3 H), 4.97 (d, J = 16.8 Hz, 1 H), 4.86 (d, J = 9.6 Hz, 1 H), 
2.94–2.86 (m, 2 H), 2.18–2.08 (m, 2 H), 1.69–1.58 (m, 2 H, partially obscured by THF 
signal); 
13
C NMR (100 MHz, THF-d8) δ 161.8, 140.8, 133.0, 126.0, 114.1, 113.3 (br), 
82.1, 50.2, 33.6, 32.6. 
 
Potassium (E)-(4-chlorophenyl)(5-deuteriopent-4-enyl)amide (III-2c). A flame-dried 
flask equipped with a magnetic stirbar was charged with pent-4-ynyl-4-
methylbenzenesulfonate (708 mg, 3.0 mmol) and purged with nitrogen for 5 min. THF 
(10 mL) was added followed by a solution of 9-BBN in THF (12 mL, 6 mmol, 0.5 M) at 
rt. The reaction mixture was stirred for 6 h at rt then PhCHO (300 µL, 2.9 mmol) was 
added. The resulting solution was stirred for an additional 3.5 h at rt and then was cooled 
to 0 °C. Acetic acid-d4 (200 μL, 3.6 mmol) was added and the solution was warmed to rt 




sequentially added, and the resulting mixture was transferred to a separatory funnel. The 
layers were separated, the aqueous layer was extracted with diethyl ether (1 × 20 mL) and 
the combined organic layers were dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo to afford (E)-(5-deuteriopent-4-enyl)-4-methylbenzenesulfonate as 
a colorless oil that was used in the next step without further purification. 
A flame-dried flask equipped with a magnetic stirbar was charged with 4-
chloroaniline (540 mg, 4.2 mmol) and purged with nitrogen for 5 min. THF (4 mL) was 
added followed by a solution of LiHMDS in THF (2.5 mL, 2.5 mmol, 1.0 M) to afford a 
dark green solution. This solution was added to a solution of the crude (E)-(5-
deuteriopent-4-enyl)-4-methylbenzenesulfonate from the previous reaction in THF (4 
mL). The resulting mixture was heated to 50 °C for 2 h then cooled to rt. Water (20 mL) 
and EtOAc (10 mL) were added, the mixture was transferred to a separatory funnel, and 
the layers were separated. The aqueous layer was extracted with EtOAc (2  10 mL) and 
the combined organic layers were dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The resulting product was purified by flash chromatography on 
silica gel to afford 271 mg (51%) of (E)-4-chloro-N-(5-deuteriopent-4-enyl)aniline as a 





H NMR (400 MHz, CDCl3) δ 7.14–7.08 (m, 2 H), 6.55–6.48 (m, 2 H), 5.90–
5.77 (m, 1 H), 5.04 (td, J = 1.2, 17.2 Hz, 1 H), 3.63 (s, br, 1 H), 3.10 (t, J = 7.2 Hz, 2 H), 
2.16 (qd, J = 1.2, 6.8 Hz, 2 H), 1.71 (quint, J = 7.2 Hz, 2 H); 
13
C NMR (100 MHz, 
CDCl3) δ 147.1, 138.0, 129.2, 121.9, 115.2 (t, JCD = 24.1 Hz), 113.9, 43.7, 31.4, 28.7; IR 
(film) 3416 cm
–1




General Procedure 7 was used for the conversion of (E)-4-chloro-N-(5-
deuteriopent-4-enyl)aniline (201 mg, 1.0 mmol) to the title compound. This procedure 
afforded 105 mg (55%) of the title compound as a yellow powder that contained ca. 1.6% 
KHMDS as judged by 
1
H NMR analysis. This material was used without further 
purification.  
1
H NMR (400 MHz, THF-d8) δ 6.61 (d, J = 8.8 Hz, 2 H), 6.00–5.85 (m, 3 
H), 5.00 (d, J = 16.8 Hz, 0.88 H), 4.90 (d, J = 15.2 Hz, 0.12 H), 2.87–2.77 (m, 2 H), 2.18 
(q, J = 6.8 Hz, 2 H), 1.75–1.65 (m, 2 H, partially obscured by THF signal); 
13
C NMR 
(100 MHz, THF-d8) δ 160.1, 140.8, 129.6, 114.1 (t, JCD = 26.1 Hz), 112.0 (br), 108.2, 
51.9, 33.9, 33.6. 











C3 was synthesized in 5 linear steps in 10% overall yield, 
starting from propargyl alcohol-
13
C3, as shown in Scheme III.5. A round-bottomed flask 
equipped with a stirbar was charged with powdered KOH (2.37 g, 42.3 mmol), TsCl 
(1.99 g, 10.4 mmol), and dry Et2O (20 mL). The resulting suspension was cooled to 0 °C 
and propargyl alcohol-
13
C3 (500 mg, 8.46 mmol) was added. The mixture was stirred for 
2.5 h and allowed to warm gradually from 0 °C to room temperature over that time. 
Water (25 mL) and Et2O (25 mL) were then added to the reaction mixture and the layers 




combined organic layers were dried over anhydrous sodium sulfate, filtered and 
concentrated in vacuo. The crude product was purified by flash chromatography on silica 
gel to afford propargyl tosylate-
13
C3 (III-S1) as a colorless oil (1.74 g, 97%). 
1
H NMR 
(CDCl3, 500 MHz) δ 7.82 (d, J = 8.0 Hz, 2 H), 7.35 (d, J = 8.0 Hz, 2 H), 4.71 (dm, J = 
154 Hz, 2 H), 2.47 (ddm, J = 72.5, 232 Hz, 1 H), 2.46 (s, 3 H). 
A solution of N-(4-fluorophenyl)acetamide
96
 (3.75g, 24.5 mmol) in 30 mL dry 
THF was added slowly to a solution of freshly prepared LDA (49.0 mmol) in THF and 
hexanes at –78 °C, and allowed to stir for 1 h. A solution of propargyl tosylate-
13
C3 (III-
S1) (1.74 g, 8.17 mmol) in 60 mL dry THF was then added slowly via addition funnel 
over the course of 1 h while maintaining a reaction temperature of –78 °C. The resulting 
solution was stirred for 3 h at –78 °C and warmed slowly to rt over the course of 2 h 
before being quenched with aqueous NH4Cl solution (40 mL). Water (120 mL) and Et2O 
(120 mL) were added, the layers were separated, and the aqueous layer was extracted 
with ether (2 × 120 mL).  The combined organic layers were washed with brine (120 
mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude 
product was purified via flash chromatography on silica gel to afford labeled amide III-
S2 as pale orange solid (1.04 g, 66%).  
1
H NMR (CDCl3, 500 MHz) δ 7.52–7.41 (m, 3 
H), 7.04–6.98 (m, 2 H), 2.66 (dm, JCH = 135 Hz, 2 H), 2.58 (quint, J = 6.2 Hz, 2 H), 2.07 
(qdd, J = 2.6, 51, 249 Hz, 1 H); 
13
C NMR (CDCl3, 100 MHz, labeled carbons only) δ 
83.0 (dd, J = 67, 171 Hz), 69.9 (dd, J = 11.2, 171 Hz), 15.0 (dd, J = 11.2, 67 Hz). 
Reduction of the alkyne was accomplished using the method of Soderquist,
97
 and 
reduction of the amide was conducted without isolating the resulting alkene. An oven-




purged with nitrogen. Anhydrous THF (20 mL) and a solution of 9-BBN in THF (0.5 M, 
42 mL, 21 mmol) were added, and the resulting solution was stirred at rt for 12 h. 
PhCHO (690 μL, 6.67 mmol) was added, and the resulting solution was stirred at rt for 7 
h. Acetic acid (650 μL, 10.6 mmol) was added, and the solution was stirred at rt for 45 
min. Water (25 mL) and ether (25 mL) were then added and the layers were separated. 
The aqueous layer was extracted with Et2O (2 × 40 mL), and the combined organic layers 
were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash 
chromatograpy on silica gel. This procedure afforded an oil, which was dissolved in 20 
mL dry THF under nitrogen, and cooled to 0 °C. A solution of LiAlH4 (1.0 M in ether, 
8.5 mL, 8.5 mmol) was added slowly via syringe, and the resulting mixture was stirred at 
0 °C for 4 h. Aqueous workup and filtration were conducted according to General 
Procedure 6. The resulting crude product was purified by flash chromatography on silica 
gel to afford p-fluoro-N-(3,4,5-
13
C3-pent-4-enyl)aniline III-S3 as a colorless oil (260 mg, 
28% from III-S2). HRMS detected only triply 
13
C-labeled compound (M–1 not observed, 
M+1 intensity was as predicted by natural abundance of isotopes).  
1
H NMR (CDCl3, 500 
MHz) δ 6.91–6.85 (m, 2 H), 6.56–6.51 (m, 2 H), 5.83 (dm, JCH = 152 Hz, 1 H), 5.05 (dm, 
JCH = 153 Hz, 1 H), 5.01 (dm, JCH = 158 Hz, 1 H), 3.48 (s, br, 1 H), 3.11–3.07 (m, 2 H), 
2.17 (dm, JCH = 126 Hz, 2 H), 1.75–1.67 (m, 2 H); 
13
C NMR (CDCl3, 100 MHz, labeled 
carbons only) δ 137.9 (dd, J = 41.6, 68.7 Hz), 115.1 (d, J = 69.1 Hz), 31.3 (d, J = 41.5 
Hz); 
19





General Procedure 7 was used for the conversion of labeled amine III-S3 (250 




77%) of a bright yellow powder which was stored in a –20 °C freezer in the glovebox.  
1
H NMR (THF-d8, 400 MHz) δ 6.50 (t, J = 8.8 Hz, 2 H), 5.92 (m, 2 H), 5.89 (dm, JCH = 
150 Hz, 1 H), 5.00 (dm, JCH = 153 Hz, 1 H), 4.89 (dm, JCH = 158 Hz, 1 H), 2.86–2.81 (m, 
2 H), 2.18 (dm, JCH = 118 Hz, 2 H), 1.73–1.65 (m, partially obscured by THF signal); 
13
C 
NMR (THF-d8, 100 MHz, labeled carbons only) δ 140.9 (dd, J = 42.2, 69.4 Hz), 114.0 (d, 
J = 69.4 Hz), 33.8 (d, J = 41.8 Hz); 
19
F NMR (THF-d8, 376 MHz) δ –143.8 (s, br). 
 
Synthesis of Authentic Samples of Pyrrolidine Products Formed in Kinetic Runs 
General Procedure 8: Pd-Catalyzed Carboamination of γ-(N-arylamino)alkenes 
with Aryl Bromides.
98
 An oven or flame-dried Schlenk tube was cooled under a stream 
of argon or nitrogen and charged with Pd2(dba)3 (1 mol % complex, 2 mol % Pd), dppf (2 
mol %), NaOt-Bu (1.0 equiv), and the ArBr (1.5 equiv). The tube was purged with argon 
or nitrogen and a solution of the amine substrate (1.0 equiv) in toluene (4 mL/mmol aryl 
bromide) was added. The mixture was heated to 60–110 °C with stirring until the starting 
material had been consumed as judged by GC or 
1
H NMR analysis. The reaction mixture 
was cooled to room temperature, quenched with saturated aqueous NH4Cl (2 mL) and 
diluted with ethyl acetate (10 mL). The layers were separated and the aqueous layer was 
extracted with ethyl acetate (2 × 10 mL). The combined organic extracts were dried over 
anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude product was 
then purified by flash chromatography on silica gel. 
 
1-(4-Fluorophenyl)-2-(4-fluorobenzyl)pyrrolidine (III-4a). General Procedure 8 was 




bromo-4-fluorobenzene (47 μL, 0.42 mmol) to afford 53 mg (68%) of the title compound 
as a colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 7.19–7.11 (m, 2 H), 7.03–6.93 (m, 4 H), 
6.60–6.53 (m, 2 H), 3.94–3.85 (m, 1 H), 3.42–3.32 (m, 1 H), 3.19–3.08 (m, 1 H), 2.94 
(dd, J = 3.2, 13.6 Hz, 1 H), 2.58 (dd, J = 8.8, 13.6 Hz, 1 H), 1.95–1.74 (m, 4 H); 
13
C 
NMR (100 MHz, CDCl3) δ 161.8 (d, J = 245 Hz), 155.0 (d, J = 234 Hz), 143.9 (d, J = 1.6 
Hz), 135.1 (d, J = 3.1 Hz), 130.9 (d, J = 7.6 Hz), 115.9 (d, J = 22.2 Hz), 115.4 (d, J = 
20.7 Hz), 112.4 (d, J = 6.9 Hz), 60.2, 49.2, 38.0, 29.9, 23.4; 
19
F NMR (376 MHz, CDCl3) 
δ –117.0 (m), –130.7 (m); IR (film) 1225 cm
–1
. MS (ESI) 274.1413 (274.1407 calcd for 




4-[2-(4-Fluorobenzyl)pyrrolidin-1-yl]benzonitrile (III-4b). General Procedure 8 was 
used for the coupling of 4-(pent-4-enylamino)benzonitrile (34 mg, 0.18 mmol) with 1-
bromo-4-fluorobenzene (40 μL, 0.37 mmol) to afford 41 mg (79%) of the title compound 
as a colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 7.52–7.45 (m, 2 H), 7.17–7.09 (m, 2 H), 
7.04–6.96 (m, 2 H), 6.64–6.57 (m, 2 H), 4.06–3.97 (m, 1 H), 3.45–3.35 (m, 1 H), 3.28–
3.16 (m, 1 H), 2.93 (dd, J = 3.2, 14.0 Hz, 1 H), 2.62 (dd, J = 8.8, 13.6 Hz, 1 H), 2.02–
1.80 (m, 4 H); 
13
C NMR (100 MHz, CDCl3) δ 161.7 (d, J = 245 Hz), 149.2, 134.0, 133.6, 
130.6 (d, J = 7.6 Hz), 120.8, 115.3 (d, J = 21.1 Hz), 111.8, 97.0, 59.6, 48.2, 37.1, 29.3, 
22.7; 
19
F NMR (376 MHz, CDCl3) δ –116.4 (m); IR (film) 2211, 1222 cm
–1
. MS (ESI) 









enyl)aniline (27 mg, 0.14 mmol) with 1-bromo-4-fluorobenzene (24 μL, 0.22 mmol) to 
afford 31 mg (78%) of the title compound as a colorless oil. This material was judged to 
contain ~87% deuterium incorporation by GC/MS and 
1
H NMR analysis. 
1
H NMR (400 
MHz, CDCl3) δ 7.21–7.10 (m, 4 H), 7.02–6.95 (m, 2 H), 6.59–6.53 (m, 2 H), 3.94–3.86 
(m, 1 H), 3.38–3.31 (m, 1 H), 3.18–3.08 (m, 1 H), 2.90 (s, 0.85 H), 2.59 (dd, J = 8.8, 14.0 
Hz, 0.13 H), 1.95–1.70 (m, 4 H); 
13
C NMR (100 MHz, CDCl3) δ 161.8 (d, J = 245 Hz), 
145.7, 134.9 (d, J = 3.1 Hz), 130.9 (d, J = 7.6 Hz), 129.3, 120.5, 115.4 (d, J = 21.4 Hz), 
113.1, 59.9, 48.8, 37.4 (t, JCD = 19.6 Hz), 29.7, 23.3; 
19
F NMR (376 MHz, CDCl3) δ –
116.9 (m); IR (film) 1222 cm
–1




The stereochemistry of III-4c was assigned by carboamination of the analogous 
N-Boc-substituted substrate with 1-bromo-4-fluorobenzene. We have previously 
demonstrated that reactions of this substrate proceed with syn-addition of the nitrogen 
atom and the aryl group across the alkene.
24
 Cleavage of the Boc-group followed by Pd-
catalyzed N-arylation of the resulting pyrrolidine with 1-bromo-4-chlorobenzene afforded 
III-4c as depicted in Scheme III.6 below. The N-arylation has been previously 












Scheme III.6 Synthesis of Stereochemistry Comparison Substrate 
 
 
Proof of Stereochemistry of III-4c via Alternative Synthesis.  
A flame-dried Schlenk tube was cooled under a stream of nitrogen and charged with 
Pd(OAc)2 (4.8 mg, 0.021 mmol), DPE-Phos (23.7 mg, 0.044 mmol), and Cs2CO3 (807 
mg, 2.5 mmol). The tube was purged with nitrogen for 5 min and a solution of (E)-tert-
Butyl-5-d-pent-4-enylcarbamate
24
 (203 mg, 1.1 mmol) and 1-bromo-4-fluorobenzene 
(150 μL, 1.4 mmol) in 1,4-dioxane (5 mL) was added. The mixture was heated to 100 °C 
with stirring for 38 h upon which time the reaction mixture was quenched as in General 
Procedure 8. The crude product was then purified by flash chromatography on silica gel 
to afford 187 mg (61%) of pyrrolidine III-S4 as a colorless oil. 
1
H NMR (400 MHz, 
toluene-d8, 100 °C) δ 6.95–6.88 (m, 2 H), 6.75 (t, J = 8.8 Hz, 2 H), 3.92–3.81 (m, 1 H), 
3.32–3.20 (m, 1 H), 3.15–3.04 (m, 1 H), 2.98–2.90 (m, 1 H), 1.46 (s, 9 H), 1.40–1.28 (m, 
4 H); 
13
C NMR (100 MHz, toluene-d8, 100 °C) δ 162.4 (d, J = 245 Hz), 154.4, 135.6, 
131.2 (d, J = 7.9 Hz), 115.4 (d, J = 20.9 Hz), 78.9, 59.1, 47.0, 39.6 (t, JCD = 19.1 Hz), 
30.0, 28.9, 23.6; 
19
F NMR (376 MHz, CDCl3) δ –116.5 (m); IR (film) 1693, 1222 cm
–1
. 






A flame-dried flask was charged with pyrrolidine III-S4 (153 mg, 0.55 mmol) 
and CH2Cl2 (3 mL). Trifluoroacetic acid (1 mL) was added and the mixture was allowed 
to stir at rt for 4 h. The reaction mixture was then concentrated in vacuo. Residual 
trifluoracetic acid was removed by addition of benzene (4 mL) followed by concentration 
in vacuo (repeated three times). This procedure afforded 160 mg (100 %) of 
pyrrolidinium trifluoroacetate salt III-S5 as a viscous brown oil that was used without 
further purification. 
Crude pyrrolidinium trifluoroacetate III-S5 was N-arylated with 1-bromo-4-
chlorobenzene using conditions developed by Buchwald for N-arylation of amines 
bearing stereocenters adjacent to the nitrogen atom.
99
 A flame-dried Schlenk tube was 
cooled under a stream of nitrogen and charged with Pd2(dba)3 (6.3 mg, 0.007 mmol), 
(rac)-BINAP (8.8 mg, 0.014 mmol), NaOt-Bu (82.1 mg, 0.85 mmol), and 1-bromo-4-
chlorobenzene (78.1 mg, 0.41 mmol). The tube was purged with nitrogen for 5 min and a 
solution of III-S5 (100 mg, 0.34 mmol) in toluene (1.1 mL) was added. The mixture was 
heated to 70 °C with stirring for 6 h upon which time the reaction mixture was quenched 
as in General Procedure 8. The crude product was purified by flash chromatography on 
silica gel to afford 47 mg (48%) of pyrrolidine III-4c as a colorless oil that was 
spectroscopically identical to the material prepared directly from III-3c, thus establishing 
the syn-addition stereochemistry illustrated above. 
 
Preparation and Characterization of (dppf)Pd(C6H4-p-F)(Br) (III-1).  
A flame-dried flask equipped with a magnetic stir bar was cooled under a stream of 




mmol). The flask was purged with nitrogen for 5 min, toluene (20 mL) and 1-bromo-4-
fluorobenzene (300 μL, 2.8 mmol) were added, and the resulting dark purple-brown 
solution was stirred at 25 °C for 2.5 h. At this time the solution had changed to a dark 
purple-yellowish color and was subsequently filtered through celite eluting with diethyl 
ether (ca. 100 mL) to obtain a yellow-orange filtrate. The filtrate was concentrated in 
vacuo to ca. 15 mL, layered with 60 mL pentane and transferred to an Erlenmeyer flask. 
The stoppered, layered solution was then allowed to settle at rt for 2 h upon which time 
significant formation of a yellow precipitate had occurred. The mixture was filtered to 
isolate 322 mg of dimeric [(o-tol)3P]Pd(C6H4-p-F)(Br) as a fluffy yellow powder that was 
subsequently used without further purification. 
A flame-dried flask equipped with magnetic stir bar was charged with 121 mg 
(0.1 mmol) of the dimeric [(o-tol)3P]Pd(C6H4-p-F)(Br) complex and dppf (115 mg, 0.21 
mmol). The flask was purged with nitrogen for 5 min and CH2Cl2 (6 mL) was added. The 
resulting orange solution was stirred for 1 h at rt and then concentrated in vacuo to ca. 0.5 
mL. Et2O (7 mL) was added, the resulting slurry was stirred for 1 min and then allowed 
to settle for 1 h at rt. The mixture was then filtered to yield 114 mg (33% over 2 steps) of 
an orange solid that was washed with Et2O (3 × 8 mL) and pentane (3 × 8 mL) to afford 
the title complex.  m.p. 185 °C (decomp).
 1
H NMR (400 MHz, CDCl3) δ 8.10–8.00 (m, 4 
H), 7.50–7.10 (m, 16 H), 6.91–6.81 (m, 2 H), 6.41–6.31 (m, 2 H), 4.71–4.65 (m, 2 H), 
4.52–4.47 (m, 2 H), 4.18–4.12 (m, 2 H), 3.66–3.60 (m, 2 H); 
13
C NMR (100 MHz, 
CD2Cl2) δ 160.7 (d, J = 239 Hz), 152.0 (s), 150.7 (s), 136.2 (m), 135.9 (d, J = 11.7 Hz), 
134.6 (d, J = 12.5 Hz), 133.9 (d, J = 13.3 Hz), 133.4 (d, J = 33.4 Hz), 130.9 (dd, J = 2.0, 




Hz), 76.7 (d, J = 11.7 Hz), 75.4 (dd, J = 2.7, 38.5 Hz), 74.9 (d, J = 8.6 Hz), 74.1 (d, J = 
7.8 Hz), 72.9 (d, J = 4.7 Hz); 
19
F NMR (376 MHz, CDCl3) δ –124.6 (m); 
31
P NMR (162 
MHz, CDCl3) δ 30.9 (dd, J = 2.3, 32.0 Hz), 9.9 (dd, J = 1.9, 32.0 Hz); IR (film) 1474, 
1435, 1211 cm
–1
. Anal calcd for C40H32BrFFeP2Pd: C, 57.48; H, 3.86. Found: C, 57.42; 
H, 3.80. 
 
Representative Procedure for In Situ Formation of Pd-Amido Complexes III-3 and 
Conversion to III-6.  
In a glovebox under nitrogen atmosphere, (dppf)Pd(C6H4-p-F)(Br) (III-1) (6.3 mg, 
0.0075 mmol) and dppf (4.7 mg, 0.0085 mmol) were placed into a small vial. THF-d8 
(550 μL) was added and the resulting orange solution was transferred to an NMR tube. 4-
Fluorotoluene (0.3 μL, 0.0027 mmol) was added as an internal 
19
F standard, and the tube 







P spectra were obtained. A solution of potassium (4-
fluorophenyl)(pent-4-enyl)amide (III-2a) (2.7 mg, 0.012 mmol) in 200 μL THF-d8 was 
prepared in the glovebox and 121 μL (1 equiv) of that solution was loaded into a gas tight 
syringe and injected into the NMR tube containing the Pd complex. The tube was 
inverted several times to ensure complete mixing, and a rapid color change from orange 
to red was observed. The tube was returned to the cold NMR probe and allowed to re-
equilibrate at –60 °C and a 
19
F spectrum was obtained. The solution was then warmed to 






P spectra were obtained. Experiments in which the ratio of Pd-
complex III-1 to dppf were varied over a range of 0.75 to 2 equivalents dppf:Pd had no 





(dppf)Pd(C6H4-p-F)[N(C6H4-p-F)(CH2CH2CH2CH=CH2)] (III-3a):  
1
H NMR (400 
MHz, THF-d8) δ 7.95–7.87 (m), 7.76 (t, J = 8.6 Hz) 7.59–7.40 (m), 7.20–7.12 (m), 7.06–
7.01 (m), 6.60 (q, J = 7.4 Hz), 6.36 (t, J = 8.4 Hz), 6.09 (t, J = 8.6 Hz), 5.62 (tdd, J = 6.8, 
10.0, 16.8 Hz, 1 H), 4.88–4.81 (m, 2 H), 2.57–2.51 (m, 1 H), 2.22–2.14 (m, 1 H), 1.70 
(m, obscured by THF), 1.42–1.30 (m, 1 H), 1.20–1.08 (m, 1H) (due to overlap and 
spectral crowding, accurate integration values for aryl protons could not be determined 
and are not reported); 
19
F NMR (376 MHz, THF-d8) δ –123.7 (m, Pd-C6H4F), –137.3 (s, 
N-C6H4F); 
31
P NMR (162 MHz, THF-d8) δ 24.9 (d, J = 38.1 Hz), 9.0 (d, J = 35.5 Hz). 
The solution of the palladium-amido complex III-3a was warmed to 15 °C, 
monitoring at 2 min intervals by 
19
F NMR for appearance of peaks at –124.1 and –133.3 
ppm (attributed to III-6a), along with diminishment of the peaks at –123.7 and –137.3 











P data are reported; the 
1
H spectrum 
for this and related compounds could not be extracted from the combined spectra of the 
species present in the reaction mixture. This general protocol was also followed for the 
reactions of III-3a-
13
C3, III-3b, and III-3c. Data for these amido complexes and 
intermediates III-6a-
13
C3, III-6b, and III-6c are provided below. 
 
(dppf)Pd(C6H4-p-F){CH2[CHCH2CH2CH2N(C6H4-p-F)]} (III-6a):  
19
F NMR (376.9 
MHz, THF-d8) δ –124.1 (s), –133.3 (s); 
31
P NMR (162 MHz, THF-d8) δ 21.3 (d, J = 24.1 
















NMR (376 MHz, THF-d8) δ –123.7 (m, Pd-C6H4F), –137.3 (s, N-C6H4F); 
31
P NMR (162 
MHz, THF-d8) δ 24.9 (d, J = 38.1 Hz), 9.0 (d, J = 35.5 Hz); 
13
C NMR (100 MHz, THF-
d8) δ 140.3 (dd, JCC = 42.0, 69.3 Hz), 114.0 (d, JCC = 69.3 Hz), 33.2 (d, JCC = 42.0 Hz) 
(data are provided only for 
13













NMR (376 MHz, THF-d8) δ –124.1 (m), –133.3 (m); 
31
P NMR (162 MHz, THF-d8) δ 
21.3 (dd, JPC = 7.6 Hz, JPP = 22.5 Hz); 16.6 (dd, JPP = 22.5 Hz, JPC = 91.5 Hz); 
13
C NMR 
(100 MHz, THF-d8) δ 62.0 (t, JCC = 37.4 Hz), 34.8 (d, JCC = 36.3 Hz), 30.0 (ddd, JCP = 
8.2, 91.1 Hz, JCC = 38.1 Hz) (data are provided only for 
13
C labeled carbon atoms). 
 
(dppf)Pd(C6H4-p-F)[N(C6H4-p-CN)(CH2CH2CH2CH=CH2)] (III-3b):  
1
H NMR (400 
MHz, THF-d8) δ 7.87–7.78 (m), 7.64–7.35 (m), 7.21–7.13 (m), 6.99–6.90 (m), 6.80–6.70 
(m), 6.22–6.12 (m), 5.64 (tdd, J = 6.8, 10.0, 16.8 Hz, 1 H), 5.57 (dd, J = 2.0, 8.8 Hz, 1 
H), 4.89-4.85 (m, 2H), 4.49 (br, 3 H), 4.40 (s, 1 H), 4.38 (s, 1 H), 4.33 (s, 2 H), 4.21 (s, 1 
H), 2.57–2.37 (m, 2 H), 1.76–1.62 (m, partially obscured by THF, ~2 H), 1.49–1.37 (m, 1 
H), 1.07–0.94 (m, 1 H); 
19
F NMR (376 MHz, THF-d8) δ –122.7 (m); 
31
P NMR (162 




F NMR (376 
MHz, THF-d8) δ –123.8 (m); 
31
P NMR (162 MHz, THF-d8) δ 21.2 (d, J = 25.4 Hz), 17.2 





(dppf)Pd(C6H4-p-F)[N(C6H4-p-Cl)(E-CH2CH2CH2CH=CHD)] (III-3c):  
1
H NMR 
(400 MHz, THF-d8) δ 7.90–7.71 (m), 7.58–7.38 (m), 7.36–7.09 (m, partially obscured), 
7.09–6.95 (m), 6.67 (q, J = 7.4 Hz), 6.56–6.45 (m), 6.12 (t, J = 8.4 Hz), 5.63 (td, J = 6.6, 
17.2 Hz, 1 H), 4.85 (d, J = 17.2 Hz, 1 H), 4.49 (s, 2 H), 4.46 (s, 1 H), 4.41 (s, 1 H), 4.39 
(s, 1 H), 4.34 (s, 1 H) (remaining Cp protons obscured), 2.53–2.43 (m, 1 H), 2.26–2.13 
(m, 1 H), 1.73–1.62 (m, partially obscured), 1.50–1.39 (m, 1 H), 1.18–1.05 (m, 1 H); 
19
F 
NMR (376 MHz, THF-d8) δ –123.4 (m); 
31
P NMR (162 MHz, THF-d8) δ 24.3 (d, J = 




F NMR (376 
MHz, THF-d8) δ –124.0 (m); 
31
P NMR (162 MHz, THF-d8) δ 21.3 (d, J = 24.1 Hz), 16.8 
(dd, J = 2.6, 23.0 Hz). 
 
Representative Protocol for Measurements of Reaction Kinetics 
In the glovebox, (dppf)Pd(C6H4-p-F)(Br) (III-1) (4.0 mg, 0.0048 mmol) and dppf (5.3 
mg, 0.0096 mmol) were accurately weighed into a small vial and THF (660 μL) was 
added to give a homogeneous orange solution. The entire solution was transferred to a 
sealable screw-top NMR tube with Teflon septum and tightly sealed. Into a separate 
small vial, potassium (4-fluorophenyl)(pent-4-enyl)amide (III-2a) (3.5 mg, 0.015 mmol) 
was accurately weighed and 2 μL of 2-fluorotoluene (internal standard) was added. THF 
(300 μL) was added to dissolve and the vial was sealed tightly via screw-cap with Teflon 




instrument where 100 μL (0.005 mmol) of the solution of III-2a was added to the 
contents of the sealed NMR tube via gastight microsyringe. Upon addition, the solution 
was inverted once to homogenize the color and then quickly placed in the NMR probe 
pre-adjusted to the appropriate temperature. Periodic monitoring by 
19
F NMR 
spectroscopy of the disappearance of Pd-amido complex III-3a, intermediate III-6a and 
appearance of pyrrolidine product III-4a afforded kinetic data over approximately 3 half-
lives. The NMR yield of the transformation was determined based on comparison of the 
19
F NMR integrations to 2-fluorotoluene (internal standard). 
 
The consumption of Pd-amido complex III-3a as it undergoes alkene insertion, is 
modeled by the first order kinetic equation given in Figure III.3. 
 

































Kinetic Model of Reaction System/Rate Constants 
Kinetic data indicates the reaction system follows a consecutive irreversible 
reaction scheme as described by Swain.
100
 As shown in Scheme 3, Pd-amido complex 
III-3a is transformed to III-6a, which then undergoes carbon-carbon bond-forming 
reductive elimination to afford pyrrolidine III-4a and (dppf)2Pd.  
For this reaction system, the consumption of III-3a obeys first-order kinetics and: 
 
d[III-3a]/dt = –k1[III-3a]         (1) 
Integrating gives: 
[III-3a] = [III-3a]0e
–k1t           (2) 
 
From which the first-order relationship between [III-3a] and reaction time gives k1 
(Figure III.3). Additionally, because III-6a is both produced by III-3a and depleted in 
production of III-4a, [III-6a] is governed by the relationship: 
 
d[III-6a]/dt = k1[III-3a] – k2[III-4a]      (3) 
 




–k2t)      (4) 
 
Equation 4 cannot be solved exactly but can be accurately approximated via the 
mathematical treatment of Emanuel.
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                (5) 
 
where βmax = ([III-6a]max/[III-3a]0) and κ = k2/k1 
The value of βmax can be calculated graphically directly from Figure III.2 and κ 
can be calculated iteratively so that equation 5 is satisfied. The value of k2 is calculated 
from the product of κ and k1.  
 
Figure III.4 Eyring Plot for k1 in the Conversion of III-3b to III-6b from 25–60 °C 
 
 
Figure III.5 Eyring Plot for k2 in the Conversion of III-6b to III-4b from 25–60 °C 
 
 





































Table III.1 Average Rate Constant Data for Eyring Plots 





III-3aIII-6aIII-4a 297 1.74 ± 0.02 x 10
-3
 1.36 ± 0.41 x 10
-3
 
III-3bIII-6bIII-4b 298 4.16 ± 0.19 x 10
-5
 4.78 ± 0.20 x 10
-4
 
III-3bIII-6bIII-4b 308 1.88 ± 0.01 x 10
-4
 1.96 ± 0.03 x 10
-4
 
III-3bIII-6bIII-4b 318 5.71 ± 0.17 x 10
-4
 6.05 ± 0.43 x 10
-3
 
III-3bIII-6bIII-4b 328 2.15 ± 0.16 x 10
-3
 1.72 ± 0.02 x 10
-2
 
III-3bIII-6bIII-4b 333 3.98 ± 0.24 x 10
-3




Description of Structural Assignment for III-6a 
The structure of III-6a was assigned through comparison of 
13
C chemical shifts of 
III-6a-
13
C3 with pyrrolidine product III-4a, amido complex III-3a-
13
C3, and through 
comparison of 
31






The assignment of the chemical shifts shown below to Ca, Cb, and Cc in 
pyrrolidine product III-4a was established through COSY and HSQC experiments. The 
signal attributed to Ca in III-3a-
13
C3 was assigned on the basis of chemical shift (the only 
labeled carbon in the aliphatic region of the spectrum). Signals assigned to Cb and Cc 
appear in the alkene region of the 
13
C NMR spectrum. The signal at δ 114.0 is coupled to 
only one other labeled carbon atom, whereas the signal at δ 140.3 is coupled to two 
labeled carbon atoms. This indicates that the signal at δ 140.3 corresponds to Cb (the 
internal alkene carbon), whereas the signal at δ 114.0 is attributed to Cc. The observation 
that the chemical shifts of the alkene carbon atoms in III-3a-
13
C3 are nearly identical to 
those of the corresponding potassium arylamide III-2a-
13




is consistent with the assignment of III-3a-
13
C3 as the four-coordinate, alkene unbound 
species illustrated below. 
A listing of key NMR data is provided below in Table III.2 Analysis of this data 
is provided below. 
 
Table III.2 Key Spectroscopic Data for the Reaction Mixture 
Molecule δCa δCb δCc δP1 δP2 
 
33.2 (d J = 
42.0 Hz) 
140.3 (dd, J 
= 42.0, 69.3 
Hz) 
114.0 (d, J 
= 69.3 Hz) 
24.9 (d, J = 
38.1 Hz) 
9.0 (d, J = 
35.5 Hz) 
 
30.0 (d, J = 
35.6 Hz) 
61.3 (app t, 
J = 35.2 
Hz) 




34.8 (d, J = 
36.0 Hz) 
62.0 (app t, 
J = 37.1 
Hz) 
30.0 (ddd, J 
= 8.1, 38.2, 
91.1 Hz) 
21.3 (dd, 
JPP = 23 
Hz, JPC = 8 
Hz) 
16.6 (dd, 
JPP = 23 
Hz, JPC = 
92 Hz) 
 
– – δCH3 = 7.8 21.3 (dd, 
JPP = 23 
Hz, JPC = 8 
Hz) 
17.8 (dd, 
JPP = 23 
Hz, JPC = 
92 Hz) 
 
Several aspects of the data shown in row 3 for intermediate III-A are consistent 
with the illustrated structure III-6a-
13
C3, and are inconsistent with other reasonable 






Evidence that Supports the Assignment of III-A as Structure III-6a 
The chemical shift, splitting pattern, and coupling constant of Cb (62.0 ppm, app t, 
J = 37.1 Hz) is nearly identical to those of Cb in the pyrrolidine product III-4a (61.3 ppm, 
app t, J = 35.2 Hz).  
The assignment of the peak at 62.0 ppm in the carbon spectrum of intermediate 
III-A as Cb is supported by the observation that Cb is an apparent triplet, indicating 
coupling to both Ca and Cc. In contrast, the signal for Ca is a doublet, indicating that Ca is 
coupled with only a single adjacent labeled carbon atom. The signal for Cc is a doublet of 
doublet of doublets (ddd), which results from coupling with a single additional labeled 
carbon and the two phosphorus atoms (noted below). 
Carbon Cc is coupled to the phosphorus atoms of the dppf ligand, which is 




 coupling constants (8.1 
Hz and 92 Hz, respectively) are identical to those reported for the known complex 
(dppf)Pd(Ph)(
13
CH3) (8 Hz and 92 Hz).  
Carbon Cc is shifted upfield in intermediate III-A (30.0 ppm) relative to Cc in the 
pyrrolidine product III-4a (38.3 ppm). This is also consistent with the presence of a Cc–
Pd bond in intermediate III-A. 




 in intermediate III-A (21.3 and 16.6 ppm) are 




 in the (dppf)Pd(Ph)(
13
CH3) complex (21.3 







Evidence that Rules out Assignment of III-A as Structure III-5a 
The chemical shift of all three labeled carbon atoms present in intermediate III-A 
are upfield of 65 ppm, and are inconsistent with the presence of alkene functionality.  
The chemical shift of P
2
 in intermediate III-A (16.6 ppm) is significantly different 
from the chemical shift of P
2
 in amido complex III-3a, suggesting that P
2
 in intermediate 
III-A is not trans to an electronegative atom. 
 
Evidence that Rules out Assignment of III-A as Structure III-7a 
The chemical shift of Cb in intermediate III-A appears at 62 ppm, which is 
inconsistent with a metal-bound carbon atom that is not adjacent to a heteroatom. The 
chemical shift of Cb in III-7a should be well upfield of 62 ppm, as Cb in this structure is 
not adjacent to an electronegative heteroatom. 
Carbon Cb in the spectrum of intermediate III-A does not show evidence for 
coupling with either of the phosphorous atoms. However, the Cb atom that would 





Carbon Cc in the spectrum of intermediate III-A shows characteristic two-bond 
P–C coupling. However, the Cc atom that would correspond to III-7a should not show 
significant P–C coupling. 
The chemical shift of P
2
 in intermediate III-A (16.6 ppm) is significantly different 
from the chemical shift of P
2
 in amido complex III-3a, suggesting that P
2
 in intermediate 



















C3 in the presence of 1.1 equiv of dppf. The observable species present in 






C3, dppf, and a small amount of free 
N-(p-fluorophenyl)pent-4-enylamine (bearing 
13
C labeled allylic and alkenyl carbon 
atoms).  
Two signals (one due to III-6a-
13
C3, and one due to III-4a-
13
C3) appear at ca. 30 
ppm. There is a ddd centered at 30 ppm (J = 8.1, 38.2, 91.1 Hz) that is attributed to Cc in 
the labeled intermediate III-6a-
13
C3. In addition, a second signal is also centered at 30 
ppm (d, J = 35.6 Hz) that is attributed to Ca in the labeled pyrrolidine product III-4a-
13
C3. The signal attributed to pyrrolidine was assigned on the basis of COSY and HSQC 
spectra from the isolated pyrrolidine III-4a. The signal attributed to III-6a-
13
C3 was 
assigned on the basis of C–P coupling through the metal. The coupling constants of 8.1 




There are two signals (one due to III-6a-
13
C3, and one due to III-4a-
13
C3) that 
appear close to each other near 60 ppm. The signal centered at 61.3 ppm (app t) has been 
assigned as Cb (the carbon adjacent to the nitrogen atom) in the pyrrolidine product III-
4a-
13
C3. This assignment was corroborated by HSQC NMR data for III-4a. A second 
signal is centered at 62.0 ppm (app t) and has been assigned as Cb (the carbon adjacent to 
the nitrogen atom) in intermediate III-6a-
13
C3. This assignment was made on the basis of 
chemical shift and the splitting pattern that indicates it is coupled to two other 
13
C labeled 








principle, appear as dd, the coupling constants are sufficiently similar to give rise to the 
apparent triplets. 
The third labeled carbon signal for III-6a-
13
C3 appears at 34.8 ppm (d, J = 36.0 
Hz). This signal has been assigned as Ca on the basis of chemical shift and its coupling to 
a single labeled carbon atom.  
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Intramolecular Insertion of Alkenes into Pd–N Bonds. Effects of Substrate and 





Studies on the synthesis and reactivity of a series of (P–
P)Pd(Ar)[N(Ar
1
)(CH2)3CR=CHR’] complexes IV-3 are described. These complexes are 
transformed to observable (P–P)Pd(Ar)[pyrrolidin-2-ylmethyl] complexes IV-4 via syn-
insertion of the pendant alkene into the Pd–N bond. Complexes IV-4 then undergo C–C 
bond-forming reductive elimination to yield N-aryl-2-benzylpyrrolidine derivatives IV-2. 
Kinetic studies indicate the rates of conversion of IV-3 to IV-4 and IV-4 to IV-2 are 
within one order of magnitude. The effects of phosphine ligand structure, alkene 
substitution, and the electronic properties of the Ar and Ar
1
 groups on reaction rates are 
reported, as are the results of deuterium isotope effect studies. The mechanism of the 
aminopalladation step is discussed in detail, and the results of the experiments described 
in this paper are most consistent with conversion of IV-3 to IV-4 via rate-determining 
ligand displacement followed by fast aminopalladation. These transformations represent 
rare examples of syn-migratory insertion of unactivated alkenes into Pd–N bonds. 
The syn-insertion of alkenes into Pd–N bonds has been implicated as a key step in 
many useful Pd-catalyzed reactions. For example, Pd-catalyzed alkene carboaminations 
between -aminoalkene derivatives IV-1 and aryl bromides are believed to involve syn-




by reductive elimination of the resulting palladium(aryl)(pyrroldin-2-ylmethyl) 
complexes (e.g, IV-4) to yield substituted pyrrolidine products IV-2 (Scheme IV.1).
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The syn-aminopalladation step leads to formation of a C–N bond, and also leads to 
generation of two stereocenters, which are retained in the pyrrolidine products. This 









 and hetero-Heck 
transformations.
107,108  
Scheme IV.1 Pd-Catalyzed Alkene Carboamination 
 
 
Despite the significance of syn-aminopalladation processes, and the influence of 
this pathway on the stereochemical outcome of synthetically useful reactions, 
documented unambiguous examples of syn-insertions of olefins into late transition metal-
nitrogen bonds are very rare,
109
 and cases involving palladium complexes have only 
recently been described by our group and Hartwig’s group. As such, little is known about 
the effect of palladium amido complex structure on the facility of aminopalladation. 
However, information on the relationship between structural features and reactivity could 
potentially be used to improve the efficiency of catalytic processes, or to guide the design 




In this Chapter, detailed studies on the synthesis and reactivity of (P–
P)Pd(Ar)[N(Ar
1
)(CH2)3CR=CHR’] complexes IV-3 are described.
110
 These complexes 
undergo syn-migratory insertion of the alkene into the Pd–N bond to provide detectable 
(P–P)Pd(Ar)(pyrrolidin-2-ylmethyl) complexes IV-4, which undergo C–C bond forming 
reductive elimination to yield N-aryl-2-benzylpyrrolidine derivatives IV-2. The rates of 
aminopalladation of IV-3 and reductive elimination of IV-4 are influenced by several 
structural parameters, including the electronic properties of the Ar and Ar
1
 groups, the 
degree of alkene substitution, and the nature of the bis-phosphine ligand. Our 
experiments suggest the alkene aminopalladation occurs from a four-coordinate complex, 
and illustrate that ligand electronic properties can be tuned to have a positive influence on 
the rates of both aminopalladation and reductive elimination. 
Following our initial experiments on the reactivity of complex III-3a (Chapter 
III), we sought to probe the effects of N-aryl group structure, Pd-aryl group structure, and 
ligand structure on the rate of the alkene aminopalladation process. To this end a series of 
(bis-phosphine)Pd(Ar)(Br) complexes were prepared using standard routes
111
 and were 
treated with potassium salts of N-(aryl)-pent-4-enylamine derivatives in a manner 
analogous to that described above in Chapter III. In all cases the amido complexes (IV-
3a-k) were generated in < 2 min at rt, and were characterized by diagnostic 
31
P NMR 
signals with chemical shifts close to those observed for III-3a. Reactions were allowed to 
proceed at rt and kinetic data were collected by 
19
F NMR spectroscopy. Rate constants 
for k1 (conversion of IV-3 to IV-4) and for k2 (conversion of IV-4 to IV-2) were then 




Hammett plots were constructed from the data shown in Table IV.1. Clear trends 
were observed in transformations of complexes IV-3a–3f bearing various N-aryl 
substituents, and linear plots of log(kR/kH) were obtained for both steps in the conversion 
of IV-3a–f to IV-2a–f (Figures IV.1 and IV.2). Best fits were obtained using the 
Hammett p parameters which gave  = –2.5 ± 0.2 for step 1 (IV-3 to IV-4) and  = –
0.92 ± 0.06 for step 2 (IV-4 to IV-2). The increased reactivity of complexes bearing 
electron-rich N-aryl groups is consistent with trends previously reported by Hartwig for 
alkene insertion reactions of cyclometalated [t-Bu2PCH2C6H4]Pd(NAr2)complexes.
12
  
A similar analysis of data obtained in reactions of N-(p-
fluorophenyl)pentenylamine derived complexes IV-3a and IV-3g–k bearing various R
2
 
groups failed to provide clear trends. Hammett plots derived from this series of 
experiments were nonlinear (Figures IV.3 and IV.4), although all values of k1 for this 
series were within a factor of 2.5 of each other, and all values of k2 for this series were 
within a factor of 7 of each other. As such, although the precise effect of Pd-aryl 
substituent on reactivity is unclear, it appears to be relatively small. We were unable to 
obtain k1 and k2 values for reactions of complexes derived from electron-poor aryl 
bromides (R = CN, CF3), as these complexes underwent rapid C–N bond-forming 
reductive elimination (full conversion was observed in < 1 min at rt) to yield N-(p-
fluorophenyl)-N-(C6H4-p-R
2
)-pent-4-enylamines, rather than the desired 




























IV-3b IV-4b IV-2b t-Bu F 5.59 ± 0.46 2.64 ± 0.45 
IV-3c IV-4c IV-2c OMe F 4.45 ± 0.70 2.18 ± 0.38 
IV-3d IV-4d IV-2d H F 2.44 ± 0.12 1.88 ± 0.07 
IV-3a IV-4a IV-2a F F 1.74 ± 0.02 1.36 ± 0.41 
IV-3e IV-4e IV-2e Cl F 0.56 ± 0.02 0.90 ± 0.02 
IV-3f IV-4f IV-2f CN F 0.042 ± 
0.006 
0.42 ± 0.14 
IV-3g IV-4g IV-2g F t-Bu 3.55 ± 0.08 4.08 ± 0.52 
IV-3h IV-4h IV-2h F OMe 4.03 ± 1.15 2.64 ± 1.13 







F CN –a –a 
Conditions: All reactions were conducted in NMR tubes with [IV-3] = 6.26 mM, [dppf] = 12.6 mM, [2-
fluorotoluene] = 11.8 mM (internal standard), THF, 24 °C. All values for k1 and k2 are the average obtained 
over duplicate runs. a. C–N bond-forming reductive elimination from IV-3 to provide the corresponding N-
(C6H4-p-F)-N-(C6H4-p-R
2)-pent-4-enylamine was the predominant reaction pathway observed. 
 







N -Aryl Hammett Plot for k1






















Figure IV.2 Hammett Correlation for the N-Aryl Group k2 
 









N -Aryl Hammett Plot for k2











































The steric and electronic properties of the bis-phosphine ligand also had a 
significant influence on reactivity in the conversion of IV-3l-r to IV-2e. As shown in 
Table IV.2, the fastest transformations were observed with wide bite angle ligands N-
methyl-nixantphos
112
 and xantphos. Amido complexes IV-3q-r bearing these ligands 
were rapidly converted to pyrrolidine IV-2e at rt with rates too fast to accurately 
measure; both reactions proceeded to completion in < 1 min. In contrast, complexes IV-
3l-o bearing ligands with relatively small bite angles failed to undergo the desired 
transformation. Complexes IV-3m and IV-3o did not react at temperatures up to 60 °C, 
and complexes IV-3l and IV-3n decomposed to afford complex mixtures of products. 
The DPE-Phos complex IV-3p was transformed to IV-2e with an observed rate constant 









































IV-3l Not observed dppe 86 Decomposition of Complex
a 
IV-3m Not observed dpp-Benzene 87 No Reaction
b 
IV-3n Not observed dppp 91 Decomposition of Complex
a 
IV-3o Not observed (rac)-BINAP 93 No Reaction
b 
IV-3e IV-4e dppf 99 k1 = 0.56 ± 0.02 x 10
–3 s–1  
k2 = 0.90 ± 0.02 x 10
–3 s–1 
IV-3p Not observed DPE-Phos 104 kobs = 0.686 x 10
–3 s–1c 
IV-3q Not observed xantphos 108 Too fast to measure
d 
 
IV-3r Not observed nixantphos-Me 114 Too fast to measure
d 
 
Conditions: All reactions were conducted in NMR tubes with [IV-3] = 6.26 mM, [dppf] = 12.6 mM, [2-
fluorotoluene] = 11.8 mM (internal standard), THF, 24 °C. All values for k1 and k2 are the average obtained 
over two or more runs.  a.Decomposition to afford a complex mixture of products was observed. The 
expected pyrrolidine IV-2e was not detected in significant amounts. b. No reaction was observed at 
temperatures up to 60 °C. c. No intermediate was detected in this reaction. d. Complete conversion to IV-2e 
was observed within 1 min of mixing IV-3q-r and the potassium N-arylamide salt. 
 
The effect of ligand electronic properties on reaction rates was examined through 
comparison of complexes bearing differently substituted dppf-derived ligands. As shown 
in Table IV.3, the presence of para-electron withdrawing trifluoromethyl groups on the 
P-Ar substituents in complex IV-3s led to acceleration of both steps of the transformation 
to IV-2d relative to the analogous reaction of parent dppf complex IV-3d. In contrast, 
decreased rates were observed for both steps in the conversion of complex IV-3t bearing 





























IV-3s IV-4s dppf-p-CF3 4.08 ± 0.03 14.6 ± 2.4 
IV-3d IV-4d dppf 2.44 ± 0.12 1.88 ± 0.07 
IV-3t IV-4t dppf-p-OMe 0.77 ± 0.01 0.59 ± 0.20 
Conditions: All reactions were conducted in NMR tubes with [IV-3] = 6.26 mM, [dppf] = 12.6 mM, [2-
fluorotoluene] = 11.8 mM (internal standard), THF, 24 °C. All values for k1 and k2 are the average obtained 
over two runs. 
 
The stereochemistry of the aminopalladation reaction was determined through 
reaction of deuterated amido complex III-3c. As shown in Scheme IV.2, this complex 
was cleanly transformed to pyrrolidine III-4c with net syn-addition of the aryl group and 
the N-atom across the C–C double bond. This supports a mechanism involving syn-
migratory insertion of the alkene into the Pd–N bond, rather than amide dissociation, 
alkene coordination, and outer-sphere attack of the pendant nucleophile. This result is 
also consistent with the stereochemical outcome of Pd-catalyzed carboamination 



















Absence of Deuterium Isotope Effect at Internal Alkene Position 
 
 
Kinetic measurements were acquired for the two-step conversion of III-3c to III-








) and were compared to 
values obtained for the analogous non-deuterated complex IV-3e. This comparison 
indicated no significant isotope effect for step 1 of the transformation (k1H/k1D = 1.06 ± 
0.09), but an isotope effect was observed for the reductive elimination (step 2, k2H/k2D = 
1.25 ± 0.05). Related experiments conducted with substrate IV-3v, which contains a 
deuterium atom at the internal alkene carbon, indicated no significant isotope effect for 
either step (Scheme IV.3). 
In order to probe the effect of alkene substitution on reactivity, complexes IV-3w-
y bearing 1,1- or 1,2-disubstituted alkenes were prepared in an analogous manner to the 
amido complexes described above. As shown in Table IV.4, complex IV-3w, which 




intermediate IV-4w at a rate that is 10-fold slower than for the analogous conversion of 
unsubstituted derivative IV-3d to IV-4d. However, the rate of reductive elimination from 
intermediate IV-4w to yield IV-2w is comparable to that for the transformation of IV-4d 
to IV-2d. Complexes IV-3x and IV-3y failed to undergo aminopalladation at 
temperatures up to 60 °C. 
Table IV.4
 



















IV-3d IV-4d IV-2d H H H 2.44 ± 0.12 1.88 ± 0.07 
IV-3w IV-4w IV-2w H H Me 0.25 ± 0.09 1.58 ± 0.16 
IV-3x Not obsd – Me H H –
a –a 
IV-3y Not obsd – H Me H –
a –a 
Conditions: All reactions were conducted in NMR tubes with [IV-3] = 6.26 mM, [dppf] = 12.6 mM, [2-
fluorotoluene] = 11.8 mM (internal standard), THF, 24 °C. All values for k1 and k2 are the average obtained 
over two or more runs. a. No reaction was observed up to 60 °C. 
 
 
Plausible Mechanistic Scenarios for the Conversion of Amido Complexes IV-3 to 
Palladium(aryl)(pyrrolidin-2-ylmethyl) Complexes IV-4 
The conversion of (P–P)Pd(Ar)[N(Ar
1
)(CH2)3C(R)=C(R)(R’) complexes IV-3 to 
(P–P)Pd(Ar)(pyrrolidin-2-ylmethyl) complexes IV-4 presumably does not occur via a 
single step, but instead likely involves: (a) intramolecular coordination of the alkene to 
palladium; and (b) syn-aminopalladation. As such, the conversion of IV-3 to IV-4 could 
potentially proceed through four different reasonable pathways (Scheme IV.4). Two 
scenarios would involve syn-aminopalladation from five-coordinate complex IV-7. The 
first would entail rate-limiting alkene coordination of IV-3 to provide IV-7, which could 




reversible intramolecular alkene coordination of IV-3 would yield IV-7, which could 
undergo rate-limiting aminopalladation to IV-4 (Path B).  
Scheme IV.4
 
Possible Mechanistic Pathways for Conversion of IV-3 to IV-4 
 
Two other possibilities would involve ligand substitution of alkene for one arm of the 
chelating bis-phosphine ligand to give four-coordinate alkene complex IV-10 
(presumably via an associative mechanism; IV-7 would be a transient intermediate en 
route to IV-10).
113
 One of these pathways (Path C) would proceed via rate-limiting 
associative substitution of IV-3 to give IV-10, followed by fast aminopalladation of IV-
10 to yield IV-4. Finally, fast and reversible associative ligand substitution of IV-3 to IV-
10 followed by rate-limiting aminopalladation from IV-10 to IV-4 is also a reasonable 
possibility (Path D).  
As shown in Scheme IV.4, Path B and Path D for the conversion of IV-3 to IV-4 
both involve rapid formation of an alkene-bound complex (IV-7 or IV-10) followed by 
rate-limiting aminopalladation (from either IV-7 or IV-10). The fact that neither IV-7 nor 
IV-10 are detectable intermediates argues against Paths B and D, but cannot be used to 
rule out these pathways as it is possible the equilibrium between IV-3 and IV-7 or IV-3 




reactions with deuterated substrates III-3c and IV-3v provide good evidence that neither 
Path B nor D are in operation.
114
 The transformations of IV-7 to IV-4 and IV-10 to IV-4 




. As such, if this 
step were rate limiting, a significant deuterium isotope effect should be observed at both 
alkene carbon atoms. However, the conversions of deuterated complexes III-3c and IV-
3v to III-4c and IV-4v respectively proceed at the same rate as the transformation of all-
protio complex IV-3e to IV-4e. Finally, the observed effect of ligand bite angle on 
reaction rate (Table IV.2) provides additional evidence against Path D, as the bite angle 
should not influence the rate of aminopalldation from IV-10 to IV-4 if the ligand is not 
bound to the metal by both phosphine groups in the rate determining step.
115
  
Paths A and C both involve rate-limiting alkene coordination to the metal center, 
but differ in the nature of the intermediate complex that undergoes aminopalladation. In 
Path A, aminopalladation would occur directly from the five-coordinate intermediate IV-
7, whereas Path C involves substitution of alkene for phosphine followed by insertion 
from four-coordinate complex IV-10. Several pieces of evidence indicate the mechanism 
of conversion of IV-3 to IV-4 does not proceed via Path A. First of all, the positive 
entropy values measured for the conversion of IV-3f to IV-4f suggest that Path A is not 
operating, as the conversion of IV-3 to IV-7 should have a fairly large negative entropy 
of activation due to the increase in organization in the transition state between complex 
IV-3 with a single chelate (P–P) and IV-7, which contains two chelates (P–P and alkene–
N). In contrast, the measured entropy of +4.6 eu is consistent with the conversion of IV-3 
to IV-10 via intermediate IV-7 (Path C), as mono-chelated complex IV-10 is less ordered 




The effect of ligand and amine properties on reaction rate can also be used to 
differentiate between Paths A and C. If transformations proceed via Path C the reaction 
rate should be strongly influenced by factors that favor phosphine displacement.
116
 In 
contrast, the rate of reactions that proceed by way of Path A should be insensitive to 
factors that favor ligand substitution, and instead should only be affected by parameters 
that influence initial alkene binding to the metal. The effect of phosphine ligand 
properties on reaction rate is most consistent with reaction via Path C. As illustrated in 
Scheme IV.3, complex IV-3s, which contains electron-withdrawing p-CF3-C6H4 groups 
on the phosphines, reacts ca. five times faster than the related complex IV-3t that bears p-
MeO-C6H4 phosphine substituents. The displacement of one arm of the electron-poor p-
CF3-dppf ligand should be more facile than for the relatively electron rich p-MeO-dppf 
ligand. In addition, although we were unable to obtain quantitative rate data for ligands 
with very large or very small bite angles, qualitatively it is clear that the transformation is 
facilitated by wide bite angle ligands and impeded by ligands with small bite angles. This 
effect is also consistent with rate-limiting associative ligand substitution (Path C).
117
  
The reactions of complexes bearing electron-rich N-aryl groups are considerably 
faster than those bearing electron-poor N-aryl groups. For example, the conversion of 
complexes IV-3b and IV-3c, which contain electron-donating p-t-Bu and p-OMe groups 
on the N-aryl moiety, to IV-4b and IV-4c are two orders of magnitude faster than the 
conversion of IV-3f to IV-4f (N-aryl = p-CN-C6H4). This electronic effect also suggests 
the conversion of IV-3 to IV-4 proceeds via Path C rather than Path A. The electron-rich 
amido groups should increase the electron density of the metal center, which should in 




coordination of the relatively electron-rich alkene should be facilitated by a less electron-
rich, more Lewis acidic metal center,
118,119
 and rates should be faster with relatively 
electron-poor N-aryl groups.  
No clear trend was observed for the influence of Pd-aryl group electronics on the 
rate of conversion of IV-3 to IV-4. As such this data cannot be used to refute any of the 
possible mechanistic pathways. The origin of these electronic effects is unclear, but the 
differences in relative rates of aminopalladation for complexes IV-3a, and IV-3g-i are 
small (within a factor of ca. 2). However, our data do indicate that the rate of C–N bond-
forming reductive elimination dramatically increases relative to the rate of 
aminopalladation in complexes IV-3j-k, which contain strong electron-withdrawing 
substituents on the Pd-Ar group. 
Influence of Structural Features on Carbon–Carbon Bond-Forming Reductive 
Elimination of IV-4 to Afford IV-2 
The rate of C–C bond-forming reductive elimination from 
(dppf)Pd(Ar)(pyrrolidin-2-ylmethyl) complexes IV-4 is also affected by structural 
features of the complexes. For example, the electronic properties of the N-aryl group 
have a significant influence on this transformation, as complexes IV-4 bearing electron-
rich N-aryl groups undergo reductive elimination five times faster than electron-poor 
derivatives. In addition, the rate of reductive elimination of the (dppf)Pd(Ar)(pyrrolidin-
2-ylmethyl) complexes IV-4 is considerably slower than the analogous reaction of the 
(dppf)Pd(Ar)(alkyl) derivative (dppf)Pd(C6H4-p-F)[CH2(cyclopentyl)] (III-8). These 
trends are likely due to inductive effects that slow the relative rate of reductive 




derivatives of IV-4. The possibility that the rate of reductive elimination is slowed by 
binding of the nitrogen atom in IV-4 to the metal center appears less likely given the fact 
that electron-poor N-aryl groups should disfavor N-coordination, but rates are slowest 
with these groups. 
The effect of ligand electronic properties and bite angle on the rate of reductive 
elimination from IV-4 to IV-2 is also consistent with prior observations on rates of C–C 
bond formation from Pd(II) complexes.
120,121
 In our system complex IV-4s, which bears a 
relatively electron-poor ligand, undergoes reductive elimination twenty-five times faster 
than the related complex IV-4t, which is ligated by a more electron-rich phosphine. This 
is likely due to the destabilizing effect of the electron-poor phosphine on the Pd(II) 
oxidation state.
120
 The reductive elimination processes also appear to be most facile with 
wide-bite angle ligands, which both destabilize the ground state of (P–P)Pd(Ar)(R) 
complexes and also stabilize the transition state for C–C bond formation.
121
 The observed 
deuterium isotope effect at the carbon undergoing bond-formation is consistent with rate-
limiting C–C bond formation in the conversion of IV-4 to IV-2, rather than rate limiting 
phosphine dissociation.  
In conclusion, our experiments on the conversion of (P–
P)Pd(Ar)[N(Ar
1
)(CH2)3CR=CHR’] complexes IV-3 to N-aryl-2-benzylpyrrolidine 
derivatives IV-2 indicate that the transformations proceed via syn-insertion of the alkene 
into the Pd–N bond. This alkene syn-aminopalladation pathway has rarely been observed 
in well-characterized palladium complexes, but plays a key role in catalytic reactions. 
These studies illustrate that ligand structure and heteroatom basicity/nucleophilicity have 




be used in the design of new catalysts for reactions involving aminopalladation. Finally, 
our data suggest that insertion occurs from a four-coordinate alkene complex, rather than 
a five-coordinate species. This mechanistic information provides insight into previously 
observed trends in asymmetric Pd-catalyzed alkene carboamination reactions. Use of 
chiral bis-phosphine ligands provides poor enantioselectivity in these transformations,
32
 




All reactions were carried out under a dry nitrogen atmosphere in flame-dried 
glassware using standard Schlenk techniques or in a nitrogen-filled glovebox. All 
reagents were obtained from commercial sources and used without further purification. 
Crude palladium dimers
122
 and pure bisphosphine-ligated Pd-complexes
123
 were prepared 
analogous to the methods of Buchwald. Toluene, THF, diethyl ether, and 
dichloromethane were purified using a GlassContour solvent purification system. THF 
used in kinetic experiments was stirred as a dark purple solution of sodium/benzophenone 
overnight under vacuum and then vacuum transferred before use. 2-fluorotoluene, 4-
fluorotoluene, and pentane were distilled from CaH2. CD2Cl2, acetic acid-d4, and THF-d8 
were obtained from Cambridge Isotope Laboratories and used as received.  Yields refer 
to isolated yields of compounds estimated to be ≥95% pure as determined by 
1
H NMR 
analysis unless otherwise noted. The yields reported in the experimental section describe 




duplicate experiments. All kinetic experiments were set up in a glovebox under nitrogen 
atmosphere. All glassware and microsyringes associated with kinetics experiments were 
oven dried at 120 °C overnight before use. 
31
P NMR shifts are given relative to an 85% 
H3PO4 external standard. 
1
H NMR shifts for the experimental section are reported 
downfield of TMS in CDCl3 or referenced to residual protia in THF-d8. 
19
F NMR shifts 
for the experimental section are referenced to residual protia in CDCl3, or to an internal 
standard of 2-fluorotoluene (–117.2 ppm) or 4-fluorotoluene (–117.9 ppm) in THF-d8.   
   
Preparation and Characterization of Potassium Amide Substrates General 
Procedure 6: Conversion of N-aryl-pent-4-enamides to N-aryl-pent-4-enylamines. 
A flame-dried flask equipped with a magnetic stirbar was charged with the appropriate N-
aryl-pent-4-enamide (1.0 equiv) and purged with nitrogen for 5 min. THF (4 mL/mmol 
substrate) was added and the resulting solution was cooled to 0 °C. To this solution, a 1 
M solution of LiAlH4 in diethyl ether (1.2 equiv) was added slowly over 10 min. The 
reaction mixture was stirred at 0 °C for 15 min then warmed to rt and stirred overnight 
(ca. 16 h). The reaction mixture was cooled to 0 °C, then water (0.05 mL/mmol 
substrate), 6 M NaOH (0.05 mL/mmol substrate) and additional water (0.15 mL/mmol 
substrate) were sequentially added. The resulting white suspension was stirred vigorously 
for 30 min, then filtered through glass wool and the white precipitate was washed with 
diethyl ether (3 × 30 mL). The filtrate was dried over anhydrous sodium sulfate, filtered, 
and concentrated in vacuo. The resulting product was purified by flash chromatography 




General Procedure 7: Conversion of N-aryl-pent-4-enylamines to Potassium N-aryl-
pent-4-enyl Amides. A flame-dried flask equipped with a magnetic stirbar was charged 
with the appropriate N-aryl-pent-4-enylamine (1.3 equiv) and purged with nitrogen for 5 
min. In the glovebox, a separate flame-dried Schlenk flask equipped with a magnetic 
stirbar was charged with solid KHMDS (1.0 equiv), capped with a septum, removed from 
the glovebox, and connected to a vacuum/nitrogen manifold. Toluene (5 mL/mmol 
KHMDS) was added to each flask to afford clear solutions. Subsequently the amine 
solution was added dropwise to the KHMDS solution at rt to afford a bright yellow 
solution. The solution was stirred for 1.5 h at rt, over which time the solution became 
progressively more cloudy. The solvent was removed under high vacuum to afford a 
crude solid, which was taken into the glovebox under vacuum. The crude solid was 
purified on a medium glass frit via rinsing/trituration with pentane (4  10 mL) The 
resulting potassium N-aryl-pent-4-enyl amides were determined to contain ca. 0.1–2.7% 
KHMDS as judged by 
1
H NMR analysis. This material was used without further 
purification. 
Potassium (4-tert-butylphenyl)(pent-4-enyl)amide (IV-6b). The conversion of 4-
pentenoic acid (2.0 mL, 19.6 mmol) and 4-tert-butylaniline (6.3 mL, 40 mmol) to N-(4-
tert-butylphenyl)pent-4-enamide was accomplished using a procedure analogous to that 
employed above for the preparation of N-(4-fluorophenyl)pent-4-enamide. This 
procedure afforded 3.10 g (68%) of N-(4-tert-butylphenyl)pent-4-enamide as a fluffy 
white solid, m.p. 103–105 °C.
 1
H NMR (400 MHz, CDCl3) δ 7.45–7.40 (m, 2 H), 7.35–




1 H), 2.52–2.40 (m, 4 H), 1.30 (s, 9 H); 
13
C NMR (100 MHz, CDCl3) δ 170.7, 147.4, 
137.1, 135.4, 126.0, 119.9, 116.1, 37.0, 34.6, 31.6, 29.7. 
N-(4-tert-Butylphenyl)pent-4-enamide (1.50 g, 6.5 mmol) was reduced according 
to General Procedure 6 to afford 1.14 g (81%) of 4-tert-butyl-N-(pent-4-enyl)aniline (IV-
1b) as a pale orange oil.
 1
H NMR (400 MHz, CDCl3) δ 7.23–7.16 (m, 2 H), 6.58–6.52 (m, 
2 H), 5.90–5.77 (m, 1 H), 5.09–5.01 (m, 1 H), 5.01–4.96 (m, 1 H), 3.50 (s, br, 1 H), 3.10 
(t, J = 7.2 Hz, 2 H), 2.20–2.11 (m, 2 H), 1.69 (quint, J = 7.2 Hz, 2 H), 1.27 (s, 9 H); 
13
C 
NMR (100 MHz, CDCl3) δ 146.2, 140.0, 138.3, 126.1, 115.2, 112.6, 43.8, 34.0, 31.7, 
31.5, 28.9; IR (film) 3411 cm
-1
. MS (EI) 217.1832 (217.1830 calcd for C15H23N). 
General Procedure 7 was used for the conversion of 4-tert-butyl-N-(pent-4-
enyl)aniline (306 mg, 1.4 mmol) to 159 mg (59%) of the title compound as a yellow 
powder containing 0.3% KHMDS.  
1
H NMR (400 MHz, THF-d8) δ 6.82 (d, J = 9.2 Hz, 2 
H), 6.04 (d, J = 9.2 Hz, 2 H), 6.02–5.90 (m, 1 H), 5.10–5.01 (m, 1 H), 4.95–4.88 (m, 1 
H), 2.97–2.88 (m, 2 H), 2.25–2.16 (m, 2 H), 1.82–1.71 (m, 2 H), 1.18 (s, 9 H); 
13
C NMR 
(100 MHz, THF-d8) δ 159.8, 141.2, 130.1, 126.9, 113.9, 110.7, 52.1, 34.2, 34.0, 33.9, 
32.7. 
Potassium (4-methoxyphenyl)(pent-4-enyl)amide (IV-6c). The conversion of 4-
pentenoic acid (2.0 mL, 19.6 mmol) and p-anisidine (4.93 g, 40 mmol) to N-(4-
methoxyphenyl)pent-4-enamide was accomplished using a procedure analogous to that 
described above for the preparation of N-(4-fluorophenyl)pent-4-enamide. This procedure 
afforded 3.28 g (81%) of N-(4-methoxyphenyl)pent-4-enamide as a white solid, m.p. 91–
93 °C.
 1




2 H), 5.94–5.81 (m, 1 H), 5.12 (dd, J = 1.6, 16.8 Hz, 1 H), 5.05 (d, J = 10.4 Hz, 1 H), 
3.78 (s, 3 H), 2.52–2.39 (m, 4 H); 
13
C NMR (100 MHz, CDCl3) δ 170.6, 156.6, 137.1, 
131.2, 122.0, 116.0, 114.3, 55.7, 36.8, 29.7. 
N-(4-Methoxyphenyl)pent-4-enamide (1.50 g, 7.3 mmol) was reduced according 
to General Procedure 6 to afford 1.27 g (91%) of 4-methoxy-N-(pent-4-enyl)aniline (IV-
1c) as a pale yellow oil.
 1
H NMR (400 MHz, CDCl3) δ 6.81–6.74 (m, 2 H), 6.60–6.53 (m, 
2 H), 5.90–5.76 (m, 1 H), 5.10–4.96 (m, 2 H), 3.73 (s, 3 H), 3.35 (s, br, 1 H), 3.07 (td, J = 
7.2, 1.6 Hz, 2 H), 2.20–2.12 (m, 2 H), 1.69 (quintd, J = 1.6, 7.2 Hz, 2 H); 
13
C NMR (100 
MHz, CDCl3) δ 152.1, 142.9, 138.3, 115.1, 115.0, 114.1, 55.9, 44.5, 31.5, 28.9; IR (film) 
3393, 1236 cm
-1
. MS (EI) 191.1305 (191.1310 calcd for C12H17NO). 
General Procedure 7 was used for the conversion of 4-methoxy-N-(pent-4-
enyl)aniline (304 mg, 1.6 mmol) to 118 mg (44%) of the title compound as a light green 
powder containing 0.4% KHMDS.  
1
H NMR (400 MHz, THF-d8) δ 6.48 (d, J = 7.6 Hz, 2 
H), 6.02–5.90 (m, 3 H), 5.03 (dd, J = 1.6, 17.2 Hz, 1 H), 4.91 (d, J = 10.4 Hz, 1 H), 3.53 
(s, 3 H), 2.90–2.81 (m, 2 H), 2.25–2.16 (m, 2 H), 1.82–1.70 (m, 2 H); 
13
C NMR (100 
MHz, THF-d8) δ 158.2, 144.9, 141.2, 118.1, 113.9, 110.2, 57.7, 52.9, 34.21, 34.16. 
Potassium pent-4-enyl(phenyl)amide (IV-6d). N-Phenylpent-4-enamide
4
 (1.50 g, 8.6 
mmol) was reduced according to General Procedure 6 to afford 1.20 g (86%) of N-(pent-
4-enyl)aniline (IV-1d) as a pale yellow oil.
 1
H NMR (400 MHz, CDCl3) δ 7.19–7.11 (m, 
2 H), 6.71–6.64 (m, 1 H), 6.62–6.54 (m, 2 H), 5.90–5.71 (m, 1 H), 5.09–4.95 (m, 2 H), 




7.6 Hz, 2 H); 
13
C NMR (100 MHz, CDCl3) δ 148.6, 138.2, 129.4, 117.3, 115.2, 112.9, 
43.5, 31.4, 28.8; IR (film) 3411 cm
–1
. MS (EI) 161.1201 (161.1204 calcd for C11H15N). 
General Procedure 7 was used for the conversion of N-(pent-4-enyl)aniline (305 
mg, 1.9 mmol) to 213 mg (72%) of the title compound as an off-white powder containing 
0.1% KHMDS. 
1
H NMR (400 MHz, THF-d8) δ 6.76–6.68 (m, 2 H), 6.03 (d, J = 8.4 Hz, 2 
H), 6.01–5.87 (m, 1 H), 5.67 (t, J = 6.8 Hz, 1 H), 5.03 (dd, J = 1.6, 17.2 Hz, 1 H), 4.94–
4.87 (m, 1 H), 2.92–2.84 (m, 2 H), 2.20 (q, J = 7.2 Hz, 2 H), 1.75 (quint, J = 8.0 Hz, 2 
H); 
13
C NMR (100 MHz, THF-d8) δ 161.6, 141.1, 130.3, 113.9, 111.4, 105.0, 51.8, 34.1, 
33.9. 
Potassium (4-chlorophenyl)(pent-4-enyl)amide (IV-6e). The conversion of 4-pentenoic 
acid (1.5 mL, 15.0 mmol) and 4-chloroaniline (4.78 g, 37.5 mmol) to N-(4-
chlorophenyl)pent-4-enamide was accomplished using a procedure analogous to that 
described above for the preparation of N-(4-fluorophenyl)pent-4-enamide. This procedure 
afforded 1.78 g (58%) of N-(4-chlorophenyl)pent-4-enamide as a white solid, m.p. 86–89 
°C.
 1
H NMR (400 MHz, CDCl3) δ 7.49 (s, br, 1 H), 7.45 (d, J = 8.4 Hz, 2 H), 7.26 (d, J = 
8.8 Hz, 2 H), 5.91–5.80 (m, 1 H), 5.11 (d, J = 16.4 Hz, 1 H), 5.05 (d, J = 10.4 Hz, 1 H), 
2.51–2.41 (m, 4 H); 
13
C NMR (100 MHz, CDCl3) δ 170.9, 136.9, 136.6, 129.4, 129.2, 
121.4, 116.2, 36.9, 29.5.  
N-(4-Chlorophenyl)pent-4-enamide (1.50 g, 7.2 mmol) was reduced according to 
General Procedure 6 to afford 1.28 g (91%) of 4-chloro-N-(pent-4-enyl)aniline (IV-1e) as 
a pale yellow oil.
 1




5.88–5.75 (m, 1 H), 5.05 (d, J = 17.2 Hz, 1 H), 4.99 (d, J = 10.0 Hz, 1 H),  3.60 (s, br, 1 
H), 3.06 (t, J = 7.2 Hz, 2 H), 2.14 (q, J = 7.2 Hz, 2 H), 1.67 (quint, J = 7.2 Hz, 2 H); 
13
C 
NMR (100 MHz, CDCl3) δ 147.1, 138.0, 129.1, 121.7, 115.4, 113.9, 43.6, 31.4, 28.6; IR 
(film) 3417 cm
–1
. MS (EI) 195.0820 (195.0815 calcd for C11H14ClN). 
General Procedure 7 was used for the conversion of 4-chloro-N-(pent-4-
enyl)aniline (392 mg, 2.0 mmol) to 240 mg (64%) of the title compound as a yellow-
green powder containing 1.1% KHMDS.  
1
H NMR (400 MHz, THF-d8) δ 6.60 (d, J = 8.8 
Hz, 2 H), 5.98–5.86 (m, 3 H), 5.02 (d, J = 17.6 Hz, 1 H), 4.90 (d, J = 10.0 Hz, 1 H), 
2.87–2.78 (m, 2 H), 2.23–2.13 (m, 2 H), 1.77–1.66 (m, 2 H); 
13
C NMR (100 MHz, THF-
d8) δ 160.5, 141.0, 129.6, 114.0, 111.8 (br), 107.7, 52.2, 34.0, 33.8. 
Potassium (4-chlorophenyl)(4-deuteriopent-4-enyl)amide (IV-6v). A flame-dried flask 
equipped with magnetic stirbar was charged with Cp2Zr(D)Cl (501 mg, 1.9 mmol) and 
purged with nitrogen for 5 min. CH2Cl2 (6 mL) was added to afford a white suspension. 
Subsequently a solution of pent-4-ynyl-4-methylbenzenesulfonate (454 mg, 1.9 mmol) in 
CH2Cl2 (2 mL) was added and the suspension clarified instantly. The resulting solution 
was stirred for 20 min at rt and then cooled to 0 °C. The chilled solution was treated with 
1 M aqueous HCl (5 mL) and the layers were separated. The aqueous layer was extracted 
with CH2Cl2 (1 × 20 mL) and the combined organic layers were dried over anhydrous 
Na2SO4. The drying agent was filtered off through glass wool and the filtrate was 
concentrated in vacuo. Purification by flash chromatography afforded 328 mg (71%) of 
4-deuteriopent-4-enyl 4-methylbenzenesulfonate as a colorless oil with >95% deuterium 
incorporation. 
1




Hz, 2 H), 4.96–4.93 (m, 2 H), 4.04 (t, J = 6.5 Hz, 2 H), 2.45 (s, 3 H), 2.08 (t, J = 7.0 Hz, 
2 H), 1.74 (quint, J = 7.0 Hz, 2 H); 
13
C NMR (100 MHz, CDCl3) δ 144.9, 136.5 (t, JC-D = 
24.1 Hz), 133.4, 130.0, 128.1, 115.9, 70.0, 29.5, 28.2, 21.9; MS (ESI) 242.0951 
(242.0961 calcd for C12H15DO3S + H
+
).  
The alkylation of 4-chloroaniline (327 mg, 2.6 mmol) with 4-deuteriopent-4-enyl 
4-methylbenzenesulfonate (298 mg, 1.2 mmol) was accomplished using a procedure 
analogous to that described above for the preparation of (E)-4-chloro-N-(5-deuteriopent-
4-enyl)aniline. This procedure afforded 211 mg (87%) of 4-chloro-N-(4-deuteriopent-4-
enyl)aniline (IV-1v) as a pale yellow oil. 
1
H NMR (400 MHz, CDCl3) δ 7.13–7.08 (m, 2 
H), 6.54–6.48 (m, 2 H), 5.07–5.03 (m, 1 H), 5.02–4.98 (m, 1 H), 3.63 (s, br, 1 H), 3.10 (t, 
J = 6.8 Hz, 2 H), 2.16 (t, J = 7.2 Hz, 2 H), 1.70 (quint, J = 7.2 Hz, 2 H); 
13
C NMR (100 
MHz, CDCl3) δ 147.1, 137.8 (t, JC-D = 23.1 Hz), 129.2, 121.9, 115.3, 113.9, 43.7, 31.3, 
28.7; IR (film) 3416 cm
–1
. MS (EI) 196.0886 (196.0878 calcd for C11H13DClN). 
General Procedure 7 was used for the conversion of 4-chloro-N-(4-deuteriopent-
4-enyl)aniline (177 mg, 0.9 mmol) to 77 mg (47%) of the title compound as a yellow-
green powder containing 1.6% KHMDS.  
1
H NMR (400 MHz, THF-d8) δ 6.61 (d, J = 8.8 
Hz, 2 H), 5.95 (d, J = 9.2 Hz, 2 H), 5.01 (s, 1 H), 4.90 (s, 1 H), 2.87–2.78 (m, 2 H), 2.17 
(t, J = 7.2 Hz, 2 H), 1.71 (quint, J = 7.6 Hz, 2 H); 
13
C NMR (100 MHz, THF-d8) δ 160.1, 
140.6 (t, JC-D = 23.1 Hz), 129.6, 113.9, 111.9 (br), 108.2, 52.0, 33.9, 33.6. 
Potassium (4-methylpent-4-enyl)(phenyl)amide (IV-6w). A flame-dried flask equipped 




(1.1 g, 11.8 mmol) and THF (10 mL). A solution of MeMgBr in diethyl ether (3.9 mL, 
11.7 mmol, 3.0 M) was added slowly at rt. The resulting mixture was stirred at rt for 30 
min, then a solution of ethyl 4-methylpent-4-enoate (1.5 g, 10.6 mmol) in THF (5 mL) 
was added slowly. The resulting solution was stirred at rt for 3 h upon which time H2O 
(30 mL) and EtOAc (25 mL) were added. The layers were separated, the aqueous layer 
was extracted with EtOAc (1 × 50 mL), and the combined organic layers were dried over 
anhydrous Na2SO4. The drying agent was filtered off through glass wool and the filtrate 
was concentrated in vacuo. Purification by flash chromatography afforded 908 mg (46%) 
of 4-methyl-N-phenylpent-4-enamide as a as a white solid, m.p. 82–85 °C.
 1
H NMR (400 
MHz, CDCl3) δ 7.50 (d, J = 8.0 Hz, 2 H), 7.44 (s, br, 1 H), 7.30 (t, J = 8.0 Hz, 2 H), 7.09 
(t, J = 7.2 Hz, 1 H), 4.80 (s, 1 H), 4.76 (s, 1 H), 2.55–2.40 (m, 4 H), 1.77 (s, 3 H); 
13
C 
NMR (100 MHz, CDCl3) δ 171.0, 144.6, 138.1, 129.2, 124.4, 120.1, 111.0, 36.0, 33.3, 
22.7. 
4-Methyl-N-phenylpent-4-enamide (735 mg, 3.9 mmol) was reduced according to 
General Procedure 6 to afford 548 mg (81%) of N-(4-methylpent-4-enyl)aniline (IV-1w) 
as a colorless oil.
 1
H NMR (400 MHz, CDCl3) δ 7.19–7.12 (m, 2 H), 6.71–6.65 (m, 1 H), 
6.61–6.55 (m, 2 H), 4.75 (s, 1 H), 4.72 (s, 1 H), 3.57 (s, br, 1 H), 3.09 (t, J = 7.6 Hz, 2 H), 
2.10 (t, J = 7.6 Hz, 2 H), 1.78–1.65 (m, 5 H); 
13
C NMR (100 MHz, CDCl3) δ 148.6, 
145.3, 129.4, 117.2, 112.8 110.5, 43.7, 35.4, 27.5, 22.5; IR (film) 3411 cm
–1
. MS (EI) 
175.1360 (175.1361 calcd for C12H17N).  
General Procedure 7 was used for the conversion of N-(4-methylpent-4-




powder containing 1.7% KHMDS.  
1
H NMR (400 MHz, THF-d8) δ 6.75–6.67 (m, 2 H), 
6.02 (d, J = 8.0 Hz, 2 H), 5.65 (t, J = 6.8 Hz, 1 H), 4.75 (s, 1 H), 4.68 (s, 1 H), 2.90–2.82 
(m, 2 H), 2.20–2.12 (m, 2 H), 1.86–1.76 (m, 5 H); 
13
C NMR (100 MHz, THF-d8) δ 162.1, 
147.9, 130.3, 111.4 (br), 109.7, 104.5, 52.5, 38.0, 32.9, 23.2. 
Potassium (Z)-hex-4-enyl(phenyl)amide (IV-6x). A flame-dried flask equipped with 
magnetic stirbar was charged with (Z)-tert-butyl hex-4-enylcarbamate (702 mg, 3.5 
mmol), Pd(OAc)2 (25 mg, 0.1 mmol), X-Phos (105 mg, 0.2 mmol), Cs2CO3 (2.56 g, 7.9 
mmol), and bromobenzene (1.1 mL, 10.4 mmol) and purged with nitrogen for 5 min. 
Toluene (15 mL) was added and the resulting mixture was heated to 100 °C for 15 h . 
The mixture was cooled to rt and saturated aqueous NH4Cl (10 mL) and EtOAc (10 mL) 
were added. The layers were separated, the aqueous layer was extracted with EtOAc (3 × 
15 mL), and the combined organic layers were dried over anhydrous Na2SO4. The drying 
agent was filtered off through glass wool and the filtrate was concentrated in vacuo. The 
resulting oil was dissolved in CH2Cl2 (5 mL) and trifluoroacetic acid (1 mL). The 
solution was stirred at rt for 2 h upon which time the solution was cooled to 0 °C and 
quenched with saturated aqueous Na2CO3 (15 mL). Water (10 mL) and CH2Cl2 (10 mL) 
were added, the layers were separated, the aqueous layer was extracted with CH2Cl2 (1 × 
20 mL) and the combined organic layers were dried over anhydrous Na2SO4. The drying 
agent was filtered off through glass wool and the filtrate was concentrated in vacuo to 
afford a crude oil, which was purified by flash chromatography to give 174 mg (28%) of 
(Z)-N-(hex-4-enyl)aniline (IV-1x) as a colorless oil.
 1
H NMR (400 MHz, CDCl3) δ 7.22–




H), 3.12 (t, J = 6.8 Hz, 2 H), 2.16 (q, J = 7.2 Hz, 2 H), 1.68 (quint, J = 6.8 Hz, 2 H), 
1.64–1.60 (m, 3 H); 
13
C NMR (100 MHz, CDCl3) δ 148.7, 129.9, 129.4, 124.9, 117.3 
112.9, 43.7, 29.5, 24.6, 13.0; IR (film) 3410 cm
-1
. MS (EI) 175.1360 (175.1361 calcd for 
C12H17N). 
General Procedure 7 was used for the conversion of (Z)-N-(hex-4-enyl)aniline 
(128 mg, 0.7 mmol) to 32 mg (26%) of the title compound as a tan powder containing 
2.7% KHMDS.  
1
H NMR (400 MHz, THF-d8) δ 6.77–6.66 (m, 2 H), 6.09–6.00 (m, 2 H), 
5.74–5.64 (m, 1 H), 5.57–5.45 (m, 1 H), 5.45–5.34 (m, 1 H), 2.94–2.81 (m, 2 H), 2.25–
2.10 (m, 2 H), 1.80–1.60 (m, 5 H); 
13
C NMR (100 MHz, THF-d8) δ 161.3, 132.7, 130.2, 
123.5, 111.4 (br), 105.2, 51.8, 34.4, 26.9, 13.1. 
Potassium (E)-hex-4-enyl(phenyl)amide (IV-6y). A flame-dried flask equipped with 
magnetic stirbar was charged with 3-butene-2-ol (3.6 mL, 42 mmol), triethyl orthoacetate 
(15.2 mL, 84 mmol), and neat acetic acid (200 µL, 2.5 mmol).  The flask was attached to 
a short-path distillation head, the system purged with nitrogen, and the mixture heated 
with stirring at 90 ºC for 45 min.  The heat was gradually increased to 120 ºC over 75 
min and the reaction was allowed to proceed for 14 h under those conditions before being 
cooled to rt.  To the reaction flask was added 1M HCl (40 mL) and Et2O (40 mL), and the 
resulting mixture was stirred vigorously for 1 h.  The layers were separated and the 
aqueous layer extracted with Et2O (3 × 40 mL).  The combined organic layers were 
washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated in vacuo.  




which contained traces of chromatography solvent which was difficult to remove due to 
product volatility.  This material was used without further purification. 
 A flame dried flask equipped with a magnetic stir bar was charged with aniline 
(3.3 mL, 35 mmol) sealed with a septum and purged with nitrogen. THF (30 mL) was 
added and the solution cooled to 0 ºC, then a solution of MeMgBr (3.0 M in Et2O, 11 mL, 
33 mmol) was added slowly via syringe.  The ice bath was removed and a solution of 
crude (E)-ethyl hex-4-enoate (4.2 g, 30 mmol) in THF was added dropwise.  The 
resulting solution was stirred 5 h at rt, quenched with water (30 mL), diluted with EtOAc 
(30 mL) and the layers separated.  The aqueous layer was extracted with EtOAc (3 × 50 
mL), the combined organic layers washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuo.  Flash chromatography of the crude oil afforded (E)-N-(phenyl)-
hex-4-enamide containing residual aniline, which was carried on without further 
purification. 
The crude (E)-N-(phenyl)-hex-4-enamide was reduced according to General 
Procedure 6 to afford 1.28 g (91%) of (E)-N-(hex-4-enyl)aniline (IV-1y) as a pale yellow 
oil.
 1
H NMR (500 MHz, CDCl3) δ 7.19–7.13 (m, 2 H), 6.71–6.66 (m, 1 H), 6.62–6.57 (m, 
2 H), 5.52–5.40 (m, 2 H), 3.61 (s, br, 1 H), 3.11 (t, J = 7.0 Hz, 2 H), 2.14–2.06 (m, 2 H), 
1.71–1.64 (m, 5 H); 
13
C NMR (100 MHz, CDCl3) δ 148.5, 130.5, 129.2, 125.6, 117.1, 
112.7, 43.5, 30.1, 29.3, 17.9; IR (film) 2930, 1603, 1508 cm
–1
. MS (EI) 175.1361 




General Procedure 7 was used for the conversion of  (E)-N-(hex-4-enyl)aniline 
(500 mg, 2.85 mmol) to 380 mg (78%) of the title compound as a yellow powder 
containing 2.0% KHMDS.  
1
H NMR (500 MHz, THF-d8) δ 6.71–6.68 (m, 2 H), 6.00 (d, J 
= 8.0 Hz, 2 H), 5.64 (t, J = 7.0 Hz, 1 H), 5.91–5.53 (m, 1 H), 5.48–5.41 (m, 1 H), 2.85–
2.82 (m, 2 H), 2.12 (q, br, J = 7.0 Hz, 2 H), 1.73–1.67 (m, 2 H), 1.64 (dd, J = 1.0, 6.5 Hz, 
3 H); 
13
C NMR (100 MHz, THF-d8) δ 162.2, 133.7, 130.3, 123.3, 111.3, 104.3, 52.2, 
34.7, 23.9, 18.4. 
Synthesis of Authentic Samples of Pyrrolidine Products formed in Kinetic Runs 
General Procedure 8: Pd-Catalyzed Carboamination of -(N-arylamino)alkenes 
with Aryl Bromides. An oven or flame-dried Schlenk tube was cooled under a stream of 
argon or nitrogen and charged with Pd2(dba)3 (1 mol % complex, 2 mol % Pd), dppf (2 
mol %), NaOt-Bu (1.0 equiv), and the ArBr (1.5 equiv). The tube was purged with argon 
or nitrogen and a solution of the amine substrate (1.0 equiv) in toluene (4 mL/mmol aryl 
bromide) was added. The mixture was heated to 60–110 °C with stirring until the starting 
material had been consumed as judged by GC or 
1
H NMR analysis. The reaction mixture 
was cooled to room temperature, quenched with saturated aqueous NH4Cl (2 mL) and 
diluted with ethyl acetate (10 mL). The layers were separated and the aqueous layer was 
extracted with ethyl acetate (2 × 10 mL). The combined organic extracts were dried over 
anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude product was 






1-(4-tert-Butylphenyl)-2-(4-fluorobenzyl)pyrrolidine (IV-2b). General Procedure 8 
was used for the coupling of 4-tert-butyl-N-(pent-4-enyl)aniline (52 mg, 0.24 mmol) with 
1-bromo-4-fluorobenzene (38 μL, 0.35 mmol) to afford 48 mg (65%) of the title 
compound as a colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 7.36–7.28 (m, 2 H), 7.23–
7.14 (m, 2 H), 7.03–6.94 (m, 2 H), 6.71–6.62 (m, 2 H), 3.98–3.82 (m, 1 H), 3.48–3.36 
(m, 1 H), 3.24–3.10 (m, 1 H), 3.00 (dd, J = 2.8, 13.6 Hz, 1 H), 2.56 (dd, J = 9.2, 13.6 Hz, 
1 H), 1.95–1.76 (m, 4 H), 1.31 (s, 9 H); 
13
C NMR (100 MHz, CDCl3) δ 161.5 (d, J = 243 
Hz), 144.8, 138.2, 135.2, 130.7 (d, J = 7.6 Hz), 126.1, 115.1 (d, J = 21.0 Hz), 111.4, 59.9, 
48.6, 38.1, 33.7, 31.6, 29.5, 23.1; 
19
F NMR (376 MHz, CDCl3) δ –117.2; IR (film) 1222 
cm
–1




1-(4-Methoxyphenyl)-2-(4-fluorobenzyl)pyrrolidine (IV-2c). General Procedure 8 was 
used for the coupling of 4-methoxy-N-(pent-4-enyl)aniline (50 mg, 0.26 mmol) with 1-
bromo-4-fluorobenzene (43 μL, 0.39 mmol) to afford 32 mg (43%) of the title compound 
as a colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 7.19–7.13 (m, 2 H), 7.02–6.94 (m, 2 H), 
6.92–6.86 (m, 2H), 6.66–6.60 (m, 2 H), 3.90–3.83 (m, 1 H), 3.77 (s, 3 H), 3.42–3.34 (m, 
1 H), 3.17–3.07 (m, 1 H), 2.97 (dd, J = 3.0, 13.8 Hz, 1 H), 2.58 (dd, J = 9.0, 13.8 Hz, 1 
H), 1.94–1.74 (m, 4 H); 
13
C NMR (100 MHz, CDCl3) δ 161.5 (d, J = 244 Hz), 150.7, 
141.9, 135.1 (d, J = 3.5 Hz), 130.7 (d, J = 7.6 Hz), 115.2, 115.1 (d, J = 20.7 Hz), 112.6, 
60.0, 56.0, 49.1, 38.0, 29.6, 23.1; 
19
F NMR (376 MHz, CDCl3) δ –117.3; IR (film) 1241 
cm
–1







1-(Phenyl)-2-(4-fluorobenzyl)pyrrolidine (IV-2d). General Procedure 8 was used for 
the coupling of N-(pent-4-enyl)aniline (50 mg, 0.31 mmol) with 1-bromo-4-
fluorobenzene (51 μL, 0.46 mmol) to afford 58 mg (74%) of the title compound as a 
colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 7.27–7.19 (m, 2 H), 7.1–7.10 (m, 2 H), 6.99–
6.91 (m, 2 H), 6.69–6.61 (m, 2 H), 3.96–3.85 (m, 1 H), 3.41–3.32 (m, 1 H), 3.19–3.07 
(m, 1 H), 2.99 (dd, J = 3.4, 13.8 Hz, 1 H), 2.59 (dd, J = 9.2, 13.6 Hz, 1 H), 1.92–1.70 (m, 
4 H); 
13
C NMR (100 MHz, CDCl3) δ 161.5 (d, J = 244 Hz), 146.9, 135.0 (d, J = 3.0 Hz), 
130.7 (d, J = 8.0 Hz), 129.3, 115.6, 115.1 (d, J = 21.0 Hz), 111.8, 59.6, 48.4, 37.7, 29.4, 
23.0; 
19
F NMR (376 MHz, CDCl3) δ –117.1; IR (film) 1221 cm
–1
. MS (ESI) 256.1508 




1-(4-Chlorophenyl)-2-(4-fluorobenzyl)pyrrolidine (IV-2e). General Procedure 8 was 
used for the coupling of 4-chloro-N-(pent-4-enyl)aniline (32 mg, 0.16 mmol), with 1-
bromo-4-fluorobenzene (25 μL, 0.23 mmol) to afford 33 mg (69%) of the title compound 
as a colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 7.22–7.10 (m, 4 H), 7.02–6.94 (m, 2 H), 
6.59–6.52 (m, 2 H), 3.96–3.86 (m, 1 H), 3.38–3.31 (m, 1 H), 3.18–3.08 (m, 1 H), 2.92 
(dd, J = 2.8, 14.0 Hz, 1 H), 2.59 (dd, J = 8.8, 14.0 Hz, 1 H), 1.95–1.70 (m, 4 H); 
13
C 
NMR (100 MHz, CDCl3) δ 161.8 (d, J = 244 Hz), 145.7, 134.9 (d, J = 3.8 Hz), 130.9 (d, 
J = 7.7 Hz), 129.3, 120.6, 115.4 (d, J = 21.4 Hz), 113.1, 60.0, 48.8, 37.8, 29.8, 23.3; 
19
F 
NMR (376 MHz, CDCl3) δ –117.0 (m); IR (film) 1222 cm
–1
. MS (ESI) 290.1107 
(290.1112 calcd for C17H17ClFN + H
+





1-(4-Fluorophenyl)-2-(4-tert-butylbenzyl)pyrrolidine (IV-2g). General Procedure 8 
was used for the coupling of 4-fluoro-N-(pent-4-enyl)aniline (52 mg, 0.29 mmol) with 4-
tert-butyl-bromobenzene (75 μL, 0.43 mmol) to afford 59 mg (65%) of the title 
compound as a colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 7.36–7.30 (m, 2 H), 7.18–
7.13 (m, 2 H), 7.01–6.93 (m, 2 H), 6.62–6.54 (m, 2 H), 3.93–3.84 (m, 1 H), 3.44–3.37 
(m, 1 H), 3.13 (q, J = 8.2 Hz, 1 H), 2.99 (dd, J  = 3.2, 13.6 Hz, 1 H), 2.49 (dd, J = 9.4, 
13.8 Hz, 1 H), 1.99–1.80 (m, 4 H), 1.32 (s, 9 H); 
13
C NMR (100 MHz, CDCl3) δ 154.7 (d, 
J = 232 Hz), 149.0, 143.7, 136.3, 128.9, 125.3, 115.6 (d, J  = 22.2 Hz), 112.1 (d, J = 6.8 
Hz), 60.2, 48.8, 38.1, 34.4, 31.4, 29.7, 23.1; 
19
F NMR (376 MHz, CDCl3) δ –131.0 (m); 
IR (film) 1227 cm
–1




1-(4-Fluorophenyl)-2-(4-methoxybenzyl)pyrrolidine (IV-2h). General Procedure 8 was 
used for the coupling of 4-fluoro-N-(pent-4-enyl)aniline (49 mg, 0.27 mmol) with 4-
bromoanisole (50 μL, 0.40 mmol) to afford 64 mg (82%) of the title compound as a 
colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 7.15–7.10 (m, 2 H), 7.01–6.93 (m, 2 H), 
6.88–6.82 (m, 2 H), 6.61–6.53 (m, 2 H), 3.90–3.83 (m, 1 H), 3.80 (s, 3 H), 3.41–3.32 (m, 
1 H), 3.16–3.07 (m, 1 H), 2.93 (dd, J = 3.2, 13.6 Hz, 1 H), 2.52 (dd, J = 9.2, 13.6 Hz, 1 
H), 1.95–1.80 (m, 4 H); 
13
C NMR (100 MHz, CDCl3) δ 158.1, 154.7 (d, J = 232 Hz), 
143.7, 131.3, 130.2, 115.6 (d, J = 21.8 Hz), 113.8, 112.2 (d, J = 7.2 Hz), 60.2, 55.2, 48.9, 
37.7, 29.6, 23.1; 
19
F NMR (376 MHz, CDCl3) δ –130.9; IR (film) 1247, 1226 cm
–1
. MS 







1-(4-Fluorophenyl)-2-benzylpyrrolidine (IV-2i). General Procedure 8 was used for the 
coupling of 4-fluoro-N-(pent-4-enyl)aniline (48 mg, 0.27 mmol) with bromobenzene (43 
μL, 0.41 mmol) to afford 55 mg (81%) of the title compound as a colorless oil. 
1
H NMR 
(400 MHz, CDCl3) δ 7.34–7.27 (m, 2 H), 7.26–7.18 (m, 3 H), 7.03–6.94 (m, 2 H), 6.62–
6.55 (m, 2 H), 3.95–3.85 (m, 1 H), 3.43–3.35 (m, 1 H), 3.18–3.08 (m, 1 H), 3.01 (dd, J = 
3.2, 13.6 Hz, 1 H), 2.56 (dd, J = 9.4, 13.8 Hz, 1 H), 1.96–1.80 (m, 4 H); 
13
C NMR (100 
MHz, CDCl3) δ 154.8 (d, J = 232 Hz), 143.7, 139.3, 129.3, 128.4, 126.2, 115.6 (d, J = 
21.7 Hz), 112.1 (d, J = 6.9 Hz), 60.1, 48.8, 38.6, 29.6, 23.1; 
19
F NMR (376 MHz, CDCl3) 
δ –130.9 (m); IR (film) 1226 cm
–1





N-(4-Chlorophenyl)-2-deuterio-2-(p-fluorobenzyl)pyrrolidine (IV-2v). In a nitrogen-
filled glovebox, IV-5a (106 mg, 0.127 mmol) and dppf (142 mg, 0.256 mmol) were 
dissolved in THF (10 mL).  To this solution was added a solution of IV-6v (29.4 mg, 
0.125 mmol) and 2-fluorotoluene (50 µL, 0.235 mmol) in THF (3 mL).  The reaction was 
sealed, removed from the glovebox, and allowed to react for 4 h at rt with periodic 
shaking.  After 4 h, the liquid was removed from a precipitate by pipette and concentrated 
in vacuo to give a red paste, which was triturated with hexanes:EtOAc (96:4, 3 × 3 mL).  
The combined extracts were purified by chromatography afford 17.9 mg (49%) of the 
title compound as a viscous colorless oil. 
 A second sample was prepared for 
13
C NMR spectroscopy following General 
Procedure 8 for the reaction of IV-1v with 1-bromo-4-fluorobenzene.  The catalytic 






C NMR signals for IV-2v were assigned from this 
mixture. 
1
H NMR (400 MHz, CDCl3) δ 7.20–7.16 (m, 2 H), 7.14–7.10 (m, 2 H), 7.00–
6.95 (m, 2 H), 6.57–6.53 (m, 2 H), 3.36–3.31 (m, 1 H), 3.12 (q, J = 8.5 Hz, 1 H), 2.90 (d, 
J = 14.0 Hz, 1 H), 2.58 (d, J = 14.0 Hz, 1 H), 1.93–1.73 (m, 4 H); 
13
C NMR (125 MHz, 
CDCl3) δ 161.6 (d, J = 243 Hz), 145.5, 134.7 (d, J = 3.4 Hz), 130.7 (d, J = 7.8 Hz), 129.1, 
120.3, 115.2 (d, J = 20.9 Hz), 112.8, 48.6, 37.4, 29.4, 23.0 (the expected triplet signal at 
or about 59 ppm for C–D was obscured); 
19
F NMR (376 MHz, CDCl3) δ –117.0 (m); IR 
(film) 1598, 1498, 1223 cm
–1





N-(Phenyl)-2-methyl-2-(p-fluorobenzyl)pyrrolidine (IV-2w). General Procedure 8 was 
used for the coupling of N-(4-methyl-pent-4-enyl)aniline (30 mg, 0.17 mmol) with 1-
bromo-4-fluorobenzene (28 μL, 0.26 mmol) to afford the title compound as a colorless oil 
containing ~12% unidentified isomeric materials. 
1
H NMR (500 MHz, CDCl3) δ 7.26–
7.23 (m, 2 H, obscured by CHCl3), 7.03–6.99 (m, 2 H), 6.91–6.86 (m, 2 H), 6.83 (d, J = 
9.0 Hz, 2 H), 6.69 (t, J = 6.5 Hz, 1 H), 3.37 (d, J = 13.5 Hz, 1 H), 3.29 (app q, J = 7.8 Hz, 
1 H), 3.13–3.08 (m, 1 H), 2.81 (d, J = 14.0 Hz, 1 H), 2.10–2.04 (m, 1 H), 1.75–1.60 (m, 2 
H), 1.48 (s, 3 H), 1.22–1.16 (m, 1 H); 
13
C NMR (125 MHz, CDCl3) δ 161.6 (d, J = 243 
Hz), 146.5, 134.5 (d, J = 3.5 Hz), 131.7 (d, J = 7.4 Hz), 129.0, 120.1, 114.7 (d, J = 21.0 
Hz), 113.8, 64.0, 50.7, 43.1, 40.9, 26.1, 21.8; 
19
F NMR (471 MHz, CDCl3) δ –117.3 (m); 
IR (film) 1598, 1506, 1353, 1222 cm
–1
. MS (ESI) 270.1647 (270.1653 calcd for 
C18H20FN, M + H
+
).  Resonances for the isomeric material were detected at: 
1
H NMR 




3.18 (d, J = 9.0 Hz), 3.03 (d, J = 8.5 Hz), 2.90 (d, J = 8.5 Hz), 2.64 (dd, J = 1.5, 15 Hz), 
1.52 (s); 
13
C NMR (125 MHz, CDCl3) δ 131.8, 129.1, 124.2 (d, J = 7.4 Hz), 121.6, 115.6, 
115.2 (d, J = 21.4 Hz), 114.9, 44.4, 44.0, 26.4; 
19
F NMR (471 MHz, CDCl3) δ –118.4 
(m). 
Preparation and Characterization of Pd-Complexes 
General Procedure 9: Preparation of a Palladium Arylbromide Dimer. A flame-
dried flask equipped with a magnetic stir bar was cooled under a stream of nitrogen and 
charged with Pd2(dba)3 (1 equiv), and P(o-tol)3 (2.5 equiv). The flask was purged with 
nitrogen for 5 min, toluene [40 mL/mmol Pd2(dba)3] and the appropriate ArBr (5 equiv) 
were added, and the resulting dark purple-brown solution was stirred at 25 °C for 1–3 h. 
At this time the solution had changed to a dark purple-yellowish color and was 
subsequently filtered through celite eluting with diethyl ether (ca. 100 mL) to obtain a 
yellow-orange filtrate. The filtrate was concentrated in vacuo to ca. 15 mL, layered with 
60 mL pentane and transferred to an Erlenmeyer flask. The stoppered, layered solution 
was then allowed to settle at rt for 2 h upon which time significant formation of a yellow 
precipitate had occurred. The mixture was filtered to isolate an {[(o-tol)3P]Pd(Ar)(Br)}2 
complex as a fluffy yellow powder that was subsequently used without further 
purification. 
General Procedure 10: Preparation of (L–L)Pd(Ar)Br.  
A flame-dried flask equipped with magnetic stir bar was charged with the appropriate 
{[(o-tol)3P]Pd(Ar)(Br)}2 complex (1 equiv) and the appropriate P–P ligand (2 equiv). The 




added. The resulting solution was stirred for 1 h at rt and then concentrated in vacuo to 
ca. 0.5 mL. Diethyl ether (7 mL) was added, the resulting slurry was stirred for 1 min and 
then allowed to settle for 1 h at rt. The mixture was then filtered and washed with diethyl 
ether (3 × 8 mL) and pentane (3 × 8 mL) to yield the desired (L–L)Pd(Ar)(Br) complex, 
which was used without additional purification. 
 
(dppf)Pd(4-tert-butylphenyl)(Br) (IV-5g). General Procedure 9 was employed for the 
reaction of Pd2(dba)3 (496 mg, 0.54 mmol), P(o-tol)3 (584 mg, 1.9 mmol) and 1-bromo-4-
tert-butylbenzene (950 μL, 5.4 mmol) in CH2Cl2 (30 mL) at 30 °C for 1 h, and palladium 
black was removed by cannula filtration to afford a yellow solution.  To the solution, 
dppf (302 mg, 0.54 mmol) was added and the reaction vessel purged with nitrogen and 
the reaction stirred for 2 h.  Work-up according to General Procedure 10 afforded 280 mg 
(59% over 2 steps) of the title compound as an orange solid, m.p. 175 °C (decomp).
 1
H 
NMR (400 MHz, CDCl3) δ 8.09–8.02 (m, 4 H), 7.50–7.30 (m, 12 H), 7.07 (td, J = 2.0, 
9.6 Hz, 4 H), 6.82 (td, J = 2.4, 6.4 Hz, 2 H), 6.58 (dd, J = 1.2, 6.8 Hz, 2 H), 4.68–4.65 (m, 
2 H), 4.47–4.45 (m, 2 H), 4.12–4.09 (m, 2 H), 3.59–3.56 (m, 2 H), 1.07 (s, 9 H); 
13
C 
NMR (100.7 MHz, CD2Cl2) δ 153.8 (dd, J = 2.3, 135 Hz), 145.0, 136.0 (d, J = 12.4 Hz), 
135.5 (dd, J = 2.0, 5.1 Hz), 134.7 (d, J = 11.7 Hz), 133.9 (d, J = 33.3 Hz), 133.8 (d, J = 
41.1 Hz), 130.7 (app. t, J = 2.5 Hz), 128.7, 128.6 (d, J = 9.3 Hz), 128.4 (d, J = 10.9 Hz), 
125.2 (dd, J = 1.5, 9.2 Hz), 77.5 (dd, J = 7.4, 49.5 Hz), 76.6 (d, J = 12.4 Hz), 75.6 (dd, J = 
2.3, 36.3 Hz), 74.8 (d, J = 8.6 Hz), 74.0 (d, J = 7.9 Hz), 72.8 (d, J = 5.4 Hz), 34.2, 31.9; 
31
P NMR (162 MHz, CDCl3) δ 30.8 (d, J = 34.3 Hz), 8.8 (d, J = 34.3 Hz); IR (film) 1481, 
1435 cm
-1





(dppf)Pd(4-methoxyphenyl)(Br) (IV-5h). General Procedure 9 was used for the 
reaction of Pd2(dba)3 (197 mg, 0.22 mmol), P(o-tol)3 (262 mg, 0.86 mmol) and 4-
bromoanisole (275 μL, 2.2 mmol) for 1 h to afford 79 mg of {[(o-tol)3P]Pd(p-
C6H4OMe)(Br)}2 as fluffy yellow powder.  
General Procedure 10 was used for the reaction of {[(o-tol)3P]Pd(p-
C6H4OMe)(Br)}2 (60 mg, 0.050 mmol) with dppf (56 mg, 0.10 mmol) to give 56 mg 
(17% over 2 steps) of the title compound as an orange solid , m.p. 165 °C (decomp).
 1
H 
NMR (400 MHz, CDCl3) δ 8.10–8.00 (m, 3 H), 7.49–7.43 (m, 6 H), 7.40–7.22 (m, 5 H), 
7.17–7.10 (m, 6 H), 6.83–6.75 (m, 2 H), 6.30–6.23 (m, 2 H), 4.68–4.64 (m, 2 H), 4.50–
4.45 (m, 2 H), 4.16–4.12 (m, 2 H), 3.67–3.63 (m, 2 H), 3.56 (s, 3 H); 
13
C NMR (100.6 
MHz, CD2Cl2) δ 156.6, 146.7 (d, J = 2.4 Hz), 145.4, 136.0 (d, J = 11.6 Hz), 134.7 (d, J = 
12.4 Hz), 134.0 (d, J = 34.0 Hz), 133.8 (d, J = 55.9 Hz), 131.7 (d, J = 10.1 Hz), 130.8, 
128.6 (d, J = 9.2 Hz), 128.4 (d, J = 10.9 Hz), 114.3 (dd, J = 2.0, 9.2 Hz), 77.5 (dd J = 7.3, 
50.2 Hz), 76.6 (d, J = 11.7 Hz), 75.6 (dd, J = 2.8, 36.3 Hz), 74.8 (d, J = 8.6 Hz), 74.0 (d, J 
= 7.0 Hz), 72.9 (d, J = 4.7 Hz), 55.6 (s); 
31
P NMR (162 MHz, CDCl3) δ 30.7 (d, J = 31.7 
Hz), 9.5 (d, J = 31.7 Hz); IR (film) 1480, 1435, 1231 cm
-1
. Anal calcd for 
C41H35BrFeOP2Pd: C, 58.08; H, 4.16. Found: C, 57.66; H, 4.10. 
 
(dppf)Pd(Ph)(Br) (IV-5i). General Procedure 9 was used for the reaction of Pd2(dba)3 
(197 mg, 0.22 mmol), P(o-tol)3 (265 mg, 0.87 mmol) and bromobenzene (230 μL, 345 
mg, 2.2 mmol) for 1 h to afford 131 mg of {[(o-tol)3P]Pd(Ph)(Br)}2 as a fluffy yellow 




General Procedure 10 was used for the reaction of {[(o-tol)3P]Pd(Ph)(Br)}2 (100 
mg, 0.088 mmol) with dppf (98 mg, 0.18 mmol) to give 30 mg (11% over 2 steps) of the 
title compound as an orange solid, m.p. 176 °C (decomp).
 1
H NMR (400 MHz, CDCl3) δ 
8.11–8.02 (m, 4 H), 7.50–7.05 (m, 16 H), 6.99–6.89 (m, 2 H), 6.60–6.45 (m, 3 H), 4.70–
4.65 (m, 2 H), 4.51–4.46 (m, 2 H), 4.16–4.12 (m, 2 H), 3.66–3.61 (m, 2 H); 
13
C NMR 
(100.6 MHz, CD2Cl2) δ 158.7 (dd, J = 2.0, 123 Hz), 136.2 (d, J = 3.0 Hz), 136.0 (d, J = 
12.2 Hz), 134.6 (d, J = 12.3 Hz), 133.9 (d, J = 34.4 Hz), 133.6 (d, J = 55.0 Hz), 130.8, 
130.7, 128.6 (d, J = 9.9 Hz), 128.4 (d, J = 10.7 Hz), 127.8 (d, J = 9.1 Hz), 122.5, 77.4 
(dd, J = 7.3, 51.1 Hz), 76.6 (d, J = 11.2 Hz), 75.5 (dd, J = 3.1, 38.8 Hz), 74.8 (d, J = 8.4 
Hz), 74.0 (d, J = 7.7 Hz), 72.9 (d, J = 4.6 Hz); 
31
P NMR (162 MHz, CDCl3) δ 30.7 (d, J = 
34.2 Hz), 9.3 (d, J = 33.6 Hz); IR (film) 1482, 1435 cm
–1
. Anal calcd for 
C40H33BrFeP2Pd: C, 58.75; H, 4.07. Found: C, 58.62; H, 4.19. 
 
(dppf)Pd(4-trifluoromethylphenyl)(Br) (IV-5j). General Procedure 9 was used for the 
reaction of Pd2(dba)3 (501 mg, 0.547 mmol), P(o-tol)3 (582 mg, 1.9 mmol) and 4-
trifluoromethylbromobenzene (763 μL, 5.46 mmol) for 3 h and palladium black was 
removed by cannula filtration to afford a yellow solution.  To the solution, solid dppf 
(302 mg, 0.54 mmol) was added and the reaction vessel purged with nitrogen and the 
reaction stirred for 1 h.  Work-up according to General Procedure 10 afforded 376 mg 
(79% over 2 steps) of the title compound as a red-orange solid containing ca 1.5% Et2O 
by mass as estimated by 
1
H NMR, m.p. 194 °C (decomp).
 1
H NMR (400 MHz, CDCl3) δ 
8.07–7.99 (m, 4 H), 7.47 (s, br, 6 H), 7.34–7.28 (m, 6 H), 7.14–7.05 (m, 6 H), 6.75 (d, br, 
J = 7.2 Hz, 2 H), 4.68 (s, 2 H), 4.49 (s, 2 H), 4.14 (s, 2 H), 3.61 (s, 2 H); 
19




MHz, CDCl3) δ –62.1 (s); 
31
P NMR (162 MHz, CDCl3) δ 30.2 (d, J = 32.7 Hz), 10.1 (d, J 
= 31.3 Hz); IR (film) 1585, 1436, 1324 (strong, CF3), 1154 cm
–1
. Anal calcd for 
C41H32BrF3FeP2Pd: C, 55.59; H, 3.64. Found: C, 55.61; H, 3.70. 
 
(dppf)Pd(4-cyanophenyl)(Br) (IV-5k). General Procedure 9 was employed for the 
reaction of Pd2(dba)3 (503 mg, 0.55 mmol), P(o-tol)3 (580 mg, 1.9 mmol) and 4-
bromobenzontrile (996 mg, 5.5 mmol) in CH2Cl2 (20 mL) at 30 °C for 2 h, and palladium 
black was removed by cannula filtration to afford a yellow solution.  To the solution, 
solid dppf (303 mg, 0.55 mmol) was added and the reaction vessel purged with nitrogen 
and the reaction was stirred for 2 h.  Work-up according to General Procedure 10 
afforded 402 mg (44% over 2 steps) of the title compound as an orange solid, m.p. 189 
°C (decomp).
 1
H NMR (400 MHz, CDCl3) δ 8.08–7.98 (m, 4 H), 7.52–7.44 (m, 7 H), 
7.39–7.30 (m, 6 H), 7.18–7.11 (m, 5 H), 6.83–6.76 (m, 2 H), 4.73–4.68 (m, 2 H), 4.55–
4.51 (m, 2 H), 4.19–4.15 (m, 2 H), 3.63–3.59 (m, 2 H);
 13
C NMR (100.6 MHz, CD2Cl2) δ 
170.8 (dd, J = 2.4, 131 Hz), 136.8 (d, J = 3.4 Hz), 135.9 (d, J = 11.9 Hz), 134.5 (d, J = 
12.0 Hz),  133.3 (d, J = 36.3 Hz), 132.9 (d, J = 54.6 Hz), 131.2 (d, J = 2.3Hz), 131.0, 
129.8 (d, J = 9.3 Hz), 128.7, 128.6 (d, J = 2.7 Hz), 120.5, 105.8, 76.8 (d, J = 12.0 Hz), 
76.1 (d, J = 6.9 remaining Cp signals from carbons α to phosphorus obscured), 75.0 (d, J 
= 8.4 Hz), 74.3 (d, J = 7.7 Hz), 73.1 (d, J = 4.9 Hz); 
31
P NMR (162 MHz, CDCl3) δ 30.9 
(d, J = 32.1 Hz), 10.6 (d, J = 32.1 Hz); IR (film) 2218, 1472, 1435 cm
-1
. Anal calcd for 





(dppe)Pd(4-fluorophenyl)(Br) (IV-5l). Complex IV-5l was prepared according to 
General Procedure 10 for the reaction of dppe with {[(o-tol)3P]Pd(p-C6H4F)(Br)}2, but 
could not be isolated in analytically pure form.  Available NMR spectral data is provided. 
 
1
H NMR (400 MHz, CDCl3) δ 7.92 (s, br, 4 H), 7.55–7.30 (m, 16 H), 6.95 (s, br, 2 H), 
6.50 (s, br, 2 H), 2.56–2.39 (m, 2 H), 2.27–2.13 (m, 2 H); 
19
F NMR (376.3 MHz, CDCl3) 
δ –123.3 (s); 
31
P NMR (162 MHz, CDCl3) δ 52.7 (d, J = 25.6 Hz), 34.0 (d, J = 25.9 Hz). 
 
(dpp-Benzene)Pd(4-fluorophenyl)(Br) (IV-5m). General Procedure 9 was modified for 
reaction of Pd2(dba)3 (500 mg, 0.55 mmol), P(o-tol)3 (578 mg, 1.9 mmol) and 1-bromo-4-
fluorobenzene (600 μL, 5.5 mmol) in CH2Cl2 (25 mL) at 30 °C for 2 h, and palladium 
black was removed by cannula filtration to afford a yellow solution.  To the solution, 
solid dpp-benzene (242 mg, 0.54 mmol) was added and the reaction vessel purged with 
nitrogen and the reaction was stirred for 2 h.  Work-up according to General Procedure 
10 afforded 324 mg (41% over 2 steps) of the title compound as a white solid, m.p. 218 
°C.
 1
H NMR (400 MHz, CDCl3) δ 7.74–7.67 (m, 5 H), 7.63–7.39 (m, 11 H), 7.33–7.26 
(m, 8 H), 6.96–6.87 (m, 2 H), 6.57–6.50 (m, 2 H); 
13
C NMR (100.7 MHz, CD2Cl2) δ 
160.7 (dd, J = 2.4, 239 Hz), 151.7 (dd, J = 2.2, 135 Hz), 144.3 (dd, J = 47.2, 49.5 Hz), 
141.0 (dd, J = 34.0, 41.2 Hz), 137.0 (m), 134.3 (d, J = 14.7 Hz), 133.9 (d, J = 14.5 Hz), 
133.8 (dd, J = 2.3, 17.3 Hz), 133.4 (d, J = 12.5 Hz), 132.1 (m), 131.2 (d, J = 37.9 Hz), 
131.1 (d, J = 2.3 Hz), 130.8 (d, J = 2.3 Hz), 129.4 (d, J = 55.3 Hz), 128.8 (d, J = 10.1 Hz), 
128.7 (d, J = 11.7 Hz), 113.8 (ddd, J = 1.5, 11.6, 18.6 Hz), one signal obscured; 
19
F NMR 
(376.3 MHz, CDCl3) δ –123.1 (m); 
31




43.8 (d, J = 26.7 Hz); IR (film) 1475, 1435, 1210 cm
–1
. Anal calcd for C36H28BrFP2Pd: C, 
59.40; H, 3.88. Found: C, 59.54; H, 3.95. 
 
(dppp)Pd(4-fluorophenyl)(Br) (IV-5n). Complex IV-5n was prepared according to 
General Procedure 10 for the reaction of dppp with {[(o-tol)3P]Pd(p-C6H4F)(Br)}2, but 
could not be isolated in analytically pure form.  Available NMR spectral data is provided. 
19
F NMR (376.3 MHz, THF-d8) δ –125.9 (m); 
31
P NMR (162 MHz, THF-d8) δ 16.2 (d, J 
= 50.7 Hz), –8.3 (d, J = 50.4 Hz). 
 
[(rac)-BINAP]Pd(4-fluorophenyl)(Br) (IV-5o). General procedure 10 was used for the 
reaction of {[(o-tol)3P]Pd(p-C6H4F)(Br)}2 (100 mg, 0.0852 mmol) with (rac)-BINAP 
(106 mg, 0.170 mmol) to give 129 mg (84%) of the title compound as an off-white solid, 
m.p. 180 °C (decomp).
 1
H NMR (400 MHz, CDCl3) δ 7.94 (dd, J = 8.8, 10.8 Hz, 1 H), 
7.82–7.76 (m, 2 H), 7.71 (dd, J = 1.6, 8.4 Hz, 1 H), 7.59–7.46 (m, 6 H), 7.45–7.29 (m, 6 
H), 7.18–7.12 (m, 2 H), 7.07–6.93 (m, 6 H), 6.77–6.58 (m, 6 H), 6.52–6.47 (m, 2 H); 
19
F 
NMR (376 MHz, CDCl3) δ –123.4 (s, br); 
31
P NMR (162 MHz, CDCl3) δ 28.8 (d, J = 




(DPE-Phos)Pd(4-fluorophenyl)(Br) (IV-5p). General procedure 10 was used for the 
reaction of {[(o-tol)3P]Pd(p-C6H4F)(Br)}2 (201 mg, 0.172 mmol) with DPE-Phos (184 
mg, 0.341 mmol) to give 189 mg (67%) of the title compound as a tan solid, m.p. 143 °C 
(decomp).
 1
H NMR (400 MHz, C6D6) δ 7.96 (s, br, 2 H), 7.20–6.60 (m, partially obscured 
by solvent signal), 6.52 (t, J = 9.0 Hz, 2 H), 6.39 (s, br, 2 H); 
19




d8) δ –124.2 (m); 
31
P NMR (162 MHz, THF-d8) δ 14.2 (d, J = 30.8 Hz), 5.0 (d, J = 33.2 




(xantphos)Pd(4-fluorophenyl)(Br) (IV-5q). General procedure 10 was used for the 
reaction of {[(o-tol)3P]Pd(p-C6H4F)(Br)}2 (200 mg, 0.17 mmol) with xantphos (197 mg, 
0.34 mmol) to give 223 mg (40% over 2 steps) of the title compound as an off-white 
solid, m.p. 216 °C (decomp).
 1
H NMR (400 MHz, CDCl3) δ 7.62 (dd, J = 2.0, 6.8 Hz, 2 
H), 7.34 (s, br, 8 H), 7.29–7.21 (m, 4 H), 7.18–7.09 (m, 12 H), 6.43 (s, br, 2 H), 5.91 (t, J 
= 9.2 Hz, 2 H), 1.79 (s, 6 H); 
13
C NMR (100.7 MHz, CD2Cl2) δ 159.9 (d, J = 238 Hz), 
155.7 (app t, J = 5.8 Hz), 149.7, 135.0 (m), 134.6 (m), 132.1, 131.6 (app t, J = 22.6 Hz), 
129.9, 128.1 (app t, J = 5.0 Hz), 127.4, 124.5 (app t, J = 3.1 Hz), 122.1 (app t, J = 20.9 
Hz), 113.3 (d, J = 19.3 Hz), 36.37, 36.35, 28.8 (s, br); 
19
F NMR (376 MHz, CDCl3) δ –
126.1 (m); 
31
P NMR (162 MHz, CDCl3) δ 9.1 (s); IR (film) 1474, 1434, 1211 cm
-1
. Anal 
calcd for C45H36BrFOP2Pd: C, 62.84; H, 4.22. Found: C, 62.94; H, 4.34. 
 
(N-Me-NiXantphos)Pd(4-fluorophenyl)(Br) (IV-5r). General procedure 10 was used 
for the reaction of {[(o-tol)3P]Pd(p-C6H4F)(Br)}2 (149 mg, 0.25 mmol) with N-Me-
NiXantphos (145 mg, 0.26 mmol) to give 139 mg (65% over 2 steps) of the title 
compound as a yellow powder, m.p. 195 °C (decomp).
 1
H NMR (400 MHz, CDCl3) δ 
7.42–7.30 (s, br, 6 H), 7.29–7.22 (m, br, 6 H), 7.16–7.10 (m, br, 8 H), 6.96 (t, J = 7.8 Hz, 
2 H), 6.82 (dd, J = 1.2, 8.0 Hz, 2 H), 6.72–6.68 (m, 2 H), 6.46–6.34 (s, br, 2 H), 5.92–
5.84 (m, br, 2 H), 3.27 (s, 3 H); 
13
C NMR (100.7 MHz, CD2Cl2) δ 159.9 (d, J = 235 Hz), 




= 22.4 Hz), 129.7, 127.9 (app t, J = 5.1 Hz), 125.6, 124.6 (app t, J = 3.9 Hz), 121.8 (app t, 
J = 21.6 Hz), 114.5, 113.0 (d, J = 19.5 Hz) 31.9; 
19
F NMR (376.9 MHz, CDCl3) δ broad 
baseline signal centered at –129 (at 25 °C); 
31
P NMR (162.1 MHz, CDCl3) δ 7.32; IR 
(film) 1474, 1208 cm
–1
. Anal calcd for C43H33BrFNOP2Pd: C, 60.98; H, 3.93, N 1.65. 
Found: C, 60.95; H, 3.97, N 1.59. 
 
(dppf-CF3)Pd(4-fluorophenyl)(Br) (IV-5s). General procedure 10 was used for the 
reaction of {[(o-tol)3P]Pd(p-C6H4F)(Br)}2 (101 mg, 0.086 mmol) with dppf-CF3 (141 mg, 
0.17 mmol) to give 102 mg (28% over 2 steps) of the title compound as an orange solid, 
m.p. 191 °C (decomp).
 1
H NMR (400 MHz, CDCl3) δ 7.96–7.89 (m, 4 H), 7.76 (d, J = 7.2 
Hz, 4 H), 7.50–7.40 (m, 8 H), 6.80–6.71 (m, 2 H), 6.45–6.37 (m, 2 H), 4.67–4.63 (m, 2 
H), 4.63–4.59 (m, 2 H), 4.33–4.29 (m, 2 H), 3.76–3.72 (m, 2 H); 
13
C NMR (100.6 MHz, 
CD2Cl2) δ 161.0 (d, J = 240 Hz), 149.0 (dm, J = 129 Hz), 137.6 (d, J = 32.4 Hz), 137.3 
(d, J = 53.0 Hz), 136.3 (d, J = 12.3 Hz), 136.0–135.8 (m), 134.8 (d, J = 12.2 Hz), 133.0 
(qd, J = 2.3, 32.5 Hz), 132.9 (qd, J = 2.3, 32.4 Hz), 126.0–125.4 (m), 124.3 (q, J = 270 
Hz, partially obscured), 124.2 (q, J = 270 Hz, partially obscured), 115.3 (ddd, J = 1.5, 
10.3, 19.4 Hz), 76.6 (d, J = 12.2 Hz), 75.1 (d, J = 7.7 Hz), 74.9 (d, J = 8.7 Hz), 74.6 (d, J 
= 7.3 Hz, partially obscured), 73.9 (d, J = 5.3 Hz), 73.5 (dd, J = 2.4, 38.2 Hz), one signal 
obscured; 
19
F NMR (376 MHz, CDCl3) δ –63.2 (m, 12 F), –123.0 (m, 1 F); 
31
P NMR 
(162 MHz, CDCl3) δ 29.6 (d, J = 32.5 Hz), 9.3 (d, J = 34.3 Hz); IR (film) 1475, 1324, 
1168 cm
-1






(dppf-OMe)Pd(4-fluorophenyl)(Br) (IV-5t). General procedure 10 was used for the 
reaction of {[(o-tol)3P]Pd(p-C6H4F)(Br)}2 (101 mg, 0.086 mmol) with dppf-OMe (116 
mg, 0.17 mmol) to give 83 mg (27% over 2 steps) of the title compound as an orange 
solid , m.p. 175 °C (decomp).
 1
H NMR (400 MHz, CDCl3) δ 8.00–7.93 (m, 4 H), 7.29–
7.22 (m, 4 H), 6.98 (dd, J = 1.2, 8.4 Hz, 4 H), 6.89–6.81 (m, 2 H), 6.67 (dd, J = 2.4, 8.8 
Hz, 4 H), 6.39 (td, J = 9.8, 2.0 Hz, 2 H), 4.61–4.58 (m, 2 H), 4.46–4.43 (m, 2 H), 4.16–
4.13 (m, 2 H), 3.86 (s, 6 H), 3.79 (s, 6 H), 3.69–3.66 (m, 2 H); 
13
C NMR (100.6 MHz, 
CD2Cl2) δ 161.9, 161.8, 160.6 (d, J = 249 Hz), 153.1 (dm, J = 128 Hz), 137.4 (d, J = 13.1 
Hz), 136.3 (m), 136.1 (d, J = 13.8 Hz), 125.0 (d, J = 35.1 Hz), 124.5 (d, J = 55.7 Hz), 
114.1 (d, J = 10.0 Hz), 114.0 (d, J = 12.2 Hz), 78.5 (dd J = 6.9, 51.8 Hz), 76.6 (d, J = 2.3 
Hz, partially obscured), 76.2 (d, J = 12.3 Hz), 74.7 (d, J = 8.4 Hz), 73.8 (d, J = 7.6 Hz), 
72.8 (d, J = 5.4 Hz), 55.93, 55.88, signal for the aryl carbons β to fluorine obscured; 
19
F 
NMR (376 MHz, CDCl3) δ –124.8 (m); 
31
P NMR (162 MHz, CDCl3) δ 28.4 (d, J = 32.1 
Hz), 7.3 (d, J = 32.1 Hz); IR (film) 1500, 1253, 1209, 1028 cm
–1
. Anal calcd for 
C44H40BrFFeO4P2Pd: C, 55.29; H, 4.22. Found: C, 55.34; H, 4.20. 
 




(400 MHz, THF-d8) δ 8.01–7.90 (m), 7.72–7.64 (m), 7.59–7.39 (m), 7.22–6.98 (m), 
6.71–6.59 (m), 6.11–6.04 (m), 5.60 (tdd, J = 6.8, 10.0, 16.8 Hz, 1 H), 4.87–4.77 (m, 2 H), 
4.57 (s, 2 H), 4.44 (s, 2 H), 4.41 (s, 1 H), 4.31 (s, 1 H), 4.22 (s, partially obscured), 4.16 




1.62 (m, partially obscured, 2 H), 1.33–1.26 (m, partially obscured, 1 H), 1.16 (s, 9 H), 
1.05–0.95 (m, 1 H); 
19
F NMR (376 MHz, THF-d8) δ –123.9 (m); 
31
P NMR (162 MHz, 
THF-d8) δ 23.7 (dd, J = 2.6, 38.1 Hz), 8.6 (d, J = 38.1 Hz). 
 
(dppf)Pd(C6H4-p-F){CH2[CHCH2CH2CH2N(C6H4-p-tert-butyl)]} (IV-4b):  
19
F NMR 
(376 MHz, THF-d8) δ –124.3 (m); 
31
P NMR (162 MHz, THF-d8) δ 20.7 (d, J = 22.8 Hz), 
16.1 (dd, J = 2.6, 22.8 Hz). 
(dppf)Pd(C6H4-p-F)[N(C6H4-p-OMe)(CH2CH2CH2CH=CH2)] (IV-3c): 
1
H NMR (400 
MHz, THF-d8) δ 7.95–7.79 (m), 7.57–7.39 (m), 7.23–7.10 (m), 7.09–6.94 (m), 6.61–6.52 
(m, 2 H), 6.29 (d, J = 7.6 Hz, 2 H), 6.05 (t, J = 8.6 Hz, 2 H), 5.62 (tdd, J = 6.4, 10.0, 16.4 
Hz, 1 H), 4.87–4.80 (m, 2 H), 4.57 (s, 1 H), 4.47 (s, 1 H), 4.44 (s, 1 H), 4.42 (s, 1 H), 4.35 
(s, 1 H), 4.32 (s, 1 H), 4.20 (s, 1 H), 4.16 (s, 1 H), 3.52 (s, 3 H), 2.45 (m, 1 H), 2.17 (m, 2 
H), 1.70 (m, partially obscured by THF signal), 1.45 (m, 1 H), 1.20 (m, 1 H); 
19
F NMR 
(376 MHz, THF-d8) δ –124.1 (s); 
31
P NMR (162 MHz, THF-d8) δ 24.8 (d, J = 40.7 Hz), 




F NMR (376 
MHz, THF-d8) δ –124.3 (s); 
31
P NMR (162 MHz, THF-d8) δ 21.3 (d, J = 24.1 Hz); 16.4 
(dd, J = 2.4, 24.1 Hz). 
(dppf)Pd(C6H4-p-F)[N(C6H5)(CH2CH2CH2CH=CH2)] (IV-3d):  
1
H NMR (400 MHz, 




(q, J = 7.2 Hz, 2 H), 6.58 (s, br, 1 H), 6.08 (t, J = 8.8 Hz, 2 H), 5.63 (tdd, J = 6.4, 10.4, 
16.8 Hz, 1 H), 4.90–4.77 (m, 2 H), 4.51–4.49 (m, 2 H), 4.45 (s, 1 H), 4.41 (s, 1 H), 4.37 
(s, 1 H), 4.32, (s, 1 H), 4.21 (obscured by dppf), 2.53–2.42 (m, 1 H), 2.29–2.20 (m, 1 H), 
1.70 (m, obscured by THF), 1.50–1.38 (m, 1 H), 1.18–1.04 (m, 1 H); 
19
F NMR (376 
MHz, THF-d8) δ –123.9 (s); 
31
P NMR (162 MHz, THF-d8) δ 24.3 (d, J = 36.8 Hz), 9.9 (d, 




F NMR (376 MHz, 
THF-d8) δ  –124.4 (m); 
31
P NMR (162 MHz, THF-d8) δ 20.7 (d, J = 23 Hz), 16.1 (dd, J = 
2.6, 22.8 Hz). 
(dppf)Pd(C6H4-p-F)[N(C6H4-p-Cl)(CH2CH2CH2CH=CH2)] (IV-3e): 
1
H NMR (400 
MHz, THF-d8) δ 7.88–7.79 (m), 7.74 (t, J = 8.6 Hz), 7.56–7.41 (m), 7.23-7.12 (m, 
partially obscured), 6.67 (app q, J = 6.8 Hz, 2 H), 6.50 (d br, J = 6.8 Hz, 2 H), 6.12 (t, J = 
8.8 Hz, 2 H), 5.67–5.58 (m, 1 H), 4.89–4.79 (m, 2 H), 4.59 (s, 1 H), 4.49 (s, 2 H), 4.41 (s, 
1 H), 4.39 (s, 1 H), 4.34 (s, 1 H), 2.50–2.45 (m, br, 1 H), 2.26–2.13 (m, 1 H), 1.73–1.61 
(m, partially obscured by THF, 2 H), 1.51–1.38 (m, br, 1 H), 1.14–1.03 (m, br, 1 H); 
19
F 
NMR (376 MHz, THF-d8) δ –123.4; 
31
P NMR (162 MHz, THF-d8) δ 24.4 (d, J = 35.6 










F NMR (376 
MHz, THF-d8) δ –124.0 (m); 
31
P NMR (162 MHz, THF-d8) δ 21.2 (d, J = 22.8 Hz), 16.8 




(400 MHz, THF-d8) δ 7.89 (t, J = 8.4 Hz, 2 H), 7.82 (t, J = 8.6 Hz, 2 H), 7.67 (t, J = 8.6 
Hz, 2 H), 7.53–7.44 (m), 7.16–7.03 (m), 6.65 (t, J = 7.6 Hz, 2 H), 6.39 (d, J = 7.2 Hz, 2 
H), 6.31 (t, J = 8.2 Hz, 2 H), 5.62 (tdd, J = 6.8, 10.0, 16.8 Hz, 1 H), 4.86–4.79 (m, 2 H), 
4.49 (s, 1 H), 4.42–4.39 (m, 3 H), 4.33 (s, 1 H), 4.16 (s, 1 H), 4.16 (s, 1 H), 2.56–2.50 (m, 
1 H), 2.36–2.23 (m, obscured by internal standard), 1.73–1.60 (m, obscured by THF), 
1.54–1.44 (m, 1 H), 1.08 (s, 9 H), 1.03–0.92 (m, partially obscured by t-Bu signal, 1 H); 
19
F NMR (376 MHz, THF-d8) δ –138.3 (m); 
31
P NMR (162 MHz, THF-d8) δ 24.0 (d, J = 





(376 MHz, THF-d8) δ –133.6 (m); 
31
P NMR (162 MHz, THF-d8) δ 20.5 (d, J = 22.8 Hz), 
16.6 (d, J = 22.8 Hz). 
(dppf)Pd(C6H4-p-OMe)[N(C6H4-p-F)(CH2CH2CH2CH=CH2)] (IV-3h):  
1
H NMR (400 
MHz, THF-d8) δ 7.88–7.71 (m), 7.52–7.38 (m), 7.22–6.93 (m), 6.53 (t, J = 7.8 Hz, 2 H), 
6.33 (t, J  = 8.4 Hz, 2 H), 5.98 (d, J = 8.0 Hz, 2 H), 5.65 (tdd, J = 6.4, 10.0, 16.4 Hz, 1 H), 




obscured by dppf), 3.44 (s, 3 H), 2.50–2.44 (m, 1 H), 2.24–2.14 (m, 1 H), 1.70 (m, 
obscured by THF), 1.62–1.52 (m, 1 H), 1.19–1.08 (m, 1 H); 
19
F NMR (376 MHz, THF-
d8) δ –137.9 (m); 
31





F NMR (376 
MHz, THF-d8) δ –133.7 (m); 
31
P NMR (162 MHz, THF-d8) δ 21.1 (d, J = 22.8 Hz), 16.1 
(d, J = 22.8 Hz). 
(dppf)Pd(C6H5)[N(C6H4-p-F)(CH2CH2CH2CH=CH2)] (IV-3i): 
1
H NMR (400 MHz, 
THF-d8) δ 7.92–7.81 (m), 7.78–7.71 (m), 7.55–7.40 (m), 7.21–7.14 (m), 7.13–7.01 (m), 
6.74–6.67 (m), 6.42–6.25 (m), 5.63 (tdd, J = 6.8, 10.0, 16.8 Hz, 1 H), 4.89–4.80 (m, 2 H), 
4.51 (s, 1 H), 4.44 (s, 2 H), 4.41 (s, 2 H), 4.33 (s, 1 H), 4.21 (s, 1 H), 4.18–4.14 (m, 1 H), 
2.59–2.47 (m, 1 H), 2.27–2.13 (m, 1 H), 1.70 (m, obscured by THF), 1.54–1.42 (m, 1 H), 
1.18–1.07 (m, 1 H); 
19
F NMR (376 MHz, THF-d8) δ –137.9 (s); 
31
P NMR (162 MHz, 




F NMR (376.9 MHz, 
THF-d8) δ –133.6 (m); 
31









(m), 7.38 (d, J = 7.6 Hz), 7.28–7.21 (m), 6.97 (app dt, br, J = 1.6, 8.8 Hz), 6.59 (app q, J 
= 7.6 Hz), 6.40 (app t, br, J = 8.4 Hz), 6.15 (app t, br, J = 8.4 Hz), 5.54 (ddt, J = 6.8, 10.8, 
16.0 Hz, 1 H), 4.98–4.89 (m, 2 H), 4.82–4.75 (m, br, 2 H), 4.70–4.63 (m, br, 1 H), 4.61 
(s, br, 1 H), 4.57 (s, br, 1 H), 4.52–4.46 (m, br, 2 H), 4.40 (s, br, 1 H; partially obscured 
by free ligand), 2.83–2.72 (m, 1 H), 2.39–2.30 (m, 1 H, partially obscured by internal 
standard), 1.72–1.64 (m, 2 H, partially obscured by THF), 1.12 (t, J = 7.2 Hz, 1 H), 0.89 
(t, J = 7.0 Hz, 1 H); 
19
F NMR (376 MHz, THF-d8) δ –61.89 s, 3 F), –61.95 (s, 3 F), –
61.97 (s, 3 F), –62.03 (s, 3 F), –122.7 (m, 1 F), –135.8 (s, 1 F); 
31
P NMR (162 MHz, 
THF-d8) δ 27.0 (d, J = 38.1 Hz), 8.2 (d, J = 38.1 Hz). 
 
(dppf-CF3)Pd(C6H4-p-F){CH2[CHCH2CH2CH2N(C6H4-p-F)]} (IV-4s′):  
19
F NMR 
(376.9 MHz, THF-d8) δ –123.1 (s, 1 F), –132.7 (s, 1 F) – CF3 signals for IV-4s′ could not 
be identified among the more prominent signals of free ligand, Pd(dppf-CF3)2, and IV-
3s′; 
31





(400 MHz, THF-d8) δ 7.98 (app t br, J = 8.6 Hz), 7.86–7.73 (m), 7.65 (app t, J = 8.6 Hz), 
7.38–7.24 (m), 7.07–6.96 (m), 6.76–6.70 (m), 6.69–6.60 (m), 6.41–6.33 (m), 6.32–6.23 
(m), 6.16–6.09 (m), 5.62 (ddt, J = 16.8, 10.0, 6.8 Hz, 1 H), 4.88–4.79 (m, 2 H), 4.67 (s, 1 
H), 4.55 (s, 1 H), 4.51 (s, 1 H), 4.43 (s, 2 H), 4.41 (s, 1 H), 4.37 (s, 1 H), 4.31 (s, 1 H), 




1.25–1.24 (m, 1 H), 1.20-1.08 (m, 1 H); 
19
F NMR (376 MHz, THF-d8) δ –123.9 (m), –
137.9 (s); 
31
P NMR (162 MHz, THF-d8) δ 22.0 (d, J = 38.1 Hz), 6.3 (d, J = 39.4 Hz). 
 
(dppf-OMe)Pd(C6H4-p-F){CH2[CHCH2CH2CH2N(C6H4-p-F)]} (IV-4t′):  
19
F NMR 
(376.9 MHz, THF-d8) δ –124.4 (s), –133.4 (m); 
31
P NMR (162 MHz, THF-d8) δ 18.4 (d, 
J = 24.2 Hz), 13.9 (dd, J = 24.2, 2.6 Hz). 
 
(dppf)Pd(C6H4-p-F)[N(C6H4-p-Cl)(CH2CH2CH2CD=CH2)] (IV-3v):  
1
H NMR (400 
MHz, THF-d8) δ 7.90–7.77 (m), 7.74 (app t, J = 8.8 Hz), 7.52–7.45 (m), 7.41 (app t, J = 
6.0 Hz), 7.23–7.10 (m), 6.68 (app q, J = 7.6 Hz), 6.56–6.42 (m), 6.12 (app t, J = 8.4 Hz), 
4.88–4.83 (m, 2 H), 4.49 (s, br, 2 H), 4.46 (s, br, 1 H), 4.41 (s, br, 1 H), 4.39 (s, br, 1 H), 
4.34 (m, 1 H), 2.53–2.43 (m, 1 H), 2.26–2.12 (m, 1 H), 1.74–1.61 (m, 2 H, partially 
obscured by THF), 1.50–1.37 (m, 1 H), 1.16–1.03 (m, 1 H), remaining Cp signals 
obscured by free ligand; 
19
F NMR (376 MHz, THF-d8) δ –123.4 (m); 
31
P NMR (162 




F NMR (376 
MHz, THF-d8) δ –124.0 (m); 
31
P NMR (162 MHz, THF-d8) δ 20.9 (d, J = 24.2 Hz), 16.5 




H NMR (400 
MHz, THF-d8) δ 7.86–7.77 (m), 7.71 (app t, J = 8.8 Hz), 7.55–7.40 (m), 7.35 (app t, J = 




H), 4.60 (s, 1 H), 4.54 (s, br, 3 H), 4.45 (s, 1 H), 4.41–4.33 (m, 4 H), 4.31 (s, 1 H), 2.42–
2.33 (m, 1 H), 2.26–2.17 (m, 1 H), 1.73–1.62 (m, 2 H), 1.59 (s, 3 H), 1.17–1.08 (m, 1 H), 
remaining alkyl signal obscured; 
19
F NMR (376 MHz, THF-d8) δ –123.8 (m); 
31
P NMR 




F NMR (376 
MHz, THF-d8) δ –124.6 (m); 
31
P NMR (162 MHz, THF-d8) δ 20.2 (d, J = 22.8 Hz), 14.0 
(dd, J = 2.1, 23.2 Hz). 
(dppf)Pd(C6H4-p-F)[N(C6H5)((Z)-CH2CH2CH2CH=CHCH3)] (IV-3x):  
1
H NMR (400 
MHz, THF-d8) δ 7.97–7.90 (m), 7.86–7.73 (m), 7.52–7.46 (m), 7.46–7.38 (m), 7.19–7.13 
(m), 7.13–7.02 (m), 6.88 (app t, J = 7.8 Hz), 6.66 (app q, J = 7.2 Hz), 6.58 (s, br), 6.08 
(app. t, J = 8.4 Hz), 5.38–5.29 (m, 1 H), 5.25–5.16 (m, 1 H), 4.54 (m, 1 H), 4.48 (s, 1 H), 
4.44 (s, 1 H), 4.41 (s, 1 H), 4.38 (s, 1 H), 4.32 (s, 1 H), 4.23–4.18 (m, 2 H), 2.56–2.45 (m, 
1 H), 2.28–2.18 (m, 1 H – partially obscured), 1.70–1.63 (m, 2 H – partially obscured by 
THF), 1.46–1.34 (m, 1 H), 1.18–1.08 (m, 1 H); 
19
F NMR (376 MHz, THF-d8) δ –123.9 
(m); 
31
P NMR (162 MHz, THF-d8) δ 23.1 (d, J = 35.7 Hz), 8.5 (d, J = 38.3 Hz). 
(dppf)Pd(C6H4-p-F)[N(C6H5)((E)-CH2CH2CH2CH=CHCH3)] (IV-3y): 
1
H NMR (400 
MHz, THF-d8) δ 7.95–7.88 (m), 7.86–7.74 (m), 7.51–7.45 (m), 7.44–7.40 (m), 7.19–7.14 
(m), 7.13–7.01 (m), 6.88 (app t, J = 7.8 Hz), 6.66 (app q, J = 7.6 Hz), 6.57 (s, br), 6.07 
(app t, J = 8.6 Hz), 5.53–5.40 (m, 1 H), 5.32–5.19 (m, 1 H – partially obscured), 4.54 (s, 
1 H), 4.48 (s, 1 H), 4.45 (s, 1 H), 4.41 (s, 1 H), 4.39 (s, 1 H), 4.32 (s, 1 H), 4.20 (s, 1 H), 




obscured), 1.46–1.34 (m, 1 H), 1.18–1.06 (m, 1 H); 
19
F NMR (376 MHz, THF-d8) δ –
123.9 (m); 
31
P NMR (162 MHz, THF-d8) δ 23.0 (d, J = 37.0 Hz), 8.3 (d, J = 36.8 Hz). 
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